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The overall aim of this thesis was to examine and compare cardiovascular risk factors, time-
trends in these risk factors, and the incidence of cardiovascular disease in Sami and non-Sami 
populations living in the same rural geographical area.  
 
For this thesis, we used information from the SAMINOR Study. This population-based study 
on health and living conditions in regions with Sami and non-Sami populations in Northern 
and Mid Norway consists of three separate surveys, conducted in two waves. Paper 1 was 
based on data from the SAMINOR 2 Clinical Survey (SAMINOR 2, 2012–2014), which was 
conducted in 10 municipalities of Northern Norway. In this paper, conventional 
cardiovascular risk factors (hereafter referred to as conventional risk factors) were compared 
and the 10-year risk of fatal or non-fatal acute myocardial infarction or cerebral stroke 
(hereafter referred to as 10-year risk) was estimated using the NORRISK 2 risk model in 
Sami and non-Sami women and men aged 40–79 years. In Paper 2, we examined the change 
in conventional risk factors and 10-year risk from the SAMINOR 1 Survey (SAMINOR 1, 
2003–2004) to SAMINOR 2 in participants aged 40–79 years that lived in 10 municipalities 
in Northern Norway. In Paper 3, SAMINOR 1 participants aged 30 and 36–79 years were 
followed until the end of 2016. Baseline information from SAMNOR 1 was linked to hospital 
discharge data provided by the Cardiovascular Disease in Norway Project (1993–2009) or the 
Norwegian Patient Registry (2010–2016); to cause of death data from the Cause of Death 
Registry; and to emigration data from Statistics Norway. The aim of Paper 3 was to measure 
and compare the risk of fatal or non-fatal acute myocardial infarction, coronary heart disease, 
ischemic stroke, cerebral stroke and a composite endpoint (acute myocardial infarction or 
cerebral stroke) in Sami and non-Sami populations.     
 
In Paper 1, we observed some small ethnic differences in conventional risk factors. The 
estimated and age-standardised 10-year risks were similar in Sami and non-Sami participants 
who were free of angina pectoris or myocardial infarction. Paper 2 showed an overall 
favourable change in conventional risk factors from SAMINOR 1 to SAMINOR 2 in both 
sexes and ethnic groups. Compared with non-Sami men, Sami men had a somewhat smaller 
change in lipids that most likely are of no clinical relevance in terms of different risk; and in 
women, Sami had a smaller decline in the estimated 10-year risk than non-Sami. Both Sami 
and non-Sami had an increase in waist circumference over time. Paper 3 showed that, during 
13 years of follow-up in SAMINOR 1, the risk of ischemic stroke and cerebral stroke was 
approximately 36% and 31% higher, respectively, in Sami than in non-Sami participants. This 
higher risk was not explained by differences in conventional risk factors, which might not be 
surprising given the similar estimated 10-year risks observed in Paper 1, and the rather similar 
change in conventional risk factors over time observed in Paper 2. However, in Paper 3 we 
also observed that adjustment for height attenuated the ethnic differences in the risk of stroke 
somewhat. We observed no ethnic differences in the risk of acute myocardial infarction, 
coronary heart diseases, or in the composite endpoint in Paper 3. 
 
The results of this thesis indicate only small ethnic differences in conventional risk factors 
and a somewhat higher risk of ischemic and cerebral stroke in Sami. Ethnic differences were 
not explained by conventional risk factors, but a substantial part was explained by height. The 
differences in the risk of stroke were small and may have been due to bias (residual 
confounding) or chance. Therefore, more studies are warranted to replicate the findings and to 





Formålet med avhandlingen var å undersøke og sammenligne konvensjonelle risikofaktorer til 
hjerte- og karsykdommer, trender i risikofaktorer og insidens av hjerte- og karsykdommer hos 
den samiske og ikke-samiske befolkningen som bor i de samme geografiske rurale områdene.  
 
Vi har brukt data fra SAMINOR til artiklene som inngår i avhandlingen. SAMINOR- 
undersøkelsen (Helse- og levekårsundersøkelsen i områder med samisk og norsk bosetting) 
som er en befolkningsundersøkelse om helse og levekår i den samiske og ikke-samiske 
befolkingen i Nord- og Midt Norge. SAMINOR består av tre separate undersøkelser 
gjennomført over to innsamlingsperioder. I den første artikkelen brukte vi data fra SAMINOR 
2 klinisk undersøkelse (SAMINOR 2, 2012–2014), hvor deltakerne var mellom 40–79 år og 
fra 10 kommuner i Nord-Norge. Vi sammenlignet konvensjonelle risikofaktorer for hjerte- og 
karsykdommer og målte 10-års risiko for fatalt og ikke-fatalt hjerteinfarkt eller hjerneslag 
(heretter 10-års risiko) hos samer og ikke-samer ved hjelp av NORRISK 2 risikokalkulator. I 
den andre artikkelen undersøkte vi om endringer i konvensjonelle risikofaktorer fra 
SAMINOR 1 undersøkelsen (SAMINOR 1, 2003–2004) til SAMINOR 2 var lik for samiske 
og ikke-samiske deltakere mellom 40 og 79 år, bosatt i 10 kommuner i Nord-Norge. I den 
tredje artikkelen ble deltakere i SAMINOR 1, som var i alderen 30 og 36–79 år, fulgt opp til 
slutten av 2016. Oppfølgingen skjedde ved at opplysninger gitt ved SAMINOR 1 ble koblet 
til Dødsårsaksregistret for opplysninger om underliggende dødsårsak, til Statistisk sentralbyrå 
for opplysninger om emigrasjon, og til CVDNOR prosjektet (Cardiovascular Disease in 
Norway Project) og til Norsk pasientregister for opplysninger om utskrivningsdiagnoser for 
henholdsvis 1993–2009 og 2010–2016. Risikoen for fatalt og ikke-fatalt akutt hjerteinfarkt, 
koronar hjertesykdom, iskemisk hjerneslag, cerebralt hjerneslag og et samlet endepunkt (akutt 
hjerteinfarkt eller cerebral hjerneslag) ble målt hos samer og ikke-samer, og gruppenes risiko 
ble sammenlignet.   
 
I den første artikkel fant vi noen små etniske forskjeller i konvensjonelle risikofaktorer. Den 
estimerte og aldersstandardiserte 10-års risikoen var lik for samer og ikke-samer som ikke 
hadde angina pectoris eller gjennomgått hjerteinfarkt før oppfølgingen startet. Den andre 
artikkelen viste at begge kjønn og etniske grupper hadde en gunstig utvikling i konvensjonelle 
risikofaktorer fra SAMINOR 1 til SAMINOR 2. Sammenlignet med ikke-samiske menn, 
hadde samiske menn en litt mindre fordelaktig utvikling av lipider, mens samiske kvinner 
hadde en mindre nedgang i 10-års risiko enn ikke-samiske kvinner. Begge etniske grupper 
hadde en økning i midjeomkrets. Resultatene fra den tredje artikkelen viste at i en oppfølging 
på 13 år, hadde samiske deltakere omtrent 36% og 31% høyere risiko for henholdsvis 
iskemisk og cerebralt hjerneslag. Den økte risikoen ble ikke forklart av konvensjonelle 
risikofaktorer for hjerte- og karsykdommer, noe som ikke var uventet gitt at gruppene hadde 
lik 10-års risiko (artikkel 1) og relativt like endringer av risikofaktorer over tid (artikkel 2). 
Ved å justere for høyde, ble de etniske forskjellene redusert. Risikoen for akutt hjerteinfarkt, 
koronar hjertesykdom eller for det samlede endepunktet, var lik hos samer og ikke-samer.            
 
Denne avhandlingen viser at det er små forskjeller i konvensjonelle risikofaktorer, og at 
samiske menn og kvinner har en noe forhøyet risiko for hjerneslag. Forskjellene i risiko var 
derimot små, og vi kan ikke utelukke at resultatene skyldes systematiske skjevheter eller 
tilfeldigheter. Derfor er det nødvendig med flere studier som kan bekrefte funnene og 





Dán dutkamuša váldomihttu lea leamaš iskat ja buohtastahttit dábálaš riskafáktoriid váibmo- 
ja varrasuotnasivaide, movt riskafáktorat rivdet, ja mihtidit movt váibmo- ja varrasuotnasivat 
dihttojit sápmelaččain ja eará čearddalaš joavkkus geat orrot seamma doaresbeale guovlluin.  
Dutkosa artihkkaliin leat geavahan dieđuid SAMINOR guorahallamis, mii lea dearvvašvuođa- 
ja eallindilleiskkadeapmi sámi álbmogis ja álbmogis geat eai leat sápmelaččat Davvi- ja 
Gaska Norggas. SAMINOR iskkadeapmái gullet golbma sierra iskosa mat leat čoggojuvvon 
guovtti áigodaga badjel. Vuosttaš artihkkalii geavaheimmet SAMINOR 2 klinalaš iskkadeami 
(SAMINOR 2, 2012–2014) mii čađahuvvui 10 suohkanis Davvi Norggas ja mas rávisolbmot 
gaskal 40 ja 79 jagi oassálaste. Mii buohtastahtiimet dábálaš riskafáktoriid váibmo- ja 
varrasuotnasivaide sápmelaččain ja eará čearddalaš joavkkus, ja mihtideimmet NORRISK 2 
riskamodeallain sin 10-jagi riskadási jápmit dahje buohccát vuoiŋŋaščaskkástagain dahje 
fáhkka váibmodohppehagain (dás maŋás 10-jahkasaš riskadássi). Nuppi artihkkalis 
guorahalaimet rivdet go dábálaš riskafáktorat ja 10-jagi riskadássi seamma ládje sápmelaččain 
ja eará čearddalaš joavkkus geat ledje gaskal 40 ja 79 jagi, orro 10 suohkanis Davvi Norggas, 
ja serve SAMINOR 1 (SAMINOR 1, 2003–2004) ja SAMINOR 2 iskkadeapmái. Goalmmát 
artihkkalis mii čuovuimet SAMINOR 1 oassálastiid geat ledje 30, ja gaskal 36 ja 79 jagi, gitta 
2016 loahpageahčai. Dieđut mat ledje čohkkejuvvon SAMINOR 1 iskkadeamis 
čadnojuvvojedje dieđuide Jápminsivvaregistaris diđoštit mainna sivain olbmot jápmet, 
Váibmo- ja varrasuotnaregistarii (CVDNOR) dahje Norgga pasieantaregistarii diđoštit mainna 
sivain buohccájit, ja Statistihkalaš guovddášdoaimmahaga registarii diđoštit leat go olbmot 
fárren eret riikkas. Mii mihtideimmet ja buohtastahtiimet dihttogo jápmin dahje fáhkka 
buohccán seamma dávjá sápmelaččain go eará čearddalaš joavkkus čuovvovaš dávddaide: 
fáhkka váibmodohppehahkii, vigit guoskevaččat váldováibmosuonaide, 
vuoiŋŋaščaskkástahkii, eará vuoiŋŋamaš vigiide ja muhtin seahkalas dávddaide. 
 
Vuosttaš artihkkala gávdnosat čájehit ahte dábálaš riskafáktoriid dáfus ledje smávva erohusat 
čearddaid gaskkas. Vuosttaš artihkkalis lei dat merrojuvvon ja ahkeheivehuvvon 10-jagi 
riskadássi seammadássásaš sápmelaččain ja eará čearddalaš joavkkus go buohtastahtiimet 
oassálastiid geain ii lean ovdalaččas angina pectoris dahje váibmodohppehat. Nuppi 
artihkkalis oaidnit ahte dábálaš riskafáktorat leat njiedjan sihke sápmelaččain ja eará 
čearddalaš joavkkus SAMINOR 1 iskkadeamis SAMINOR 2 iskkadeami ektui, earetgo 
seakkášmihttu, mii lei sturron. Buohtastasttedettiin vuhtiimet ahte sámi dievdduin lei 
buoidemearri varas njiedjan veahá unnit go eará čearddalaš joavkkus. Nissonolbmuid gaskkas 
fas vuhttui ahte sámi nissoniin lei merrojuvvon 10-jagi riskadássi njiedjan veahá unnit go eará 
čearddalaš joavkkus. Goalmmát artihkkalis čuovuimet oassálastiid 13-jagi ja mihtut čájehedje 
ahte sápmelaččain dihttojedje vuoiŋŋamaš vigit 36% dávjjibut ja vuoiŋŋaščaskkástagat 31% 
dávjjibut go eará čearddalaš joavkkus. Dábálaš riskafáktorat eai čilgen manin sápmelaččain 
lei alibuš riska, mii ii lean nu imáš go eai han lean mearkkašeaddji erohusat 10-jagi riskadásis 
ja riskafáktoriin vuosttaš ja nuppi artihkkalis. Olbmo allodat čilgii daid čearddalaš erohusaid, 
muhto ii ollislaččat. Eat gávdnan čearddalaš erohusaid das man dávjá dihtto fáhkka 
váibmodohppehat, vigit guoskevaččat váldováibmosuonaide ja muhtin seahkalas dávddaide.           
 
Dát dutkamuš čájeha ahte sápmelaččain ja eará čearddalaččain geat orrot seamma guovlluin 
leat ovttalágan dásit riskafáktoriiguin, muhto sápmelaččat dohppehallojit veahá dávjjibut 
vuoiŋŋamaš vigiide ja vuoiŋŋaščaskkástagaide. Dákkár dutkama ferte geardduhit go eat sáhte 
áibbas sihkkarit earuhit leat go meattáhusat dutkanvugiin dahje soahttáhat mat dagahit dákkár 
bohtosiid. Maiddái lea dárbu iskat movt olbmo allodat sáhttá váikkuhit vuoiŋŋamaš vigiide 
dáin čearddalaš joavkkuin.          
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Incident cases: the number of new cases that occur in a population of known size (person-
years) within a defined time-period. [1] It may be measured as frequency, a rate or a 
proportion.[2]  
Incidence rate: computed by dividing the number of new cases in a population in a given 
time-period, by the number of people who are at risk (person-years) of getting the disease 
within that same time-period.[2] 
Prevalence: the number of cases (old and new) at a specific time-point in a population of 
known size, [1] also known as point prevalence.
 
1 
1 Introduction  
Cardiovascular disease (CVD) was the most common cause of death in 2013, accounting for 
about 32% of all deaths worldwide.[3, 4] CVD also accounted for most deaths across 52 
member countries of the European Society of Cardiology (ESC) in 2007–2017.[5] Globally, 
among the different CVD related deaths, coronary heart disease (CHD) and cerebral stroke 
(CS) ranked as the two most common causes of death in 2013,[4, 5] except in some Balkan 
countries.[4] Although CVD has been a leading cause of death, age-standardised CVD 
mortality rates have decreased across Europe since 2003, and some Western European 
countries actually experience more deaths due to cancer than to CVD.[3, 5] In 1980 to 2016, 
overall CS mortality declined across Europe and Central Asia, with the largest decline 
observed in Western European countries, and a plateauing trend was observed for Western 
and Central Europe in the most recent period.[6]  
   
Guidelines for the prevention of CVD recommend assessing the impact of several risk factors 
simultaneously, using risk models that estimate absolute risk.[7, 8] The risk of CVD is 
continuous and multifactorial, i.e. there are modifiable and non-modifiable risk factors that 
act both independently and together. Non-modifiable risk factors include, but are not limited 
to, age, sex, and family history of premature CHD. Modifiable CVD risk factors include 
behavioural factors such as tobacco use, alcohol consumption, diet, and physical activity, and 
markers in blood e.g. lipids, including low-density lipoprotein (LDL), high-density 
lipoprotein (HDL) cholesterol, non-HDL cholesterol, triglycerides, and total cholesterol; 
hypertension; obesity; and diabetes.[9] In high-income countries, more than 60% of population 
attributable risk for CVD were due to behavioural risk factors and markers in blood.[9] 
Hypertension, hyperlipidaemia, smoking, and diabetes are considered to be conventional 
cardiovascular risk factors,[10] or sometimes referred to as termed as traditional cardiovascular 
 
2 
risk factors together with age and sex.[11] In this thesis, the factors included in the NORRISK 
2 model[12] (section 1.3) are termed ‘conventional risk factors’ and refers to triglycerides, 
HDL cholesterol, total cholesterol, systolic and diastolic blood pressure (SBP and DBP), use 
of antihypertensive medication, smoking, and family history of premature CHD disease.   
 
The Sami are the indigenous population in Norway. However, the Sami people also live in 
Sweden, Finland, and the Kola Peninsula in the Russian Federation. Internationally, 
indigenous populations experience poorer health outcomes and have a shorter life expectancy 
than their reference populations, which is often the majority population in the country or 
region.[13, 14] The region of the Sami Parliament subsidy schemes for business development 
has been used as a surrogate measure for being Sami,[15] and in 2013, this region had 1.6 
fewer years of life expectancy at birth than the rest of the Norwegian population.[13] However, 
the subsidy region comprise a mixed-ethnic population including Sami, Norwegians, and 
Kven, who are descendants of Finnish-speaking people that came from Sweden and Finland 
in the 1700s and 1800s.[16] There are no studies comparing life expectancy in Sami and their 
reference population (hereafter referred to as non-Sami) using individual-level data. There is 
still some uncertainty as to whether Sami in Norway have similar or poorer cardiovascular 
health than non-Sami, as previous studies show small to no differences [17-22] in conventional 
risk factors. The incidence of CHD has been found to be similar in Sami and non-Sami,[23] 
whereas studies on CVD mortality show contradicting results.[24, 25] Incidence of and mortality 
from CS have been reported to be similar [26] and higher,[25] in Sami compared to non-Sami 
populations in Norway. Therefore, there is still a need to monitor conventional risk factors in 
Sami and compare them to their non-Sami counterparts. Also, there is a need for a better 
understanding of the associations between Sami ethnicity and cardiovascular health that calls 
for more research on this topic.  
 
3 
1.1 Cardiovascular disease  
CVD is a diseases of the circulatory system, which includes the heart and the blood vessels. 
Common to some CVD is the underlying pathological process known as atherosclerosis, and 
conventional risk factors contribute to the formation of atherosclerosis. This thesis concerns 
descriptive epidemiology of conventional risk factors and the risk, i.e. fatal or non-fatal, of 
two groups of CVD: CHD, which is defined by International Statistical Classification of 
Diseases and Related Health Problems, the 10th revision (ICD-10) [27] codes I20–I25, and 
include acute myocardial infarction (AMI) and subsequent myocardial infarction, defined by 
ICD-10 codes I21–I22; and CS, which in this thesis comprises bleedings defined by ICD-10 
codes I60–I61, and infarctions and unspecified strokes, defined by ICD-10 codes I63–I64, but 
not ICD-10 code I63.6 that represents cerebral infraction due to cerebral venous thrombosis, 
non-pyogenic. The defined endpoint included in this thesis are the same as used in the 
NORRISK 2 model [12] (section 1.3).       
 
Epidemiology of cardiovascular disease in Norway 
Since the 1970s, there has been a constant decline in CVD mortality in Norway (Figure 1), 
which has been reflected by a decline in mortality from CHD and CS (Figures 2 and 3). 
Northern Norway have from 1970s and up till today consistently shown a higher CVD 




Figure 1. Age-standardised mortality rates per 100,000 of cardiovascular disease in men and women in 
Norway and in health region North (constituting the counties Finnmark and Troms, and Nordland) 
from 1970 to 2018. Source: Cause of Death Registry, Norwegian Institute of Public Health. 
 
 
Figure 2. Age-standardised mortality rates per 100,000 of coronary heart disease and stroke in men in 
Norway and in health region North (constituting the counties Finnmark and Troms, and Nordland) 
from 1994 to 2018. Coronary heart disease include the International Statistical Classification of 
Diseases and Related Health Problems, the 10th Revision (ICD-10) codes: I20–I25, which 
corresponds to the definition used in this thesis. Strokes includes the ICD-10 codes: I61, I63, and I64, 
which is different from the definition of cerebral stroke in this thesis, as it does not include 
subarachnoid haemorrhage (ICD-10 code I60). Source: Cause of Death Registry, Norwegian Institute 





Figure 3. Age-standardised mortality rates per 100,000, of coronary heart disease and stroke in women 
in Norway and in health region North (constituting the counties Finnmark and Troms, and Nordland) 
from 1994 to 2018. Coronary heart diseases include the International Statistical Classification of 
Diseases and Related Health Problems, the 10th Revision (ICD-10) codes: I20–I25, which 
corresponds to the definition used in this thesis. Stroke includes the ICD-10 codes: I61,I63, and I64, 
which is different from the definition of cerebral stroke in this thesis, as it does not include 
subarachnoid haemorrhage (ICD-10 code I60). Source: Cause of Death Registry, Norwegian Institute 
of Public Health. 
 
The aforementioned decline in mortality of CVD coincided with a decrease in conventional 
risk factors and an improvement in treatment, both medical and surgical. In 2001–2014, there 
was an annual decline in the incidence of AMI in those aged 25–85 years, which was 
attributable to a greater decline in CHD mortality than to AMI hospitalisations.[28] A similar 
decline was observed in hospitalisation rates of and mortality from CHD in 1995–2010 in the 
Tromsø Study, which is a population-based cohort study that includes the adult population of 
the municipality Tromsø in Northern Norway, and has been repeated seven times since 1974. 
[29] In the Tromsø Study, a favourable decline in modifiable risk factors accounted for 66% of 
the total decline in the incidence of CHD; total cholesterol, blood pressure, smoking, and 
physical inactivity contributed the most.[29] In 2001–2014, preliminary results in Norway 
suggested that there was a 20% decline in the age-standardised incidence rate of all CS in 
those aged >45 years, whereas an annual 2% increase in ischemic stroke (IS) and 
haemorrhagic stroke was observed in men aged 22–44 years and >85 years, respectively.[30] In 
1995–2010 in the Tromsø Study,[31] an overall 24% absolute decline in the incidence of IS 
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was observed, and changes in modifiable risk factors accounted for 57% of this decline, 
wherein a decline in SBP and the prevalence of smoking contributed the most.[32]  
 
Atherosclerosis 
The underlying pathophysiology of CVD is complex. For CHD and many CS types, it is 
caused by atherosclerosis.[33, 34] Atherosclerosis is a chronic inflammatory condition, in which 
the arterial walls are stiffened and thickened due to a gradual accumulation of lipids and 
fibrous elements that creates a lesion known as plaque.[33] Atherosclerotic lesions lead to a 
narrowing of the arterial vessel lumen and a lower oxygen supply to the heart, brain, or 
extremities, which may cause an ischemic condition in the tissue. Atherosclerosis might be 
viewed as a biological response to an injury in the arterial endothelium, or as an endothelial 
dysfunction, to which the body reacts with complex mechanisms. Endothelial dysfunction 
leads to a destruction of the different layers in the vessel wall, which enables lipids and 
leucocytes to enter the sub-endothelium. This starts a cascade of reactions, including the 
formation of foam-cells (high content of lipids) and the migration of smooth muscle cells into 
the sub-endothelium, and the release of inflammation factors that further facilitates the 
passage of lipids and leucocytes into the sub-endothelium.[35] The damaged endothelia is 
coved by a fibrous cap that keeps the plaque content separate from the blood stream. New 
blood vessels supply the lesion with blood, but these immature vessels are fragile; if they 
rupture, bleeding will occur within the plaque and increase the size of the lesion, which can 
make it unstable. The death of macrophages within the plaque and necrosis of the plaque core 
can contribute to further instability.[35] The formation of plaque by atherosclerosis may take 
decades and may be accelerated by cycles of haemorrhage, erosion, or disruption of the 
plaque. Atherosclerosis can cause an acute condition if the plaque increases to the size of the 
arterial vessel lumen, due to erosion or rupture of the plaque that forms a thrombus (i.e., blood 
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clot) that flows with the blood stream and cause a blockage in small passages, or due to a 
bleeding in the plaque that activates thrombocytes and the coagulation system to create a 
blood clot that increases the plaque size (Figure 4).[36] Conventional risk factors such as 
cholesterol and smoking [37] initiate and contribute to the progression of injury or dysfunction. 
The associations between different conventional risk factors and CVD differ by CVD type. 
For example, total cholesterol seems to be more important in AMI than CS.[29, 32] However, 
the strength of association between a risk factor and CHD [38] or CS [39] is independent of 
whether these conditions lead to morbidity or mortality.  
 
 
Coronary heart diseases 
CHD is an umbrella term for diseases affecting the coronary arteries. The coronary arteries 
are the heart’s own arteries; they supply heart muscle cells with blood and oxygen. The 
narrowing of the coronary arteries by atherosclerosis and subsequently plaque may be partial 
or complete and acute or chronic, giving rise to several coronary syndromes, such as angina 
pectoris and AMI. Angina pectoris is a condition caused by atherosclerosis in the coronary 
arteries and defined by episodic symptoms of myocardial ischemia (e.g. chest paint), often 
due to an increase in the heart’s oxygen demand (e.g. walking uphill), but which subsides 
typically with rest or nitroglycerine administration and causes no permanent damage to the 
Figure 4. Atherosclerosis and acute 
ischemic event. Upper left, blood flow is 
reduced because of atherosclerosis, which 
forms a lesion known as plaque. The plaque 
causes a narrowing of the artery. Upper 
right: A complete densification of the 
artery, which causes an acute condition. 
Lower left: A rupture of a plaque, which 
creates a blood clot that enters the blood 
flow. The rupture also causes haemorrhage 
that enlarges the plaque. Lower right: a 
blood clot (due to erosion of a plaque) 
enters a small passage and cause a blockage, 
or the haemorrhage cause an enlargement of 
the plague that completely blocks the artery 




tissue.[40] AMI is an acute, life-threatening condition caused by a sudden lack of oxygen 
supply to the heart muscle, most often due to plaque rupture and thrombus formation in one or 
several coronary arteries, causing tissue damage. CHD can be treated both medically (e.g. 
platelet inhibitors, statins, beta-blockers) and surgically (e.g. percutaneous coronary 




CS is an umbrella term for cerebral conditions defined by lack of oxygen in the brain tissue, 
where the two main causes are thromboembolic ischemia (i.e. IS) and haemorrhage (i.e. 
haemorrhagic stroke). Among the different CS types, IS accounts for 80–85%. The rest are 
due to haemorrhagic strokes or bleedings,[42] which can either be intracerebral (10–12%) or 
subarachnoid (3%), depending on the location of the bleeding. Both bleedings and infarctions 
are acute conditions where the supply of oxygen to the brain is reduced, which causes a 
cellular hypoxia and ultimately, if left untreated, cell death. IS and haemorrhagic stroke have 
different aetiology. Haemorrhagic stroke occurs when there is a rupture of the vessel wall that 
causes bleeding, whereas IS is due to an occlusion of the arteries [34] as a consequence of 
atherosclerosis or formation of clot. As the aetiology of haemorrhagic and IS varies,[42] they 
have differing risk profiles and treatments. IS is most often a consequence of the 
atherosclerotic process and blood clot formation, with its conventional risk factors, whereas 
hypertension, aneurysms, and malformations are strong risk factors of haemorrhagic 
stroke.[34] The blood clot causing IS may be located in arteries within the brain or outside the 
brain. A blood clot may also travel with the blood stream up to the brain and cause blockage 
of the blood supply, causing ischemia. This is termed an embolus, and hence an embolic 
ischemic stroke. The embolus may be formed in arteries outside the brain or within the 
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chambers of the heart.[34] Atrial fibrillation is a common cause of clot formation in the heart, 
and is associated with a 2–5 fold increased risk of CS.[43] IS is treated with drugs that dissolve 
the blood clot or by platelet inhibitors; haemorrhagic stroke is an absolute contraindication of 
such treatment, and treatment relies mostly on hypertension control and supportive care.[34] 
Haemorrhagic strokes seems to have a higher mortality than ischemic strokes.[44] 
 
1.2 Risk factors for cardiovascular disease 
1.2.1 Modifiable risk factors 
 
Lipids 
Total cholesterol is positively associated with CHD incidence and mortality in both sexes, and 
this association decreases with age.[45, 46] An absolute reduction in total cholesterol is 
associated with a proportional decrease in the incidence of CHD, and this reduction may yield 
a larger decrease in incidence in younger than older adults.[46] Some studies have suggested 
that elevated total cholesterol is a more important risk factor for CHD [29] than for CS,[12, 45] 
whereas for CS, hypertension might be more important.[9, 47] However, the associations 
between total cholesterol and the risk of all CS types as a group might be less evident in 
studies because the aetiology of CS types differs.[48] 
 
There is an inverse relationship between triglycerides and HDL cholesterol.[49] Low levels of 
HDL cholesterol is regarded as a risk factor for CVD, but how it is related to CVD remains 
uncertain.[49] The combination of low levels of HDL cholesterol and high levels of 
triglycerides are markers of a lipid profile (metabolic syndrome and insulin resistance) with 
an increased risk of CVD.[7, 8] The independent impact of triglycerides on CVD and their 
causal relationship is uncertain.[50, 51] Nevertheless, high levels of triglycerides are markers of 
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increased CVD risk, [51] because they are indicators of remnants that are rich in cholesterol, 
which contributes to plaque formation within the arterial endothelium.[50]  
 
Blood pressure 
Independent of age, SBP and DBP are positively associated with CHD and CS mortality, 
although different thresholds have been observed for when SBP or DBP starts to be positively 
associated.[52] Age interacts with blood pressure in fatal CS and all-cause mortality.[52] For 
example, in young adults (>19 years), elevated DBP seems to be a more important risk factor 
for CS mortality than elevated SBP, whereas with increasing age, SBP becomes more 
important than DBP.[52] With respect to the incidence of AMI, IS and CS, the risk increases 
with increasing SBP or DBP, although the association attenuates with increasing age.[47]  
 
Hypertension 
Hypertension is commonly defined as SBP ≥140 mmHg, DBP ≥90 mmHg, or current use of 
antihypertensive medications.[53] Hypertension is associated with an elevated risk of AMI, IS, 
and CS when compared to those with normal blood pressure,[47] and it is a more important 
risk factor for CS than for CHD.[9, 47] Use of antihypertensive medications that lower SBP by 
10 mmHg is estimated to lower the risk of fatal or non-fatal CHD events by approximately 
17%, CS by 27%, major CVD events by 20%, and all-cause mortality by 13%, irrespective of 
baseline SBP or comorbidities.[54] Although the goal of medical treatment of hypertension is 
often to achieve a SBP of <140 mmHg, some studies have suggested that the benefit or 
absolute risk reduction is larger if the target is <130 mmHg.[55] Also, the risk reduction in 
lowering SBP seems to be greater as the absolute risk for CVD increases, which implies that 
individuals at the highest risk (e.g. those with characteristics that are associated with elevated 




The risk of fatal and non-fatal AMI and most variants of CS is more than two-fold in current 
smokers compared to never smokers.[57, 58] Former smokers seem to have an elevated lifetime 
risk of CVD compared to never smokers, and this risk decreases with increasing number of 
years since cessation.[37, 39, 58] Second-hand smoking seems to increase the risk in a dose-
dependent way,[59] where the risk rises with increasing exposure. Smoking is suggested to be 
more detrimental for women than men (RR=1.25 for women vs. men) in relation to fatal or 
non-fatal CHD.[60]   
 
Obesity 
Obesity is a condition of excess adipose tissue. Body mass index (BMI, a person’s weight in 
kilograms divided by the square of height in meters) and waist circumference are measures of 
body fatness. General obesity is defined as BMI ≥30 kg/m2,[61] whereas abdominal obesity is 
often defined as waist circumference >88 cm for women and >102 cm for men.[62, 63] 
Abdominal obesity is associated with an elevated risk of CHD and CS, but the association 
decreases with increasing age.[64] The effect of high body mass index on CHD and CS may be 
mediated by increases in total cholesterol, SBP, and glucose.[65] BMI or waist circumference 
do not seem to improve risk prediction when conventional risk factors are included in the risk 
models.[64]  
 
Type 2 diabetes  
Type 2 diabetes is a chronic lifestyle-related disease comprising peripheral tissue insulin 
resistance and progressively reduced insulin production in the pancreas, leading to increases 
in levels of blood glucose.[66] Type 2 diabetes is associated with end-organ damage in tissues 
in the heart, brain, kidney, nerves and retina, due to pathology in both large and small vessels. 
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Individuals with type 2 diabetes have an approximately 2-fold increase in the risk of CHD and 
CS compared to individuals without type 2 diabetes.[67] In Norway in 2009–2014, the 
incidence of type 2 diabetes declined by an average of 10.1% each year, whereas the 
prevalence have increased probably due to diagnosis at younger ages and increased 
longevity.[68] Type 2 diabetes is positively associated with obesity.[69] 
 
1.2.2 Non-modifiable risk factors  
Age and sex 
Age is the single most important risk factor for CVD.[70] After the age of 55 years, for each 
10-year increase in age, the incidence rate of CS more than doubles in both sexes.[70] Meta-
analyses suggest that the risk of CS among men is 1.3 times that in women.[71] Data from the 
Global Burden of Disease Study showed that the incidence of IS was higher in men than in 
women in 2013, and the sex gap increased in 1990–2013 due to a deceasing trend of IS in 
women in this period.[72] Men also have a risk of AMI that is twice that in women, even after 
adjustment for risk factors that confound the relationship between sex and AMI. Still, the 
relative sex gap for AMI decreases with age.[73]  
 
Family history of coronary heart disease   
Family history of premature CHD or CS are risk factors for and predictors of future risk of 
CVD.[74] In this thesis, we focused on family history of premature CHD in first-degree 
relatives. The age at which CHD is considered premature varies by study and sex.[7, 75] 
According to the the Norwegian guidelines for the primary prevention of CVD, a family 
history of premature CHD is present if CHD occurred in a family member before the age of 
60 years,[8] which is the threshold that we have applied in Paper 3. The risk of CHD or CS 
also seems to be dependent on the number of relatives affected, and it has been questioned 
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whether the increased risk is due to a genetic component or to shared lifestyles. A previous 
study have shown that the prevalence of CS was about four times higher in mono- than 
dizygotic twins,[76] which supports the hypothesis of a genetic component in the aetiology of 
CS.[42] In one study in Norway, self-reported history of premature AMI in one or both parents, 
or in one or more siblings was associated with elevated CHD mortality in men when 
compared to those with no family history.[77] In women, a history of premature AMI in 
siblings, or in both parents and siblings, was in that study associated with higher mortality of 
CHD.[77] The risk estimations were modestly attenuated when adjusting for conventional risk 
factors, and a subsequent adjustment for socioeconomic status had no impact.  
 
Adult height 
There are studies showing that height is inversely associated with the risk of CHD [78-81]  and 
CS [78, 79] in both sexes; however, there are also studies that have found no association.[81, 82] 
Researchers have questioned whether the effect of height on CHD and CS is due to the 
association with certain genes or due to being a marker of unfavourable environment.  
 
Approximately 60–90% [83, 84] of height is heritable, and the genetic contribution of height is 
the result of small contributions from many genes,[85] which is why it is a considered to be a 
polygenetic trait. Genetic studies have found a link between genes associated with adult 
height and genes that code for adverse lipid profiles,[80, 81] blood pressure [80] and 
hypertension,[78] and factors involved in the formation of atherosclerosis.[80] Others have 
suggested that the effect of height on CHD is mediated by lung capacity.[86] But despite this, 
height is considered to be a surrogate measure for environmental exposures like nutrition and 
diseases in childhood,[87, 88] socioeconomic conditions during childhood,[89] and conditions in 
foetal life.[90, 91] The average height in Europe increased from 1850 to 1980, most likely due to 
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improvements in environmental factors.[92] The average height of Norwegian conscripts 
increased from 1900 to 1980, but conscripts from Northern Norway have consistently had a 
lower average height than conscripts in Mid and Southern Norway.[93, 94] These studies 
suggest that, with respect to population height, environmental factors might be more 
important than genetics, as the average population height has increased in accordance with 
improvement in living conditions. It seems that genetics determine the potential for height in 
an individual, whereas environment factors determine the actual attained height. 
 
1.3 Risk models 
Risk models for predicting future risk of CVD have been developed because the risk of CVD 
is multifactorial and not only dependent on single risk factors, and each risk factor contribute 
to risk with different weights.[95] The levels of single risk factors might be rather low, but the 
cumulative contribution of several risk factors might put an individual at high absolute risk. 
The Norwegian guidelines for the primary prevention of CVD [8] recommend using the 
NORRISK 2 risk model to estimate the absolute 10-year risk of fatal or non-fatal AMI or CS 
combined. NORRISK 2 is a Norwegian risk model,[12] available at 
http://hjerterisiko.helsedirektoratet.no/. It estimates the absolute 10-year risk as a probability 
(percentage) based on sex, age, and the following conventional risk factors HDL cholesterol, 
total cholesterol, SBP, use of antihypertensive medications, smoking status, and history of 




Figure 5. The NORRISK 2 risk chart. The chart show 10-year risk of acute myocardial infarction or 
cerebral stroke in percentages, in men and women with high-density lipoprotein (HDL)-cholesterol 
>1.0 mmol/L and 1.3 mmol/L, respectively, currently not taking antihypertensive medication, and with 
no family history of premature CHD (i.e., occurring before the age of 60 years).[12] Republished with 
permission of SAGE Publications, from Selmer R, Igland J, Ariansen I, Tverdal A, Njølstad I, Furu K, 
et al. NORRISK 2: A Norwegian risk model for acute cerebral stroke and myocardial infarction. Eur J 
Prev Cardiol 2017; 24: 773-782; permission conveyed through Copyright Clearance Center.     
 
The intention of the risk model is to identify individuals at high 10-year risk who need to 
lower their risk by initiating use of medications or lifestyle changes.[12] The risk model 
identifies individuals at high risk defined according to the following age-specific thresholds: 
≥5% risk in the age group 45–54 years, ≥10% risk in the age group 55–64 years, and ≥15% 
risk in the age groups 65–74 years.[12] Thus, the model is a tool for medical doctors to help 
them evaluate when to start an intervention. The risk chart (Figure 5) can also help medical 
doctors to convey information to patients about the benefits from risk reduction from for 




Briefly, NORRISK 2 is designed by using information from the Cardiovascular Disease in 
Norway (CVDNOR) project.[12] The project have collected baseline information from 
population-based studies (questionnaires, clinical examinations and blood samples) conducted 
in Norway in 1994–1999. Participants’ records were then linked to national hospital records 
and to the Cause of Death Registry for information on main or secondary discharge diagnoses 
and underlying cause of death, respectively.[96] To the development of NORRISK 2, 
participants aged 40–79 years that were free of angina pectoris, AMI, or CS, were followed 
from 1994 to 2009 for first occurrence of AMI or CS, which included either hospitalisations 
(non-fatal cases) or deaths (fatal cases). Fatal or non-fatal AMI was defined by the ICD-10 
codes I20–I25 (all CHD) and I21–I22 (AMI and subsequent myocardial infarction), 
respectively. Fatal or non-fatal CS was defined by the ICD-10 codes I60–61 (subarachnoid 
and intracerebral haemorrhage) and I63–64 (cerebral infarction and unspecified stroke), 
except I63.6 (cerebral infarction due to cerebral venous thrombosis, non-pyogenic). 
NORRISK 2 was designed using the cumulative incidence function, which takes into 
consideration competing risks, in this case, deaths from other causes. NORRISK 2 was 
validated using regional health surveys from Norway, carried out in 2000–2003. The 
validation showed overall good agreement between the predicted and observed 10-year risk of 
AMI or CS, although somewhat poorer agreement with increasing age, possibly due to an 
increase of comorbidities with age.[12] 
 
There are country and region-specific risk models that estimate the absolute 5- or 10-year risk 
of fatal or non-fatal CVD, or both, and models that are disease-specific or predict a composite 
endpoint. The risk models are based on national-specific CVD mortality and morbidity rates, 
sex and age distributions, and the prevalence of conventional risk factors.[12, 97-101] The risk 
models may differ in which age ranges they are applicable to, and in which additional risk 
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factors are included, such as HDL cholesterol, diabetes and family history of premature 
CHD.[12, 97, 98, 101] There are some conditions listed in the guidelines that elevate the estimated 
risk, and these should be taken into account: South-Asian ethnicity, rheumatoid arthritis, 
abdominal obesity, psychosocial stress, and depression/medically-treated psychotic 
disorders.[7, 8] South-Asian ethnicity is associated with a different phenotype for fat 
distribution that makes them more susceptible to insulin resistance and type 2 diabetes at 
lower BMI levels than other ethnic groups.[102] This, in turn, puts them at increased risk of 
CVD[103-105] and is the reason why their 10-year risk estimation has been suggested to be 
multiplied by 1.5. For rheumatoid arthritis, it is recommended to multiply the estimated 10-
year risk by 1.4, whereas for the other conditions, no such factors are specified.[7, 8] 
 
1.4 Cardiovascular disease in Sami compared to non-Sami 
In this overview on the risk of CVD in Sami compared to their non-Sami reference 
population, I have included studies from Norway, Sweden, and Finland. Incidence refers to 
the first occurrence, whether the outcome is hospitalisation or death, thus studies including 
both outcomes are of relevance.  
 
Acute myocardial infarction and coronary heart disease in Sami 
A rather similar incidence of AMI have been observed in Sami and non-Sami populations in 
the previous Finnmark County (per date merged with Troms County into Troms and 
Finnmark County) in 1974/75–1989.[23] Using individual data from the previous Finnmark 
County collected in roughly the same period, Sami men had lower mortality rates for CHD, 
CVD, and somewhat lower for total deaths than non-Sami men in adjusted models, whereas 
similar risks were observed in women.[24] A study in 1970–1989 linked census data to Cause 
of Death Registry in Norway and found a somewhat higher CHD, CVD and total mortality in 
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Sami than in their non-Sami reference population.[25] An assumed higher consumption of 
reindeer meat was associated with lower CHD mortality in Sami men and CVD mortality in 
Sami women in Northern Norway in 1970–1998.[25]  
 
In Sweden, a sample of Sami was constructed by linkage to registries, and individuals were 
followed in 1961–2000 [106] and in 1985–2002.[107] Similar incidence of AMI have been 
observed in Sami and their demographical matched reference population in Sweden in 1985–
2002,[107] but a higher CHD mortality was observed in Sami women in Sweden in 1961–2000, 
except in reindeer herding women,[106, 107] who had lower incidence of AMI than their 
demographical matched reference population in 1985–2002.[107] Sami men had similar CHD 
mortality as their demographically-matched reference population.[106, 107] Sami in Finland had 
lower CHD mortality in 1961–1990 compared to a district representing the Finnish 
population,[108] whereas in 1974–2005, Sami men had similar and Sami women lower CHD 
mortality [109] than their non-Sami counterparts.  
 
Cerebral stroke in Sami 
A similar,[26] or possibly higher incidence of CS was found in Sami when compared to non-
Sami living in the previous Finnmark County in 1974–1989,[23] and a higher incidence of CS 
was observed in men with a mixed Sami and Finnish background.[26] These studies were 
stratified into sex and ethnic groups, resulting in groups of small numbers and consequently 
low precision in the estimates. In Northern Norway, Sami men and women had higher CS 
mortality in 1970–1989 than their demographical matched reference population.[25] A trend of 
lower CS mortality was observed in Sami men as their assumed consumption of reindeer meat 
increased. A lower CVD mortality trend was observed in Sami women and men with an 
assumed higher consumption of reindeer meat.[25] In Sweden in 1961–2002, the incidence of 
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CS and subarachnoid haemorrhage among Sami was overall higher than in their 
demographically-matched reference population.[107] Mortality of CS in Sami and their non-
Sami counterpart was found to be similar in Sweden in 1985–2002 [107] and Finland in 1979–
2005,[109] whereas the mortality of subarachnoid haemorrhage were similar [107] or higher [106] 
in Sami in Sweden compared to their demographically-matched reference population in 
1961–2002. However, lower incidence of CS was observed in Swedish Sami men with 
associations to reindeer herding compared with their demographically-matched reference 
population in 1985–2002.[107] Sami women in Sweden with an association to reindeer herding 
had a higher incidence of CS and subarachnoid haemorrhage in 1985–2002,[107] and had 
higher mortality of CS compared to the Swedish population in 1961–1985.[110] In Sweden in 
1961–2000, CVD mortality was overall higher in Sami than non-Sami women.[106]  
 
Incidence of acute myocardial infarction or cerebral stroke in Sami 
The studies on risk of CHD and CS from Finland and Sweden are of more recent years 
compared to the studies conducted in Norway, which might makes them more relevant. It may 
be acceptable to compare incidence and mortality in Sami in Finland and Sweden with that in 
Norway, as all the countries have universal access to healthcare and higher education. Also, in 
Norway and Sweden, reindeer herding is a culturally specific trade engaged by only Sami 
individuals, which suggests that reindeer herding is a reliable marker of Sami ethnicity in 
these countries.[111] Moreover, all countries have their own Sami Parliaments, but only 
Norway has ratified the ILO Convention No.169 that imposes obligations and expectations on 
the government in terms of protection of indigenous rights.[112] Despite these similarities, 
careful comparisons are warranted as the studies vary by design, time-period, and study 
setting (different countries), and because Sami ethnicity is defined differently in these studies. 
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Also, the relative risks were small and some studies have low precision, which overall makes 
it uncertain if the risk of AMI and CS differ by ethnicity. 
 
1.5 Risk factors in Sami compared to non-Sami 
In this overview of conventional risk factors in Sami, we have included studies from Norway 
and Finland (only men), and one from Sweden. The studies compare risk factors in Sami to 
their non-Sami reference populations that live either in the same municipality or in a region 
close by. The associations between non-modifiable risk factors, such as age and sex, and 
CVD most likely do not differ by ethnicity; however, studies concerning family history of 
CHD and adult height have been included, as there has been speculation as to whether Sami 
are protected from CVD through their diet [113] or genetically.[24]  
 
Lipids 
Overall similar levels of triglycerides, HDL cholesterol, and LDL cholesterol, with the 
exception of some small differences in single studies, have been observed in Sami and non-
Sami men in Northern Norway, in Sweden, and in Finland.[19, 113-117] In the SAMINOR 1 
Survey (SAMINOR 1), which was conducted in 2003–2004 and included individuals aged 30 
and 36–79 years, small differences in lipids that varied by age were observed. Sami men and 
women aged 36–49 years had higher mean levels of total cholesterol than Norwegians, 
whereas Sami women aged 65–79 years had lower mean levels than their non-Sami 
counterparts.[19] Sami women aged 36–49 years also had the highest mean levels of 
triglycerides, and Sami women aged 50–64 years had lowest mean levels of HDL cholesterol 
compared to Norwegians and Kven.[19] Use of lipid-lowering medications was similar in Sami 




Blood pressure and hypertension 
In a study from previous Finnmark County carried out in the 1970s, Sami men aged 20–49 
years had a statistically significantly lower SBP than non-Sami,[119] whereas no differences 
were observed in women. Later studies, including SAMINOR 1, have found a similar DBP, 
and a similar or somewhat lower SBP in Sami compared with non-Sami.[19, 116, 117] In the 
study from Finnmark County carried out in 1974–1975, use of antihypertensive medications 
was higher in Sami than in Finnish and Norwegian women, whereas the opposite was 
observed in men.[23]  
 
Smoking 
Some studies have observed no differences in smoking habits between Sami and non-
Sami,[114, 116, 117] whereas others have observed that Sami women smoke less than non-Sami 
women.[19, 23]  
 
Obesity 
In SAMINOR 1, Sami women who reported that they themselves, both parents and all four 
grandparents spoke Sami at home had more often a BMI ≥30 kg/m2, a waist circumference 
≥88 cm, and a waist-to-hip ratio >0.85 than Norwegians, whereas fewer Sami than 
Norwegians men had a waist circumference ≥102 cm.[17] Other studies have also observed a 
tendency towards a higher prevalence of obesity in Sami women.[23, 114]  
 
Type 2 diabetes  
Similar prevalence of type 2 diabetes were observed in Sami and non-Sami in both 
SAMINOR 1 and the SAMINOR 2 Clinical Survey (SAMINOR 2), carried out in 2012–2014. 
when diabetes was defined based on self-report or random plasma glucose with cut-off of 7.5 
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mmol/L or above,[120] and when combining self-reported diabetes status and medication use 
(SAMINOR 1).[121] When using glycated haemoglobin with a cut-off of 6.5% in SAMINOR 
2, a higher prevalence was observed in Sami than non-Sami, and waist-to-height ratio 
explained this in women.[20]  
 
Family history of coronary heart diseases  
A doctoral thesis used information collected in the previous Finnmark County in 1974–1988, 
and suggested that Sami and non-Sami populations had similar proportions of family 
members that had history of AMI and angina pectoris.[122] Later, a study including part of the 
same population, found a lower proportions of Sami with a family history of CHD.[114] In 
SAMINOR 1 [118] and in Sweden,[117] a somewhat higher proportion of Sami had a family 
history of AMI and CVD, respectively, when compared to their non-Sami counterparts.  
 
Adult height 
Studies have observed a lower average height in Sami across Norway, Sweden, and Finland 
when compared to their non-Sami reference populations.[17, 24, 116, 117] A possible inverse 
gradient has been observed between height and degree of Sami affiliation, where those with a 
strong Sami language connection (reporting Sami as home language for themselves, both 
parents and all four grandparents) had the lowest height.[17] In a study from 1974 including the 
population in the previous Finnmark County, height was inversely associated with CS, even 
after adjusting for other factors.[26]  
 
Modifiable and non-modifiable risk factors for cardiovascular disease in Sami  
The differences in the modifiable and non-modifiable risk factors listed above are small and 
caution must be applied when considering these results, as they are few, have small sample 
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sizes, are geographically specific, and define Sami ethnicity differently. The somewhat higher 
obesity level in Sami women and the lower stature in Sami seem to be a consistent 
observation. 
 
1.6 Ethnicity as a determinant of cardiovascular disease  
Ethnicity is a socially constructed variable based on shared characteristics like language, 
religion, traditions, diet, ancestry, and common history and origin;[2, 123] it is considered multi-
dimensional and complex[124, 125] and is closely related to the concept of culture.[126] These 
markers of ethnicity might be considered as distinct to each ethnic group, and may be 
associated with different health outcomes. Ethnicity is commonly included as a study variable 
in epidemiological research, where the categorisation of ethnicity has been criticised for being 
imprecise, and self-identification for being fluid.[125] Ethnicity in epidemiology is not viewed 
as a risk factor in itself, but a marker for membership to a group with shared characteristics 
that may be associated with a given disease.[123, 125] That said, an ethnic category is not 
biologically based in contrast to the term race. The term race gives a notion of genetic, 
biological or physical differences that have previously been used to rank some people 
according to races or physical appearance,[127] which also the Sami and Kven populations 
were exposed to.[128-130] The terms race and ethnicity vary by place and time, and have been 
used interchangeable in social sciences.[131] The term race has, however, limited scientific 
values,[131, 132] as there are limited genetic differences between populations. In recent time, it 
has become more common to use the term ethnicity than race in epidemiology.[133]  
 
Social determinants of health  
In order to have an idea of how ethnicity can be related to health, conceptual diagrams for 
social determinants of health (Figure 6) such as the one suggested by Brunner and 
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Marmot,[134] might be applied. Shortly, social determinants of health constitutes the conditions 
or circumstances that people are born into, live in, and grow and age in, and the systems that 
deal with ill health.[135] Brunner and Marmot suggest that factors above and at the individual 
level determine health. Factors above the individual level are social structures, such as 
material factors, work, and the social environment. They influence health behaviours and 
individual psychological factors like stress. However, individual health is also determined by 
early life experiences, as well as genetic and cultural factors throughout one’s life. Finally, the 
social structures vary by location and historical circumstances.[134]  
 
Brunner and Marmot included culture in their conceptual diagram. Kohrt, Hadley and 
Hruschka describe culture to include a set of ‘beliefs, values, norms and behaviour that are 
transmitted through social learning’.[136] Cultural factors influences the way we do things and 
way of thinking, and in a broader perspective the ethnic-specific lifestyle of individuals. As 
for ethnicity,[125] the concept of culture as an explanatory factor for ethnic differences in 
health has been criticised for being crude and simplistic with regards to intra-group 
heterogeneity, and possible inaccurate as researchers often lack a concrete model for how 
culture influence health outcomes.[126, 137] Historical factors that may have influenced the 
ethnic groups differently. In the context of Sami and non-Sami, the governmental assimilation 
process in 1850–1960 known as ‘norwegianisation’ were directed towards the Sami and Kven 
[138] and had political and social consequences [139] in relation to use of Sami language and 
self-determination to own and use geographical regions. Moreover, the Second World War 




Figure 6. Social determinants of health.[134] Republished with permission from Oxford University 
Press, from Brunner E and Marmot M. Social determinants of health. 2nd. ed In: Marmot M and 
Wilkinson RG (eds.) Oxford: Oxford University Press, 2006. Chapter 2, Social organizations, stress, 
and health; p.6-30.; reproduced with permission of the Licensor through PLSclear. 
 
In recent times, the revitalisation and establishing of Sami institutions, such as Sami 
University College, and the Sami Parliament might have strengthened the local Sami 
communities by improving the social structures and social environment in term of political 
acknowledgement and Sami self-determination.[141]  
 
Ethnicity as a determinant of cardiovascular diseases in Arctic indigenous populations 
Due to the lower CHD mortality observed in Sami men in Norway [24] and Finland,[113] 
particularly in with those with an affiliation to reindeer herding,[25] researchers have 
hypothesised that Sami people were protected from CHD due to their diet [113] or by their 
genetics.[24] However, the latter has not been supported by studies on the incidence of AMI 
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and CS in Sami.[23, 25] Also, a similar aetiology of these conditions is assumed in Sami and 
non-Sami, as the relative risks changed in similar directions for the incidence of CS and AMI 
when adjusting for the same variables.[23] There is only one study that have found genetic 
variations in Sami with association to lipid metabolism and consequently CVD. This study 
analysed allele frequencies of apolipoprotein A-IV (a protein associated with lipid 
metabolism) in 71 Sami vs. 177 Finns in northern Finland in 1989, and found a somewhat 
higher allele frequency of apolipoprotein A-IV-2 in Sami.[142] The Sami with this phenotype 
had higher HDL cholesterol levels than Finns with this phenotype, suggesting an effect of the 
lipoprotein allele on HDL cholesterol in Sami but not in Finns. However, overall levels of 
lipids did not differ statistically significantly between the groups.[142] In the 1950s to mid-
1970s, lower CHD mortality was observed in the Greenland Inuit population compared to the 
population in Denmark, and it was suggested that the Inuit populations were protected against 
CHD either genetically,[143] or by their traditional diet, which had high levels of 
polyunsaturated fatty acids.[144] However, a subsequent systematic comparison of risk in 
Arctic Inuit populations showed a similar or lower incidence of and mortality from CHD and 
CVD compared to their reference populations,[145] which challenged the assumed protective 
effect of diet and differences in genetic susceptibility.[146] One recent study indicated a 
possible increased risk of type 2 diabetes in the Greenlandic Inuit population.[147] Moreover, 
the Greenland Inuit population has been found to be genetically distinct from other European 
and East Asian populations, possibly due to their isolation on an island, a generally low 
population size, and periods of high mortality (bottlenecks).[148] This is most likely not the 
case for Sami, although this has been suggested by some.[149] Sami in Norway have had close 
interaction with the Kven and Norwegians over centuries, which may have resulted in more 




It has also been suggested that the transition that indigenous populations have made from a 
traditional lifestyle to a modern or westernised lifestyle, have made them more susceptible for 
lifestyle diseases such as CVD, type 2 diabetes, obesity, and social, physical, and mental 
disorders.[150] Reindeer herding is assumed to represents a more traditional lifestyle with a 
different dietary pattern,[151] with an assumed higher intake of reindeer meat,[25] other 
nutrients (alpha‐tocopherol, albumin and selenium) that may be protective against CHD,[113] 
and higher level of physical activity.[107] On the contrary, one study in Mid Sweden compared 
dietary habits to reindeer herding Sami, non-Sami and historical Sami in 1930s–50s (the latter 
by interview of decedents), and suggests that the traditional Sami diet is the diet consumed by 
present-day reindeer herding Sami and resembles the diet to historical Sami. The traditional 
Sami diet was suggested to consists of high amounts of meat, fatty fish, blood and organ 
dishes, berries, boiled coffee and high in total fat, and low amounts of vegetables, bread and 
fibres,[152] which is in contrast to the nutritional recommendation of low fat content and 
consumption of fibres and vegetables to prevent CVD.[7] However, reindeer herding Sami had 
a higher physical activity level during work than non-herding Sami and non-Sami.[152] In a 
Swedish non-Sami population, the traditional Sami diet was associated with a small non-
beneficial effect on CVD mortality.[153] In SAMINOR 2, Sami ethnicity and inland residency 
rather than coastal residency has been associated with higher consumption of reindeer 
meat,[154] but no ethnic differences were observed in nutritional intake that were likely to give 
differences in health outcomes.[155] Others have suggested that Sami might be more 
susceptible to chronic lifestyle diseases due to ethnic discrimination,[156] acculturation 
processes,[157] and due to being more marginalised and possible chronic stress that 




1.7 Aim of the thesis 
Due to the mentioned shortcomings in the studies on conventional risk factors and the risk of 
AMI or CS in Sami, there is a need for an update. A simplified conceptual framework for this 
thesis is illustrated in Figure 7. The main exposure is Sami ethnicity, which is assumed to be 
associated with a unique language, religion, traditions, diet, ancestry, and common history 
and origin, and a unique set of values, believes, and behaviour. These characteristics may 
translate to a different lifestyle that influence the risk of CVD through conventional risk 
factors and height. As such, adult height and conventional risk factors are intermediate factors 
between the lifestyle and risk of CVD.[158] These intermediate factors can be used to estimate 






The specific aims of this thesis were: 
- To explore whether individual conventional risk factors and the estimated 10-year 
cardiovascular risk based on multiple conventional risk factors (the NORRISK 2 model) 
are similar in Sami and non-Sami populations.  
- To estimate changes in conventional risk factors between two time-points and investigate 
whether these changes differ by ethnicity.   
- To determine and compare the incidence of AMI, CHD, CS, IS, and a composite endpoint 
in Sami and non-Sami populations. 
- If ethnic differences are observed, to identify intermediate factors that may explain 
differences in risks. 
 
    Exposure      Intermediate variables            Outcome 
 
 
     Ethnic-specific lifestyle                    Height, conventional risk factors               Risk of CVD  
 





2.1 The SAMINOR Study 
The SAMINOR Study (the Population-based Study on Health and Living Conditions in 
Regions with Sami and Norwegian Populations) is run by the Centre for Sami Heath Research 
at UiT the Arctic University of Norway. The study consists of three cross-sectional surveys: 
the SAMINOR 1 Survey (SAMINOR 1) conducted in 2003–2004,[159] the SAMINOR 2 
Questionnaire Survey from 2012, and the SAMINOR 2 Clinical Survey (SAMINOR 2) 
conducted in 2012–2014.[160] Paper 1 used information from SAMINOR 2, Paper 2 used 
information from SAMINOR 1 and SAMINOR 2, and Paper 3 is a follow-up of participants 
in SAMINOR 1.  
 
SAMINOR 1 
All individuals aged 30 and 36–78/79 from 24 municipalities (in six municipalities, only the 
population in selected districts were invited), were invited (n=27,987) (see footnotes to Table 
3, and www.saminor.no). In total, 16,865 completed at least one of three questionnaires 
(initial, main, or additional questionnaire) or attended the clinical examinations, which gave a 
response rate of 60.3%.[159] The sampling design of SAMINOR 1 changed after it was 
completed in the municipalities of Kautokeino, Karasjok, Tana, and Nesseby. In these 
municipalities, invitees received an initial questionnaire by mail. They could chose to 
participate in the study by completing the initial questionnaire only, or in addition, agree to be 
invited to the clinical examination. Those who chose to be invited to the clinical examination 
received their appointment information by mail, along with the main questionnaire. This two-
stage invitation procedure led to low attendance to clinical examinations, as only people who 
had returned the initial questionnaire were invited to the clinical examination. Therefore, in 
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these four municipalities, all individuals were invited to the second round of clinical 
examinations, regardless of their response on the initial questionnaire. As a result, some 
attended the clinical examination without completing the initial questionnaire, which included 
questions on ethnic affiliation. In 2006, the initial questionnaire was mailed to those that 
participated in the clinical examination without completing the initial questionnaire, 
increasing the number of completed initial questionnaires. In the subsequent municipalities, 
the initial and main questionnaires were merged (hereafter referred to as screening 
questionnaire), and mailed to the invitees together with a scheduled time for clinical 
examination. At the clinical examination, participants handed in the screening questionnaire 
and completed the additional questionnaire. Four weeks after the examination, participants 
received the results of their clinical measurements. If abnormalities were present, participants 
were recommended to contact their local primary physician. The questionnaires, 
informational brochures, the consent form, and the reminder note (Appendix A), were 
prepared in Norwegian and translated into Northern Sami (available at www.saminor.no). The 
Northern Sami version of the questionnaires was available in the municipalities of 
Kautokeino, Karasjok, Porsanger, Tana, Nesseby, Lyngen, and Kåfjord, but 98% of all 
participants completed the Norwegian version. In Finnmark and Troms County, non-
responders were offered a second chance to participate in the study, which led to a higher 




In SAMINOR 2, invitations were sent to all inhabitants aged 40–79 years residing in 10 
municipalities (n=12,455) (see footnotes to Tables 1 and 2, and available at www.saminor.no) 
of the counties of Finnmark and Troms, and Nordland. Four weeks before clinical data 
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collection started, invitees received a pamphlet (Appendix B), with information on the study 
in Norwegian and in most municipalities also Northern Sami. In the municipalities of 
Porsanger and Storfjord, invitees also received information in the Kven language, whereas in 
the municipalities of Skånland and Evenes, invitees received only the Norwegian version. 
Questionnaires and informational brochures were sent (Appendix B), along with a scheduled 
date for the clinical examination, about 2 weeks before the data collection started in each 
municipality. The questionnaire and informational brochure were prepared in Norwegian and 
translated into Northern Sami. Residents of Porsanger and Storfjord received the 
informational brochure in all three languages; in Skånland and Evenes it was distributed only 
in Norwegian. All participants received the Norwegian version of the questionnaire. The 
Northern Sami translation was sent to participants in the municipalities of Kautokeino, 
Karasjok, Tana, and Nesseby. For the invitees in the municipalities of Kåfjord, Storfjord, and 
Porsanger, the Sami version was available upon request. Participants returned the 
questionnaire at the clinical examination. Less than 5% of all the participants used the Sami 
version of the questionnaires. When the collection was at the halfway point, a reminder was 
posted to the invitees who had not yet participated. In total of 6,004 agreed to participate, 
completed the questionnaires and attended the clinical examination, which gave a response 
rate of 48.2%.[160] 
 
2.2 Clinical examination 
The clinical examinations are described in detail in the papers. Briefly, in both surveys, the 
clinical examination included measures of blood pressure, weight, height, and waist 
circumference. Triglycerides, HDL cholesterol, total cholesterol, glucose, and glycated 
haemoglobin (the latter only in SAMINOR 2) were measured in non-fasting blood samples. In 
SAMINOR 1, the clinical examinations took place in buses placed at central locations in the 
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municipalities for 1–18 weeks, depending on the population size of the municipality (in the 
municipalities included in Paper 2 buses were placed for 1–6 weeks), and were conducted by 
trained personnel from the National Health Screening Service. In SAMINOR 2, rooms were 
rented in central locations in each municipality, and the clinical examinations were conducted 
within 2–7 weeks. Certified health workers primarily from the local community, were 
employed as temporarily fieldworkers and trained to perform the clinical examinations.  
 
2.3  Ethnicity: main exposure 
There is no registry of Sami ethnicity in Norway, as information about ethnicity is regarded as 
sensitive,[161] and it is prohibited to include in official registries. Therefore, in health surveys 
in Norway, information on ethnicity is usually obtained through self-reporting. Sami ethnicity 
was categorised similarly in Papers 1–3. Questions related to ethnicity (in total 11) were 
phrased identically in SAMINOR 1 and 2, with multiple options (Norwegian, Kven, Sami or 
‘other’, specify) that could be ticked for each question. We used nine of the 11 questions 
related to ethnicity for our categorisations. To be categorised as Sami, two criteria had to be 
met: Self-definition as a Sami in addition to a Sami language connection. That is, participants 
had to 1) report either Sami ethnic background for themselves, or 2) consider themselves to be 
Sami. In addition, 3) Sami had to be spoken at home by the respondent him/herself, 4–5) by 
one of his/her parents, or 6–9) by one of his/her grandparents. Two additional question related 
to ethnicity, 10) ethnic background to father and 11) mother were not included in the main 
analyses, but used in sensitivity analyses regarding ethnic categorisation. All those that did 
not fulfil the two criteria for Sami ethnicity were categorised as non-Sami. That included: 
participants who reported Kven, Norwegian, or ‘other’ as their ethnic background, and 
considered themselves as any of these; and participants who reported Sami on some of the 
questions, but did not fulfil both criteria for Sami ethnicity. Moreover, those who were 
categorised as Sami may have reported multiple ethnic backgrounds or self-perceived 
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ethnicities, such as Kven, Norwegian, or other in addition to Sami. Participants with missing 
information on ethnicity were excluded in the analytical sample of Paper 1–3. 
 
2.4 Paper 1 
2.4.1 Study sample 
The 10-year risk of fatal or non-fatal AMI or CS was estimated for participants in SAMINOR 
2. The 10-year risk was based on sex, age, and the conventional risk factors included in the 
NORRISK 2 (HDL cholesterol, total cholesterol, SPB, use of antihypertensive medication, 
and smoking status) except family history of premature CHD, which was not available in 
SAMINOR 2. Figure 8 shows who were excluded from the analytical sample, and Table 1 
shows some sample characteristics in those invited, in those who participated in clinical 
examination, and in final analytical sample. South-Asian ethnicity was not considered 
specifically in Paper 1, however, less than 6% of the study sample reported that they 
considered themselves as ‘other’ in addition to Sami, Kven or Norwegian. Thus, South-Asian 
ethnicity most likely does not influence the estimations in any of the ethnic groups. 
Additionally, rheumatoid arthritis, depression/medically-treated psychotic disorders, and 
























Figure 8. Flow chart for Paper 1 showing exclusions from the SAMINOR 2 sample. Abbreviations n: 
number, SBP: systolic blood pressure. 
  
n=6,004 (48.2%) participated and consented to be part of medical research 
n=2,169 Sami  n=3,149 non-Sami  
21 excluded for not answering the 
questionnaire  
n=5,983 








26 excluded due to missing values for total 
cholesterol  
3 excluded due to missing values for SBP  
193 excluded due to self-reported angina 
pectoris 
124 excluded due to missing values for 
smoking habits 




2.4.2 Sample characteristics  
 
Table 1. Selected characteristics (frequency and percentages) of invitees, those who attended the 
clinical examination, and of the analytical sample of Paper 1. 
 Invited Clinical examination Analytical sample 
Total, (%) 12,455 6,004 (48) 5,318 (43) 
Sex    
Men 6,469 (52) 2,747 (46) 2,346 (44) 
Women 5,986 (48) 3,257 (54) 2,972 (56) 
Age    
40–54 years 5,065 (41) 2,015 (34) 1,912 (36) 
55–64 years 3,587 (29) 1,869 (31) 1,694 (32) 
65–79 years 3,803 (30) 2,120 (35) 1,712 (32) 
Region of residence    
Region 1† 2,616 (21) 1,289 (21) 1,138 (21) 
Region 2† 4,034 (32) 2,011 (34) 1,793 (34) 
Region 3† 5,805 (47) 2,704 (45) 2,387 (45) 
Duration of education    
0–9 years  1,729 (29) 1,432 (27) 
10–12 years  1,681 (28) 1,511 (28) 
≥13 years  2,321 (39) 2,170 (41) 
Missing  273 (4) 205 (4) 
Ethnicity    
Sami  2,409 (40) 2,170 (41) 
Non-Sami  3,499 (58) 3,148 (59) 
Missing   96 (2) 0 
Marital status    
Married  3,364 (56) 3,026 (57) 
Cohabitant  850 (14) 791 (15) 
Divorced  545 (9) 483 (9) 
Unmarried  708 (12) 642 (12) 
Widow(er)  385 (6) 325 (6) 
Missing values  152 (3) 51 (1) 
†Municipalities included in Region 1, Kautokeino, and Karasjok; Region 2, Tana, Nesseby, and Porsanger; 
Region 3, Skånland, Evenes, Storfjord, Lyngen, and Kåfjord. 
 
2.4.3 Statistical analyses 
Differences in crude sample characteristics between Sami and non-Sami were tested with 
two-sample t-test and Pearson’s chi-square tests. Ethnic differences in ordered groups were 
tested with Wilcoxon’s rank sum test. Sex- and age-specific, high-risk thresholds suggested 
by Selmer et al.[12] were used to identify individuals at high 10-year risk. The means and 
proportions in Sami versus non-Sami within these strata were compared using the two-sample 
t-test and Fisher’s exact test, respectively. The overall crude mean 10-year risks in Sami and 
non-Sami were compared with the two-sample t-test, and proportions with Pearson’s chi-
square test. We used the direct method to age-standardise the overall means and proportions 
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according to the invited sex-specific SAMINOR 2 population, using 5-years intervals. When 
comparing the mean age-standardised 10-year risks by two-sample t-tests, we used the 
standard deviation estimated from the standard population, which increased the precision and 
lowered the p-values. The age-standardised proportions were tested with two-sample test of 
proportions.  
 
2.5 Paper 2 
2.5.1 Study sample 
In Paper 2, we estimated changes in conventional risk factors, and in the 10-year risk of fatal 
or non-fatal AMI or CS from SAMINOR 1 to SAMINOR 2. The 10-year risk was based on 
sex, age, and the conventional risk factors included in NORRISK 2 (HDL cholesterol, total 
cholesterol, SPB, use of antihypertensive medication, and smoking status) except family 
history of premature CHD, which was not available in SAMINOR 2. Some SAMINOR 1 
participants also participated in SAMINOR 2, and the samples were linked for the 16,778 
SAMINOR 1 participants who accepted to have their information linked to other studies. To 
achieve a sample that was comparable to SAMINOR 2 with regard to residency (10 
municipalities) and age (40–79 years), we excluded 9,513 participants from SAMINOR 1. In 
SAMINOR 2, all those who had attended the clinical examination (n=6,004) consented to 
linkage. From the combined sample (n=13,269, Figure 9), we excluded SAMINOR 1 
participants who did not attend the clinical examination or did not complete the screening 
questionnaire. If information on ethnicity was missing in one of the surveys, we used 
information from the other survey. Those with missing information on ethnicity in both 
surveys, were excluded. The analytical sample consisted of 6,417 participants from 
SAMINOR 1 and 5,956 participants from SAMINOR 2 (Table 2), of whom 50.6% in 
SAMINOR 1 also participated in SAMINOR 2, constituting 54.6% of the SAMINOR 2 
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sample. The reproducibility of ethnicity by Cohen’s kappa suggested a high agreement (0.93, 
p<0.001) [162] of Sami ethnicity from SAMINOR 1 to 2 among those that participated twice 
(n=3,723). In SAMINOR 1 and 2, 41% (n=1,538) and 42% (n=1,565) of participants were 
















Figure 9. Flow chart for Paper 2 showing exclusions from the SAMINOR 1 and SAMINOR 2 sample. 
Abbreviations; S1: SAMINOR 1; S2: SAMINOR 2, n: number. 





n=3,249 participated in both 
surveys 
n=7,265 participated 
in S1   
n=6,004 participated 
in S2  
715 excluded from S1 because they 
did not participate in the clinical 
examination 
132 from S1 and 38 from S2 were 
excluded because of missing 
information on ethnicity  
1 from S1 and 10 from S2 were 
excluded because they did not 
answer the screening questionnaire 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.5.3 Statistical analyses 
We assessed if the change in conventional risk factors and 10-year risk [163] from SAMINOR 
1 to 2 differed in the ethnic groups. We tested this statistically by including an interaction 
term between survey and ethnicity using linear and logistic generalised estimating equations 
by Liang and Zeger.[164, 165] The generalised estimating equations give population-averaged 
estimates [165] and corrects for dependence between observations by adding a term for within-
subject correlations. We used the exchangeable correlation matrix that assumes a similar 
correlation for the within-subject observations.[166] Generalised estimating equation analyses 
assume that missing values are missing completely at random,[167] i.e., that the pattern of 
missing values is independent of both observed and unobserved data.  
  
2.6 Paper 3 
2.6.1 Study sample 
To estimate the risk of the specified CVD endpoints, we used baseline data SAMINOR 1. 
Among the invitees, 16,865 participated, which gave a participation rate of 60.3%. Among 
these, 1,149 individuals were excluded because they did not consent to linkage, did not 
complete the screening questionnaire, or did not attend the clinical examination, which gave a 
sample of 15,716 (Table 3). Moreover, we excluded those with missing information on 
ethnicity, those with self-reported myocardial infarction, angina pectoris or CS, and those that 
had a hospital discharge diagnosis of CHD or CS prior to participation in SAMINOR 1. To 
get a complete case sample with regard to the variables that might explain potential ethnic 
differences in risk: ethnicity, adult height, and conventional risk factors included in 
NORRISK 2, we excluded all participants with missing values for these variables, which gave 




Figure 10. Flow chart for Paper 3 showing exclusions from the SAMINOR 1 sample. Abbreviations: 
n: number; AMI: acute myocardial infarction; CHD: coronary heart disease; CS: cerebral stroke: ICD-
10: International Statistical Classification of Diseases and Related Health Problems, the 10th revision. 
 
 
1,580 excluded due to self-reported 
AMI, CS or angina pectoris 
147 excluded due to missing values on 
conventional risk factors and height 
n=15,665 
51 excluded due to missing information 
on ethnicity 
 n=15,716 participated in the clinical examination, completed the 




151 excluded due to hospital discharge 
diagnosis of CHD (ICD-10 codes I20–
25) or CS (ICD-10 codes: I60–I61, I63–
I64 except 163.6) prior to start of 
follow-up   
n=2,990 Sami 
 
n=10,797 non-Sami  
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2.6.2 Sample characteristics  
Table 3. Selected characteristics (frequency and percentages) of invitees, those who attended clinical 
examination, completed the screening questionnaire, and consented to medical research and linkage, 
and the analytical sample of Paper 3. 
 Invited Clinical examination, screening questionnaire, 
consent to medical research and linkage 
Analytical sample 
Total 27,987 15,716 (56) 13,787 (49) 
Sex    
Men 14,541 (52) 7,523 (48) 6,379 (46) 
Women 13,446 (48) 8,193 (52) 7,408 (54) 
Age    
30, 36–39 years 4,028 (14) 1,740 (11) 1,702 (12) 
40–54 years 11,500 (41) 6,558 (42) 6,257 (45) 
55–64 years 6,590 (24) 4,123 (26) 3,537 (26) 
65–79 years 5,869 (21) 3,295 (21) 2,291 (17) 
Duration of education    
0–9 years  5,472 (35) 4,370 (32) 
10–12 years  4,432 (28) 4,077 (30) 
≥13 years  4,848 (31) 4,622 (33) 
Missing  962 (6) 718 (5) 
Ethnicity    
Sami  3,456 (22) 2,990 (22) 
Non-Sami  12,209 (78) 10,797 (78) 
Missing  51 (1) 0 
Marital status*    
Single 7,057 (25) 3,066 (20) 2,819 (21) 
Married 15,394 (55) 9,769 (62) 8,565 (62) 
Widow(er) 1,826 (7) 989 (6) 749 (5) 
Divorced 3,071 (11) 1,596 (10) 1,385 (10) 
Separated 638 (2) 296 (2) 269 (2) 
Missing values 1 0 0 
*Marital status retrieved from Statistics Norway: married and same-sex partnerships were merged.  
 
2.6.3 Linkage to national registries 
The dates and discharge diagnosis to non-fatal cases of AMI, CHD, IS and CS were retrieved 
from CVDNOR and Norwegian Patient Registry for the periods 1993–2009 and 2010–2016, 
respectively. Both main and secondary discharge diagnosis were retrieved, and the first 
discharge diagnosis including one of the specified endpoints were used in the analyses. 
CVDNOR project is run by the University of Bergen together with the Norwegian Knowledge 
Centre for Health Services.[96] The CVDNOR have collected information of all 
hospitalisations with CVD (ICD-9 codes 390–459; ICD-10 codes I00–I99) or diabetes as 
main or secondary discharge diagnosis. This hospitals information is retrieved from the 
Patient Administrative System,[168] which seems to be of relative good quality as 99% of the 
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patients records on AMI, CS, and hip fractions had correct information on time, date of 
admission, and main diagnosis.[169] The CVDNOR has a 7-year look-back period starting in 
1994–2001, which ensures that the incident cases in Paper 3 have no previous hospitalisations 
with the same discharge diagnosis.[170] The CVDNOR have observed few missing values for 
municipality and age, and have corrected for overlapping and multiple hospitalisations within 
24 hours.[168] Death within 28 days after a hospitalisation was considered to be part of the 
hospitalisation.[96]  
 
The Norwegian Patient Registry is used for reimbursement and management purposes, and 
have a high level of completeness, which indicates that all the necessary data have been 
registered.[171] Similar to CVDNOR, the patient information is retrieved from hospitals’ 
Patient Administrative System.  
 
The dates and underlying cause of deaths were retrieved from Cause of Death Registry for 
2003 to 2016. The performance to the Cause of Death Registry has been compared with other 
national registries using an index based on six measures of quality, and Norway scored 87.6 
out of the 100 points possible; Hungary obtained the highest score at 95.7 points.[172] Due to 
extensive use of non-meaningful or unspecified codes, the Norwegian Cause of Death 
Registry had a low index score.[173] Dates of emigration were retrieved from Statistics Norway 
for 2003–2016. The personal identification number that are assigned to all citizens in Norway 
enables a complete and unique linkage to different national registries.  
 
2.6.4 Statistical analyses  
Cox proportional hazards regression was used to explore whether the incidence of AMI, 
CHD, IS, CS, and a composite endpoint consisting of AMI or CS differed between Sami and 
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non-Sami. We ran separate models for each outcome, and adjusted for sex and age. 
Intermediate variables that could explain ethnic differences were included in a temporal order 
[174] and chosen based on previous studies of the Finnmark population that showed that height 
was inversely associated with CS and possibly also with AMI,[23, 26] and the conventional risk 
factors included in NORRISK 2 model (HDL cholesterol, total cholesterol, SPB, use of 
antihypertensive medication, smoking status, family history of premature CHD).[12] 
Participants were followed from the time of enrolment in SAMNOR 1, until occurrence of an 
event (fatal or non-fatal), moved out of the predefined municipalities, death from other 
causes, or end of follow-up (December 31st 2016). Attained age was used as the time-scale in 
the Cox models. Age at entry is preferable to time-on study as the time-scale variable when 
age is a strong risk factor for the outcome and covariates.[175] Intermediate variables were 
treated as covariates. Covariates that violated the proportional hazards assumption were 
included as time-varying covariates. The assumption in Cox regression is that censoring is 
independent, which means that the probability of being censored at any time does not depend 
on a participant’s prognosis for failure at any given time.[176] Studies have suggested that 
Sami are at higher risk of violent death [25] and death from external causes [106] than non-Sami, 
which might hinders the events of interest from occurring,[177] leading to fewer person-years 
and possibly an underestimation of risk in Sami when comparing their risk to non-Sami. 
Therefore, we performed sensitivity analyses to account for competing events using the Fine 
and Gray cumulative incidence function.[178] The results from Fine and Gray analyses (results 
not shown) were similar to those from the Cox regression, indicating that we did not have 





SAMINOR 1 and 2 are part of the SAMINOR Study, which has been approved by the 
Norwegian Data Protection Authority (02/01525-4), and by the Regional Committee for 
Medical and Health Research Ethics for region North (REC North) (2011/1840). This project 
has been accepted by REC North (2015/2204) and by the SAMINOR Project Board. All 
participants were invited by mail, volunteered to participate, and could withdraw from the 
studies at any time. Those included in the analytical samples of Papers 1–3 have given their 
written informed consent to medical research. In Papers 2 and 3, those that were included in 
the analytical sample also consented to have their information linked to registries. All 
statistical analyses were done using de-identified data files. For Paper 3, Statistics Norway 
linked SAMINOR 1 with emigration data, data from CVDNOR, the Norwegian Patient 
Registry, and the Cause of Death Registry. The complete data file was stored, and all the 
statistical analyses were conducted on a secure platform for sensitive data at the University of 
Oslo.   
 
According to international guidelines, racial and ethnic minorities are considered as 
vulnerable populations.[180] This calls for special awareness when conducting research, so as 
not to inflict any harm. Vulnerability in the Sami context is suggested to be related to the 
preservation efforts that Sami communities have to make in order to maintain their existing 
culture in terms of public and governmental acknowledgment and acceptance to have an 
educational system that strengthen the use of the Sami languages, to have property rights, to 
have cultural diversity and avoiding stereotyping, and reliable statistics, and most of all, the 
acceptance of being Sami.[181] Interpreting vulnerability as such, our work may strengthen 
Sami communities, as we provide valuable health statistics on the Sami population.  
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3 Main results 
3.1 Paper 1 
In our analytical sample from SAMINOR 2, Sami men were somewhat younger than non-
Sami men. Sami men had higher unadjusted mean levels of lipids, and a larger proportion had 
elevated levels of these than non-Sami men. No ethnic differences were observed in blood 
pressure, use of antihypertensive medication, or smoking status when comparing crude levels 
in men. Sami women were a bit younger than non-Sami women. Sami women had somewhat 
unfavourable levels of triglycerides, HDL cholesterol, and a larger waist circumference when 
comparing crude mean levels with non-Sami women. No ethnic differences were observed in 
total cholesterol, blood pressure, and similar proportions of Sami and non-Sami women used 
antihypertensive medication and were smokers.  
 
The small ethnic differences in single risk factors were not reflected in the 10-year risk of 
AMI or CS in Sami and non-Sami men and women when using the NORRISK 2 model. The 
crude, mean 10-year risk and age-standardised estimates were similar in non-Sami and Sami 
men and women. In the age group 55–64 years, more Sami than non-Sami (36.1% vs. 26.7%, 
p-value 0.006) men had an elevated (>10% risk) 10-year risk. Overall, a similar proportion of 
non-Sami and Sami men and women were at high 10-year risk, and this did not change when 
comparing age-standardised proportions. 
 
3.2 Paper 2 
In our analysis of changes in conventional risk factors and 10-year risk of AMI or CS in Sami 
and non-Sami from SAMINOR 1 to SAMINOR 2, we observed that total cholesterol declined 
in women (by -0.50 mmol/l, 95% confidence interval (CI) -0.54, -0.45). Sami men had a 
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statistically significantly smaller decline (-0.43 mmol/l, 95% CI -0.51, -0.35) than non-Sami 
men (-0.60 mmol/l, 95% CI -0.66, -0.53). Small and probably negligible ethnic differences 
were observed in men for changes in triglycerides and HDL cholesterol, whereas women had 
similar changes in these variables. SBP and DBP declined by -3.1 (95% CI -3.89, -2.27) and -
0.7 (95% CI -1.20, -0.28) mmHg in men, and -3.6 (95% CI -4.36, -2.88) and -1.0 (95% CI -
1.39, -0.57) mmHg in women, respectively. Men were more likely to be using 
antihypertensive medications in SAMINOR 2 than in SAMINOR 1 (odds ratio 1.17, 95% CI 
1.06, 1.31), but the likelihood of having hypertension did not change. In women, use of 
antihypertensive medications did not change, but the likelihood of having hypertension 
declined by 6.2 percentage points (odds ratio 0.77, 95% CI 0.70, 0.85). The likelihood of 
being a daily smoker was lower in SAMINOR 2 than in SAMINOR 1; in men, the odds ratio 
was 0.54 (95% CI 0.49, 0.60) and in women it was 0.65 (95% CI 0.59, 0.71), corresponding 
to a decline of 11.3 and 8.2 percentage points, respectively. Waist circumference increased in 
men by 5.9 cm (95% CI 5.50, 6.31), and in women by 6.7 cm (95% CI 6.24, 7.70). The 10-
year risk decreased for similarly in men, whereas in women, Sami women had a somewhat 
smaller decline comped to non-Sami women.  
 
3.3 Paper 3 
Our investigation of the incidence of some CVD among Sami and non-Sami showed that 
Sami ethnicity was associated with a 36% (hazard ratio 1.36, 95% CI 1.10, 1.68) and 31% 
(hazard ratio 1.31, 95% CI 1.08, 1.58) increased risk of IS and CS, respectively, after 
adjustment for sex and age. Low adult height explained a considerable part of the higher risk 
of IS and CS in Sami, as this variable attenuated the hazard ratio to 1.26 (95% CI 1.00, 1.59) 
and 1.18 (95% CI 0.96, 1.44), respectively. Further adjustment for conventional risk factors 
changed the hazard ratio for IS and CS only slightly. The sex- and age-adjusted hazard ratio 
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indicated similar risks in Sami and non-Sami for AMI (hazard ratio 0.99, 95% CI 0.83, 1.17), 
CHD (hazard ratio 1.03, 95% CI 0.93, 1.15), and for the composite endpoint (hazard ratio 
1.09, 95% CI 0.95, 1.24). When accounting for differences in height, the hazard ratio declined 
slightly for AMI, CHD, and the composite endpoint, and subsequent adjustment for 




4 Discussion of methods 
4.1 Study design used in Papers 1–3 
We used a cross-sectional design in Paper 1, repeated cross-sectional design in Paper 2, and a 
prospective cohort design in Paper 3, which are all observational studies. A cross-sectional 
study includes a specific population in a specific place at one time-point, which gives an 
opportunity to observe the frequency of diseases and the distribution of factors that may cause 
disease. A prospective cohort study includes individuals at a specific time-point and follows 
them over time, usually to observe whether an event of interest occurs. Thus, compared to 
cohort studies, cross-sectional studies are less time-consuming and cost less to conduct, as 
there is no follow-up.[182] All observational designs enables the study of associations, but only 
prospective cohort studies enables researchers to ensure that the exposure comes before the 
effect, also known as temporality. In a cross-sectional study, it is more difficult to distinguish 
whether the outcome or the exposure came first, as both are observed at the same time.[183] 
Temporality is one of the Bradford Hill criteria`s used for determining if an association from 
an observational study might be causal, but it is not enough to claim causality.[184] Thus, 
cross-sectional studies are considered to be descriptive and suitable for estimation of 
prevalences and useful for generating hypotheses, whereas prospective cohort studies are 
more analytical, i.e., suggesting causation.  
 
The prospective design in Paper 3 made it possible to exclude participants with CVD prior to 
follow-up, thus we avoided issues with temporal bias or reverse causality.[183] Temporal bias 
occurs when people with a disease, for example AMI, adopt a heathier lifestyle and improve 
their levels of total cholesterol as a consequence of the AMI event. This leads researchers to 
falsely underestimate the associations between cholesterol and AMI.[183] We used hospital 
discharge diagnoses from the CVDNOR and the Norwegian Patient Registry, in addition to 
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self-reported diagnoses, to exclude individuals with CVD prior to follow-up. Although we 
used both self-reported and registry information, there might have been prevalent cases of 
CVD that were counted as new cases. However, as both ethnic groups parish to the same 
hospitals and the hospitals most likely apply similar discharge codes to the same CVD 
independent of the patient`s ethnic belonging, we believe that the prevalent CVD cases were 
excluded in a similar way in both ethnic groups.  
 
4.2 Internal validity 
The validity of a study consists of internal and external validity, and the latter is dependent on 
the former. Internal validity describes how accurate and precise, or how true, the results are 
for the target population.[185] Therefore, an estimate has to be both accurate and precise to be 
valid. Internal validity requires the absence of random and systematic errors; the latter is 
known as bias and tends to give erroneous results.[183] Random errors do not necessarily give 
incorrect results, but they lead to variation that affects the precision and reproducibility of 
results, particularly when sample sizes are small.[183] Systematic errors in studies can occur at 
the design stage, during the collection of information, or during the process of data 
analysis.[183] Systematic errors that influence the groups compared to a similar extent, 
independent of other factors,[182] create a non-differential bias that, in most situations, 
underestimates the strength of the associations between the exposure and outcome.[182] 
Systematic errors that affect the comparison groups unequally creates differential bias, which 
either under- or overestimates the strength of the associations.  
 
Observational studies are prone to errors, but it is difficult to know to what extent. Biases are 
often categorised into three main types: selection bias, information bias, and confounding,[182, 
183, 186] although confounding is sometimes considered to be different from bias. The biases 
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can be related to each other and might overlap. Due to the possibility of bias and 
confounding, the results from observational studies need to be interpreted critically and 
cautiously. 
 
4.2.1 Information bias  
Information bias is also known as observation, classification, or measurement bias. These 
biases occur due to an incorrect measurement or classification of an outcome, an exposure, or 
both.[185] Standardisation in data collection can prevent information bias. In this thesis, the 
clinical examination, including blood sample, was standardised by following strict protocols 
and using trained personnel to conduct the examinations. We are not aware of any systematic 
biases that have influenced the clinical measurements. Also, the use of questionnaires might 
be regarded as a standardised way of collecting information. Biases related to difficulties in 
understanding the Norwegian language among Sami responders are likely small, as only a 
few (<5%) filled in the Sami version of the questionnaires in the municipalities with the 
largest Sami populations (results not shown). However, this might also indicate that the Sami 
questionnaires were difficult to understand, as primary and secondary schools did not allow 
the use of the Sami language until 1969. Moreover, the present writing style for the Northern 
Sami language was set in 1979, and for other Sami languages it was accepted even later.[187] 
Participants were, however, able to receive help from the staff at the research stations to 
complete the questionnaires.  
 
The use of self-reported variables is associated with larger uncertainty than the use of 
standardised measurements. The following self-reported variables were included in the 
analyses: presence of CVD, use of antihypertensive medications, smoking status, family 
history of premature CHD, and ethnicity. According to Senior and Bhopal, a sound 
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epidemiological variable needs to fulfil three criteria: 1) it should be measured accurately, 2) 
it should differentiate populations in underlying relevant characteristics, and 3) the observed 
differences should generate testable aetiological hypotheses or be applicable to the planning 
or delivery of health care.[188] I will consider to what extend these criteria are present for 
ethnicity by describing issues related to heterogeneity and stability of Sami ethnicity, and 
challenges with lack of a golden standard. These conditions influence how well we might 
have been able to differentiate the populations. As ethnicity is multifaceted and a socially 
constructed trait, it may be inappropriate to use it for generating testable aetiology hypothesis. 
Moreover, I briefly mention how planning or delivery of health care to people with Sami 
ethnicity might be applicable. Lastly, I will discuss some limitation of other self-reported 
variables included in Paper 1–3, and strengths and limitations when using data from national 
registries.  
 
Comparing ethnicity criteria with Sami electoral roll 
The criteria used for the ethnic categorisation of Sami in Papers 1–3 resembles that of the 
Sami Parliament electoral roll, as both require that individuals perceive themselves as Sami 
and have a linguistic marker.[189] But the electoral roll differs from our categorisation in that 
they also include linguistic markers in great-grandparents, and the possibility to register 
themselves if they are descendants of someone already enrolled. Given that the legitimacy of 
the Sami Parliament is dependent on an electoral roll that is representative of the Sami people, 
one might argue that the ethnic categorisation used in the papers, on which this thesis is 
based, have high accuracy and represent the Sami population. On the other hand, the criteria 
for registration in the Sami electoral roll, have been constructed in relation to the political 
rights that Sami are granted due to their ethnicity. Such political rights, and hence the ethnic 
categorisation used herein, might be irrelevant for health research. 
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Intra-group heterogeneity in Sami  
The criteria for ethnic categorisation might have determined whether or not we observed 
ethnic differences. Assuming that ethnic differences increase with the degree of ‘Saminess’, a 
strict definition of who are considered Sami might demonstrate ethnic differences, whereas a 
broad definition might dilute ethnic differences, which would make it more difficult to 
demonstrate important ethnic differences. The criteria used for ethnic categorisation, 
determine the sample size of each ethnic group, and hence, the precision of the estimates. A 
strict categorisation of Sami might give imprecise estimates due to a smaller sample size, but 
these estimated would be reliable if ethnic differences increase with ‘Saminess’. A broad 
definition of Sami on the other hand, might give larger precision, but ethnic differences would 
more likely be diluted.  
 
Participants who fulfilled only one of the criteria (either perceived themselves as Sami/had 
Sami ethnic background themselves, or had Sami as the home language of one of three 
generations of their family) were categorised as non-Sami although they clearly demonstrated 
a Sami background or connection. However, we treat the groups as mutually exclusive,[190] 
despite that many categorised as non-Sami have Sami ancestors. Likewise, participants were 
categorised as Sami even if, in addition to Sami, they chose Kven, Norwegian, or other, in 
their responses to questions on ethnic background, self-perceived ethnicity, and language use 
in three generations, which created a heterogeneous Sami group. The main limitation of 
heterogeneous groups is that associations can be hidden.[190] Heterogeneity might bias the 
results non-differentially if both groups have a similar level of heterogeneity, or differentially 
if the heterogeneity is present in only one of the groups. Potential heterogeneity within the 
Sami and non-Sami groups was assessed by repeating the analyses using an alternative ethnic 
categorisation, which consisted of one non-Sami group and two Sami groups that differed in 
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their number of Sami ethnicity markers. The non-Sami group consisted only of those who had 
no Sami ethnicity markers, i.e., Kven, Norwegians and those that had ticked ‘other’. One of 
the Sami groups consisted of those who had ticked Sami for all 11 ethnicity-related questions, 
and the other consisted of those who had 1–10 Sami ethnicity markers. We did not observe a 
consistently different pattern when using the alternative ethnic categorisation in any of the 
papers, which suggests that our ethnic categorisation of the Sami group rendered robust 
results.  
 
Stability of the Sami ethnicity variable – misclassification 
Self-perceived ethnicity can change in relation to social and political contexts and time.[125] 
However, a comparison of the answers on self-reported Sami ethnicity (linguistic markers in 
three generations and self-perceived ethnicity) from the 1970 population census with the 
answers from SAMINOR 1, suggests that Sami ethnicity is stable.[191] We computed Cohen’s 
kappa (section 2.5.1) to explore the level of agreement for reporting Sami ethnicity at both 
surveys compared to what would be expected by chance. The Cohen’s kappa suggested that 
Sami ethnicity had high reproducibility, which supports the high stability of Sami ethnicity 
and supported our decision to impute ethnicity in those that participated in both SAMINOR  1 
and 2, but had missing information for ethnicity in one of those surveys.  
 
Evaluation of Sami ethnicity 
We do not know how accurately we have measured ethnicity, as we do not have a registry of 
ethnicity that might be considered to provide a standard. But, even if there were a registry of 
ethnicity, the question of who would register themselves as Sami and non-Sami, and on which 
criteria, would still exist. Nonetheless, the criteria to the Sami electoral roll might be 
considered to be a standard for categorisation of Sami ethnicity. Given this, we might 
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consider our ethnicity criteria to be as accurate as possible given the available information. 
We might also assume that we have differentiate the populations correctly, as there was no 
indication of the contrary when doing sensitivity analyses using a different ethnic 
categorisation. In terms of generating testable aetiology hypothesis, Paper 3 suggests that 
height difference in Sami and non-Sami reflect an exposures that also determines their risk of 
CS. In terms of applicability of the ethnic categorisation for planning or delivery of health 
care, the resemblances between our ethnic categorisation and the Sami electoral roll suggests 
that targeted measures could be applied in a similar way as other targeted measures from the 
Sami Parliament directed towards the Sami people.  
 
In recent time, Raj Bhopal has suggested, that the research question itself should determine 
how ethnicity is applied.[192] The ethnic categorisation chosen in Paper 1–3 might be in 
accordance with the research question, as we have included self-perceived ethnicity or ethnic 
background that captures the social dimension by ethnicity. The risk of CVD is also partly 
dependent of family history and inheritance, which we have embodied in the categorisation by 
including questions of Sami language use in one of three generations. It should be noted, that 
by including inheritance we only consider genetic susceptibility within families, and not that 
Sami are genetically different from non-Sami. 
 
Self-reported smoking  
Self-reported smoking can be underestimated, as smoking is perceived to be an undesirable 
behaviour in general, and in particular when smoking cessation is expected due to pregnancy, 
cancer, or other chronic diseases.[193] The precision of self-reported smoking has been found 
to be dependent on the study setting and population, how the question is posed, and the 
purpose of the study.[194] The smoking-related questions used in SAMINOR 1 and 2 have not 
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been validated in a Sami population, and they were posed differently in the surveys. In all of 
the papers in this thesis, we estimated the proportion of current smokers in Sami and non-
Sami and included smoking status in the computation of 10-year risk. In Papers 1 and 3, we 
excluded all participants with missing values on smoking. In Paper 2, those with missing 
values on smoking (58 missing items in SAMINOR 1; 68 in SAMINOR 2) were categorised 
as non-smokers, which may not have been the correct assumption. Excluding those with 
missing items for smoking in Paper 2 (both SAMINOR 1 and SAMINOR 2) gave somewhat 
lower odds ratios and prevalences of smoking, but the conclusions regarding a significant 
decline in smoking in the overall and sex- and ethnicity stratified analyses did not change 
(results not shown).  
 
Differentiating smokers from non-smokers might be regarded as crude and inaccurate, as the 
associations between smoking and CVD are dependent on duration (years) and intensity of 
smoking (number of cigarettes smoked per day), also known as pack-years.[195] However, as 
there were additional missing items for number of cigarettes smoked per day, and duration of 
smoking in years in both smokers and former smokers we chose not to include pack-years, as 
this would have given us an even smaller sample size. Moreover, we did not consider former 
smokers in any of the papers; we simply merged them with never smokers to create the 
category of non-smokers. Former smokers have higher mortality relative to never 
smokers,[196] and merging them with never smokers can underestimate the relative risk of 
smoking. Due to potential residual confounding from the imperfect operationalisation of 
variables in Paper 3, we included pack-years (number of cigarettes smoked per day divided by 
20, multiply by years of smoking) of smoking instead of smoking as a dichotomous variable 
in the models for each endpoint. Using pack-years in a somewhat smaller sample did not 
change the relative risks of any of the investigated CVD endpoints (results not shown).  
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 Use of antihypertensive medications and misclassification of item non-response 
In all papers, missing items for self-reported use of antihypertensive medication were 
considered as negative responses, and merged with previous and never users to distinguish 
them from current users. Considering missing items as negative responses might be a correct 
assumption, as users are likely aware of their conditions, whereas those not taking any 
medication might find the question irrelevant and ignore it. In Paper 1, 171 participants had 
missing values on the use of antihypertensive medications; in Paper 2, this was the case for 
105 participants in SAMINOR 1 and 299 in SAMINOR 2; and in Paper 3, there were 142 
participants with missing items for use of antihypertensive medications, all of which were 
categorised as non-users. This is a strong assumption, however, and no literature supports this 
form of ad-hoc imputation. Therefore, as an additional sensitivity analysis, we excluded 
participants with missing items for antihypertensive medications in Papers 1–3 and repeated 
some of the analyses. The results for the sex-, ethnicity- and age-specific 10-year risks 
(n=5,147) in Paper 1, the sex- and ethnicity-specific GEE regression for use of 
antihypertensive medications and hypertension in Paper 2 (n=11,636), and the hazard ratio for 
ethnicity (model 3) in Paper 3 for the various CVD endpoints resembled the original results, 
thus the conclusions did not change.  
 
Self-reported cardiovascular disease 
We excluded those with self-reported angina pectoris and AMI in Paper 1, and in Paper 3, 
excluded those with self-reported CS. Self-reported AMI and CS in SAMINOR 1 had high to 
moderate agreement when validated against hospitalisation discharge codes, and no ethnic 
variation was observed in the validity of these.[197] Thus, ethnic differences in exclusion of 




Misclassification of endpoint in Paper 3 
We compared fatal and non-fatal CVD cases in Sami and non-Sami, by using information 
from national registries. The main and secondary discharge diagnosis to CS in the Norwegian 
Patient Registry have been found to be adequate complete (i.e. to what extent all data that 
could have been registered is registered) and correct when compared to medical records from 
hospitals.[198, 199] The correctness to a registry is often measured by positive predictive value 
and describes to what extend the results confirms with the true. The correctness for CS in 
Norwegian Patient Registry varied from 68% to >90% and improved when restricting the 
comparison to main discharge diagnosis only.[198-200] The most common cause for incorrect 
diagnosis of acute CS was previous CS events that should have been coded as sequela and 
rehabilitation after CS.[198, 199]  
 
The main and secondary discharge diagnosis to AMI in the Norwegian Myocardial Infarction 
Registry and the Norwegian Patient Registry were compared with the discharge diagnosis to 
patients admitted to a hospital in Mid Norway from July to December 2012 with a cardiac 
troponin T plasma value. Both registries were found to be adequately complete and correct. In 
terms of the latter, both registries had a positive predictive value >90% when compared to the 
hospital discharge diagnosis that was based on the comprehensive medical history.[201] As 
with CS, restricting the comparisons to only main diagnosis of AMI, improved the correctness 
for Norwegian Patient Registry.[201] These studies indicate that the Norwegian Patient 
Registry provide adequately complete and corrected data for both main and secondary 
discharge diagnosis of CS[198-200] and AMI,[201] which might eliminated potential differences 




A study conducted in Norway in 1965–2005, compared the underlying cause of death among 
1,140 individuals with autopsy records [202] to that in Cause of Death Registry, and found a 
somewhat lower agreement between CS deaths than CHD deaths, but an overall a substantial 
agreement between the two records. Assuming that these data hold for the CHD and CS 
deaths included in Paper 3, we might not have large issues with misclassification of deaths. 
Out-of-hospital deaths among individuals aged >80 years might be underreported, as 
comorbidities increase with age, and possible silent AMI or silent IS/CS [203] is not recognised 
when ICD-10 R96 (instantaneous death) and R98 (unattended deaths) are used as the 
underlying cause of death.[204] Using data from the Tromsø studies in 2001–2009, one study 
showed that age- and sex-specific trends in AMI did not change after the inclusion of cases 
with R96 and R98 as the underlying cause of death,[204] which suggests that excluding these 
codes from the AMI endpoint might not threaten our conclusions regarding AMI. How the 
use of R96 and R98 influence the incidence of CS is uncertain.  
 
Use of specialist health care in geographical areas that represents Sami, i.e. municipalities 
included in the administrative area for Sami languages (varying from six to eight 
municipalities), have been compared with geographical areas (varying by study) with an 
assumed small proportion of Sami, representing non-Sami. The public expenditures to 
somatic hospitals and specialist services in 2002–2006 [205] and use of radiotherapy in cancer 
treatment in 1999–2008 [206] showed similar use in geographical areas representing Sami and 
non-Sami. Use of mammography screening for breast cancer was more common in areas 
representing Sami women than by their non-Sami counterparts in 2001–2010.[207] Use of 
conventional radiography, magnetic resonance, computerised tomography, and ultrasound in 
2003–2009, showed smaller use of the two latter and more of magnetic resonance in areas 
representing Sami, which they assumed to be caused by a lower cancer risk in Sami.[208] 
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Overall, these studies [205-208] indicate no systematically different use of specialist health care 
in Sami and non-Sami areas. The coding of discharge diagnosis is assumed to be similar in all 
hospitals in Norway, as Norwegian hospitals have a similar governmental reimbursement 
system. Therefore, it is unlikely that main and secondary discharge diagnosis and the 
underlying cause of death differ systematically by ethnicity. Potential misclassification is 
probably similar for both of the comparison groups, which potentially underestimates the 
associations between ethnicity and risk of CVD.  
 
4.2.2 Selection bias 
Descriptive studies (Paper 1 and 2) and measures like incidence rates (Paper 3), are important 
as they reflect the health of the target population. However, the descriptive measures from a 
sample should be representative of the target population to be valid. If the descriptive 
measures are valid, it might be possible to extrapolating the figures to populations with 
comparable demographical characteristics.[209] If individuals have different probabilities of 
being included in a survey, there might be a selection of participants. A selection might cause 
systematic differences in participants and non-participants in relevant characteristics such as 
the exposure and outcome,[210] in which case we might have a selection bias.[183, 185] 
 
Different participation by ethnic groups 
A review investigated racial and ethnic minorities’ willingness to participate in health 
research from 20 different health research studies conducted after 1984 mainly in US. The 
review showed that racial and ethnic minority groups were as willing as non-Hispanic white 
people to participate despite an assumed mistrust in medical research.[211] It is rather unlikely, 
however, that these results are generalizable to Northern Norway, as similar studies in 
Scandinavia with respect to Sami ethnicity and participation in health research do not exist. 
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Therefore, to what extent participants and non-participants in SAMINOR 1 and SAMINOR 2 
differ in ethnicity, is unknown. It might be that Sami reframe from medical research as 
previous scientific research studies included scull measurements and physical appearance to 
place Sami as inferior to Norwegians.[128, 130] All invitees received the informational brochures 
where it was stated that information was collected in geographical regions where Sami and 
non-Sami live and that the survey was conducted by a Sami research centre. This could have 
increased participation of Sami as their presence in these regions were acknowledged, and 
could give lower participation among those that do not acknowledge Sami language and 
culture due to history of assimilation.[138] If this have induces a different selection of Sami and 
non-Sami participant into the surveys, and if such selection might bias the estimates, is 
however, unknown. 
 
Non-participants in SAMINOR 1 and SAMINOR 2 
As roughly half of those invited to SAMINOR 1 and SAMINOR 2 participated, there may 
have been a selection that makes the participants differ from non-participants (Tables 1–3). 
However, it is impossible to know to what extent if no research is done to compare 
participants with non-participants. We have limited information about the non-participants to 
SAMINOR 1 and 2, other than non-participants to both surveys were more often younger 
men,[160] and in SAMINOR 1, the non-participants were also more often single.[159] This is 
also reflected when comparing characteristics of the invitees with those included in the 
analytical samples in Tables 1–3, which suggests that the descriptive results from Paper 1–3 
may be slightly prone to selection bias. 
  
Surveys conducted in Norway with comparable participation rates to the papers included, 
have observed that non-participants were more often men, young, not married, were likely to 
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be receivers of disability pensions, and had lower education or income.[212-214] In the Tromsø 
study in 1994–1995 and 2007–2008, those with the highest level of education have better 
levels of conventional risk factors and smoke less than those with the lowest level of 
education.[215] If non-participants to SAMINOR 1 and 2 have lower education than those that 
participated, as observed by others[213, 214] and hence, have more adverse levels of 
conventional risk factors, then estimations of conventional risk factors in Paper 1 and 2 might 
be an underestimation of the true levels in the target population.  
 
The third Nord-Trøndelag Health Study, also known as the HUNT 3 study, was conducted in 
2006–2008 and 50,807 were invited, wherein 54% participated. The non-participants were 
more often younger, unmarried men,[213] comparable to the characteristic observed in non-
participants to SAMINOR 1 and 2. Additionally, the non-participants to the HUNT 3 study 
had a higher prevalence of drug-treated hypertension, myocardial infarction, angina pectoris, 
CS, diabetes, psychiatric disorders, higher mortality, as well as being more inactive and 
having lower education and income.[213] Given that the HUNT 3 study and the SAMINOR 1 
and SAMINOR 2 had resemblance in participation rate, and non-participants were more often 
younger and men, it might be that the non-participants to these surveys resemble each other in 
other characteristics as well. If that is the case, the incidence rates of CVD in Paper 3 might 
be somewhat underestimated as those with myocardial infarction, angina pectoris, CS, 
participated less. As no research is done among the non-participants to SAMINOR 1 and 
SAMINOR 2, we can only speculate how they may had influence our observations.  
 
One study of non-participants to the Oslo health study that was conducted in 2000–2001, 
wherein 40,888 aged 30–76 were invited and 46% attended, explored how different 
prevalences in smoking, obesity and diabetes among non-participant changed the prevalences 
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of these conditions in the target population.[214] Their analyses showed that differences in 
prevalences in participants and non-participants, had only small effect on the overall results, 
which suggested that the sample was representative of the target population despite somewhat 
low response rate.[214] Similarly, the overall anthropometric and disease prevalence estimates 
in the HUNT 3 study did not changes substantially when merging the values to non-
participants with those to participants, despite non-participants having poorer health and 
lower education.[213] It should be noted, the HUNT 3 study and the Oslo health study had 
substantial sample sizes. This suggests that despite only half of those invited participate in a 
survey, bias from selection might not be a problem, as long as the sample size is large. It is 
likely that the prevalences and mean values vary in participants and non-participants to 
SAMINOR 1 and SAMINOR 2, but our results in Paper 1 and Paper 2, and incidence rate in 
Paper 3 may still be valid for the target population as the sample sizes are relative large. It 
should be noted, that our assumption of negligible different selection of participants and valid 
estimates rest on an assumption that there are no different selection by ethnicity or by other 
variables related to ethnicity.      
 
Estimation of change in risk factors in Paper 2 
Table 2 show that the analytical sample in SAMINOR 2 tended to be older than the sample in 
SAMINOR 1. SAMINOR 1 had the fewest participants from Region 1, which included 
municipalities with that the highest proportions of individuals with Sami affiliation,[159, 160] 
whereas SAMINOR 2 had the fewest participants from Region 3, which included 
municipalities were Sami are in the minority. This was also reflected in the ethnic 
compositions of participants, with more participants of Sami ethnicity in SAMINOR 2 
(40.4%) than in SAMINOR 1 (35.3%). However, as noted previously, this is most likely due 
to issues with the design of SAMINOR 1 (see section 2.1), not people’s willingness to 
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participate in the surveys. However, if and how this issue might have influenced the ethnic 
comparisons, is unknown.   
 
In Paper 2, we used a statistical method (generalised estimating equations) that assumes that 
missing values are missing completely at random.[167] However, the missing values in the 
surveys depended on the birth cohorts invited to SAMINOR 1 and 2, which might bias the 
regression coefficients when using this statistical method. We explored this, by excluding 
those who were not eligible for invitation to both surveys; we excluded those aged ≥70 years 
from SAMINOR 1 (n=820), and those aged 40–50 years from SAMINOR 2 (n=1,275). When 
the generalised estimating equations analyses were repeated in this sample (n=10,278), the 
results resembled those of the original analyses, except for SBP, which showed a different 
decline for non-Sami and Sami women (-5.2 and -3.7 mmHg, respectively). Overall, we 
consider the estimates from our study to be fairly robust. 
 
Relative risk estimations in Paper 3 
In order to have valid relative risk estimates from cohort studies (Paper 3), losses to follow-up 
should be independent of the outcome. In Paper 3, we had complete follow-up for all 
participants and 101 were lost to follow-up due to emigration. The losses to follow-up did not 
differ by ethnicity (results not shown), and assumed to be independent of the incidence of 
CVD, which was not explored.  
 
Effect estimation that stem from aetiological relationships are less likely to be influenced by 
bias from selection, but the strength of association might vary by population.[182, 212, 214, 216] 
In Paper 3, height explained the excessive risk of CS and IS in Sami, which is supported by 
some studies [78, 79] whereas other studies show no associations.[81] A meta analyses estimated 
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a steeper risk reduction at lower height and suggested an inflection point at 170 and 160 cm 
for men and women, respectively, where height is no longer associated with CS.[217] The lack 
of an inverse association between height and CS between different studies might partially be 
due to variations in population average height, and due to a possible presence of an inflection 
point where height is no longer inversely associated with CS and IS. Therefore, it is likely 
that the association between height and CS and IS are valid for the target population, but the 
strength of association might vary between participant and non-participant as their average 
height differ.     
 
4.2.3 Confounding and intermediate variables 
 
Confounding is a phenomenon that can create a statistical association between an exposure 
and an outcome when the groups that are compared, in this case Sami and non-Sami, differ in 
other variables that are causally or non-causally associated with the exposure, and causally 
associated with the outcome.[183]  
 
In an ideal comparison, the groups should be similar to each other in all aspects other than 
exposure status, which is why sample characteristics in the exposed and non-exposed groups 
are compared, with particular attention paid to factors that are thought to be causally 
associated with disease.[182] If the groups differ in factors that might be causally associated 
with the outcome, this can create a false association caused by the confounder and not by the 
exposure. In contrast to information and selection bias, it is possible to correct for 





A confounder is different from an intermediate variable,[183] which is a variable in the causal 
pathway between an exposure and an outcome. Intermediate variables can cause variation in 
the outcome, and vary themselves by variation in the exposure.[35] In contrast to confounders, 
one should not adjust for intermediate variables if one is interested in the full effect of the 
exposure, unless this is done intentionally, as in Paper 3 when trying to explain what variables 
might explain differences in risks. We considered height and conventional risk factors as part 
of the causal pathway between ethnicity and risk of CVD. The risk of CVD is mediated 
through height as surrogate measure of genetic composition and environmental exposure, and 
conventional risk factors are considered mediators of a potential ethnic differences in risk.     
      
The usefulness of an adjustment depends on how well the confounding variable is measured, 
if it is measured at all, and whether the researchers are aware of the confounders and actually 
adjust for them. Imperfect data collection of confounding variables, failing to take into 
account confounding variables, or the use of a suboptimal regression model can lead to biased 
estimates, and is known as residual confounding.[183] In Paper 3, we suggest that residual 
confounding might partly explain the observed association between Sami ethnicity, and CS 
and IS, as observational studies are prone to bias due to things like the imperfect collection of 
data.  
 
4.2.4 Interaction  
Interaction is present when the association between the exposure and an outcome change in 
the presence of a third variable, which is then considered to be an effect modifier.[183] An 
effect modifier is different from a confounder as the exposure–outcome association differ in 
levels or strata of the effect modifier, whereas the exposure–outcome association is similar in 
all levels of a confounder.[218]  
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In Paper 2, we formally tested whether continuous and discrete conventional risk factors 
changed differently by ethnicity from SAMINOR 1 to SAMINOR 2. This was tested on a 
multiplicative scale.[219] Moreover, the changes in risk factors were illustrated in figures in the 
supplementary figures (to Paper 2), which suggested that the interactions observed in men and 
women were most likely due to random variation, as the changes fluctuated by age group.  
 
In Paper 3, for each variable that was entered, we tested if sex or ethnicity modified the 
associations with the endpoint. This was done by including a product term with ethnicity and 
a product term with sex in separate models. If the product term was statistically significant (p-
value <0.05), the product term was included in the final model for each endpoint. The risk of 
CS and the composite endpoint were lower in women than men, and only in women, an 
inverse association was observed between height and both endpoints. For men, the association 
was also negative, but not statistically significant (Paper 3, Supplementary table 2). The 
product term between sex and height was not statistically significant (p=0.078) in the final 
model for composite endpoint. However, we chose to include it as it was statistical significant 
in the complete model for CS. Men had significantly higher risk of AMI than women, but 
only in women the use of antihypertensive drugs was associated with higher risk of AMI.  
 
4.2.5 Statistical associations and chance findings  
In all the papers included, we performed several statistical tests, like testing for interactions 
(Paper 3), which increases the probability of type 1 error, i.e., falsely-rejected null-hypotheses 
[220] and chance findings. We used the α-level of 0.05 for all tests in the papers, which means 
that the probability of type 1 error in a single test was 5%. However, when doing several tests 
on the same dataset, the probability of at least one falsely-rejected null-hypothesis is larger. 
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This is commented specifically in Paper 1 in relation to the significant difference in risks 
observed among men aged 55–64 years, but it applies to all papers.  
 
A larger sample size increases the power of a study, and leads to smaller standard errors and 
narrower CI. Small differences between groups may be statistically significant simply because 
of a large size of the sample, but may not be clinically or practically meaningful, i.e., they 
may indicate a difference in health outcomes that is so small that is does not merit attention. 
Judging whether or not a difference is clinically significant is done on the basis of expert 
knowledge in the field of study. As mentioned, in Paper 2, we found that Sami and non-Sami 
had different changes in total cholesterol and triglycerides (men only), HDL cholesterol (both 
sexes), and in 10-year risk (women only), but the ethnic differences were small, the results 
fluctuated by age group, and the analyses included multiple tests, which suggests that the 
results might be partly due to random variation or chance, and might not be clinically relevant 
in terms of differences in health outcomes.  
 
Conclusion regarding internal validity 
We acknowledge that there are several potential biases and weaknesses in our study samples 
and analyses. Regarding potential misclassification of Sami and non-Sami ethnicity, this 
might be similar in both ethnic groups, which suggest a non-differential bias that might 
underestimate any ethnic differences. The repeating of the analyses after excluding missing 
values to self-reported variables (use of antihypertensive medication in all papers; smoking in 
Paper 2) and replacing dichotomous smoking variable with pack-years (Paper 3), suggest that 
we do not have serious misclassification bias as the results resembled the original results. 
Concerning selection bias, it might be differences in means and prevalence estimates between 
those that participated and non-participants to SAMINOR 1 and SAMINOR 2. But, as the 
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analytical samples were relative large the results from Paper 1–3 may still provide a true 
picture of the health status to the target population and of potential ethnic differences. In 
Paper 3, incidence were measured by linking SAMINOR 1 to information from national 
registries that are independent of ethnicity, which strengthens the estimates and comparisons. 
The association between height and IS and CS are likely to be applicable to the target 
population and other population, but the strength of association might vary by populations as 
the mean height vary in populations. In the papers included, confounding was not considered 
as Paper 1 and 2 were mainly descriptive studies, and in Paper 3, incidence rate and potential 
intermediate variables were identified. Despite these limitations, we believe that the internal 
validity of our findings was not compromised, and that the results reflect the health status and 
associations in the target population in a relatively unbiased way. Young, unmarried men 
participated less than older men, which suggests that the results might be less representative 
of the former population.  
 
4.3 External validity 
The external validity refers to whether the results from a study can be generalised to 
populations other than the target population,[2] and is also referred to as generalisability. As 
mentioned, in order to have external validity, the study has to be valid for the target 
population, i.e. have internal validity. 
 
Although the internal validity of the papers in this thesis seems to be acceptable, the 
generalisability of the results from Papers 1 and 2 are limited to rural regions in Northern 
Norway where Sami and non-Sami co-exist. However, the applicability of the findings 
included in the Paper 1 and 2 might not be relevant to the Sami population today, as the 
results are from a survey in 2012–2014. These findings might on the other hand indicate that 
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Sami and non-Sami lifestyles do not contribute to different levels of conventional risk factors 
or differences in 10-year risks as the levels were rather similar in the time-period 2003–2004 
to 2012–2014 (Paper 1 and 2).  
 
The analytical sample in Paper 3 included the complete SAMINOR 1 sample, which covered 
a substantial part of the Sami population in rural Northern and Mid Norwegian. One might 
therefore argue that the results in Paper 3 can be generalised to all Sami populations in rural 
Norway, but not to those living in cities. The individuals in Paper 3 were followed to the end 
of 2016, and the ethnic comparison may still be valid to present day Sami and non-Sami aged 
30 and 36–79 years, given that the change in conventional risk factors were rather similar 
from SAMINOR 1 to SAMINOR 2. However, the incidence rates might on the other hand be 
somewhat overestimated as conventional risk factors are expected to decline and treatment is 
expected to improve over time. Concerning the relative risk estimations between height and 
Sami ethnicity, similar associations are likely to be observed in populations that differ in 
height, although with varying strengths.     
 
As for the non-Sami population included in Papers 1–3, the results might only be 
generalisable to Norwegians, and not to the Kven population living in rural areas of Northern 




5 Discussion of main results 
5.1 Paper 1  
The sex-specific and age-stratified mean risks and proportions at high risk were overall 
similar in Sami and non-Sami men and women in 2012–2014. Studies up till today [19, 23, 113-
117] have observed none or only small ethnic differences in conventional risk factors, which 
support our observation of no ethnic differences in 10-year risk.  
 
Concerning abdominal obesity, Sami women had a larger mean waist circumference than 
non-Sami, as observed by others.[17, 23, 114] Together with the observation of higher prevalence 
of type 2 diabetes in Sami men and women in SAMINOR 2,[20] these characteristics may 
contribute to a higher 10-year risk of AMI or CS in mainly Sami women. However, the 
mechanism and aetiology of CS and IS are complex, and risk and protective factors for CS 
and IS might differ in time and in the ethnic groups.  
 
The incidence of AMI and CS has most likely declined from the time when the regional 
health surveys (from 2000–2003) used in the validation of the NORRISK 2 model were 
conducted, and SAMINOR 2. As mentioned, in 1995–2012 decline in conventional risk 
factors accounted for roughly 60% of the decline in incidence of CHD [29] and CS.[32] As the 
decline in incidence of AMI and CS was not entirely caused by a decline in conventional risk 
factors, the 10-year risk might be overestimated. Paper 2 indicate no substantial ethnic 
differences in change of conventional risk from SAMNOR 1 to SAMINOR 2, which suggests 
that the observation of no ethnic differences in the risk of the composite endpoint observed in 




A study of a multi-ethnic cohort in the US suggested to include height in risk models of CVD 
to increase their predictive value,[221] as adding new predictive factors can help correctly 
classify those at borderline risk and avoid further laboratory testing.[95] If the NORRISK 2 is 
applied in populations that differ in height, including adult height might improve the 10-year 
risk estimation, as height provides information on the interaction between genetic and 
environmental factors. But, as risk models are seldom improved when adding new predictive 
factors beyond sex, age, and conventional factors,[11, 222] the addition of height might only 
help to correctly classify those at borderline risk.    
 
5.2 Paper 2 
From 2003–2004 to 2012–2014, Sami and non-Sami populations in the 10 rural 
municipalities had favourable declines in total cholesterol, blood pressure, and number of 
current smokers, which have been observed in studies in Norway [223-227] and in western high-
income countries.[228-231] Small, but less favourable change were observed in some 
conventional risk factors in Sami compared to non-Sami men and women. However, the 
differences were small and possibly due to chance or random variation. The conventional risk 
factors in Sami and non-Sami are considered to be intermediate factors between ethnicity and 
risk of CVD, and they are expected to reflect an ethnic specific lifestyle.[158] As the changes in 
conventional risk factors were rather similar in the ethnic groups, Paper 2 suggest that Sami 
and non-Sami have had a similar changes in lifestyle from SAMINOR 1 to SAMINOR 2.  
 
The SAMINOR 1 and 2 samples in Paper 2 included different birth cohorts. Compared to 
SAMINOR 1, SAMINOR 2 did not include those born in 1925–1934, but did include those 
born in 1964–1973, which increased the level of education in SAMINOR 2. Studies have 
shown an educational gradient in CHD mortality,[232, 233] where a low level of education is 
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associated with unfavourable levels of among other smoking. This suggests that the 
favourable decline in total cholesterol, blood pressure, and smoking observed in Paper 2 
might be driven by a general improvement in education in rural Northern Norway.  
 
5.3 Paper 3 
Acute myocardial infarction and coronary heart diseases in Sami  
We observed no ethnic differences in the incidence of AMI or CHD, which is supported by 
other studies that indicates a similar incidence of AMI in Sami and non-Sami,[23, 107] also 
when including studies on mortality from CHD despite variation in these. With regards to 
mortality from CHD, the studies show a higher,[25, 107] lower,[24, 108, 109] or similar mortality [106, 
107] that vary by sex and reindeer herding, where the latter have lower incidence in women [107] 
and lower mortality in men.[25] In SAMINOR 1, Sami men and women reported more often to 
have angina pectoris and symptoms of these compared to non-Sami,[234] which is somewhat 
surprisingly give the observation of no differences in incidence of AMI or CHD. However, 
self-reported myocardial infarction has been reported to be similar in Sami and non-Sami in 
SAMINOR 1 [118] and the question posed in SAMINOR 1 is found to have high positive 
predictive value when compared to hospital discharge data.[197]  
  
Cerebral stroke and ischemic stroke in Sami 
Sami had a 36% higher risk of IS and a 31% higher risk for CS. In absolute terms, this 
suggest that while non-Sami have 2–3 persons affected by CS or IS per 1,000 person-years, 
Sami have 3–4, which may translate to a relative small excess risk. The study on incidence of 
CS in Norway indicate a possibly higher incidence in Sami.[23, 26] Together with a study from 
Sweden in 1985–2002, including incidence of subarachnoid haemorrhage,[107] these studies 
give support of higher incidence of CS in Sami that may vary by attachment to reindeer 
 
73 
herding. Including studies from Sweden, Finland and Norway, variation was observed in 
mortality of CS showing similar [107, 109] or higher,[25] where the latter was also observed in 
reindeer herding women [107] but not in reindeer herding men.[25, 107] Unfortunately, we did not 
conduct separate analyses on fatal and non-fatal cases nor in relation to reindeer herding, 
which could have provided important knowledge on mortality and variations among 
subgroups. In our study, the relative risks for IS and CS were rather small with large 
variations, as observed in comparable studies.[25, 26, 107] Due to the low strength of the 
associations, it is possible that the excess risk was caused by biases or residual confounding, 
as observational studies are prone to bias.[185]  
 
The composite endpoint 
We found no ethnic differences in the composite endpoint consisting of AMI or CS. When 
splitting the composite endpoint into AMI and CS, we observed ethnic differences in the 
incidence of CS, but not that of AMI or CHD. It might be that the small number of CS events 
that exhibited an ethnic difference were cancelled out when they were merged with AMI 
events that exhibited no ethnic differences. One study in Sweden in 1985–2002 [107] compared 
the risk of a composite endpoint consisting of AMI and/or CS, which resembles the composite 
endpoint in Paper 3. They observed no ethnic differences, except that non-herding Sami men 
had higher incidences, and reindeer herding Sami men had lower incidences of the composite 
endpoint than their demographically-matched counterparts.[107]  
 
Reindeer herding was associated with lower mortality of CHD in Sami men,[25] lower 
incidence of AMI in women in women,[107] lower incidence of CS in men,[25, 107] and higher 
incidence of CS in Sami women.[107] The higher incidence of CS and subarachnoid 
haemorrhage observed in Sami women within reindeer herding was hypothesised to be related 
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to psychosocial factors, as income and education did not explain differences between reindeer 
herders, non-herding Sami and a demographical-matched reference population reference.[107] 
In the papers included in this thesis, we did not do separate analyses for Sami with affiliation 
to reindeer herding, as we only had information on those financially responsible for the 
husbandry unit, which might be incorrect due to the organisation of members of ‘siida’.[111] 
According to the Norwegian government there are about 3000 people that have reindeer 
herding as their main occupation,[235] which suggests this that reindeer herding Sami might 
constitutes a small subgroup within the Sami population.  
 
Population mean height  
Height explained more of the ethnic differences in CS and IS than conventional risk factors 
did, but it is not clear how height is associated with risk of CS and IS. Also, what height 
represents in the context of Sami versus non-Sami is difficult to disentangle, as it is unlikely 
that physical appearance itself increase the risk of CS.  
 
Anders Forsdahl, who was a medical doctor and professor, observed high CVD mortality in 
the municipality of South Varanger in Finnmark County in the 1970s. His ecological studies 
suggested that poor living conditions in childhood and prosperity in adulthood were risk 
factors for later CHD through conventional risk factors, and that adult height was an indicator 
of poor living conditions in childhood.[236] Barker and others have suggested that early life 
factors,[91, 237] already present in foetal life, can alter the risk of CS. Some suggest that 
epigenetic modification such as DNA methylation can occur in the fetus if maternal 
nutritional deficiency occur during important periods in the development to the fetus, which 
predispose individuals to future CVD.[238, 239] Researchers have suggested that living 
conditions were harder for the Sami and Kven populations as compared to Norwegians,[240] 
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and that the living conditions in the previous Finnmark County were poorer as compared to 
the rest of the Norway,[241] which could explain why Sami and conscripts from Finnmark have 
a lower mean height.[93, 94] Moreover, one study suggested that haemorrhagic CS is more 
related to childhood socioeconomic conditions than CHD.[242] Although the living conditions 
of Sami and non-Sami may be perceived as rather similar today given the similar level of 
education and conventional risk factors, it is possible that childhood living conditions were 
poorer for Sami than for non-Sami participants. This perspective suggests that exposure 
through lifetime might be relevant in the context of Sami versus non-Sami and risk of CVD. It 
might also be possible that poor living conditions in previous generations still influence 
present day population height, as it takes time for population mean height to increases.[92]   
 
Figure 6 illustrates the complex interplay between social environment that influence the 
psychological conditions, and health behaviour, which together with genetic, culture and early 
life factors determine the health of individuals. When exploring ethnic differences, it has been 
recognised that socio-economic position, often measured by education, income or occupation, 
is a powerful determinant of health and CVD.[125, 243] In the papers included in this thesis we 
have not adjusted for socio-economic position as the sample characteristic and other studies 
[107] did not indicate large differences in education. In the context of Sami and non-Sami, 
other unknown socio-economic variables than education and income might be relevant in 
explaining differences in CVD risk, as suggested by Sjölander.[107] Adult mean height in Sami 
and non-Sami populations in SAMINOR 1 might actually represent childhood living 
conditions, i.e. childhood socio-economic conditions [89] to the included birth cohorts or to 




One of the main differences between Sami and non-Sami populations in Norway is that Sami 
were exposed to governmental assimilation,[138] similar to other Arctic indigenous 
populations. The structural assimilation policies [14] might be considered as one of the social 
structures that determines health (Figure 6). In SAMINOR 1, Sami and Kven report more 
ethnic discrimination and bullying [244] and stress [156] than Norwegian. Some have suggested 
that marginalisation induced chronic stress in Sami that make them more prone to ill health, 
i.e., higher proportions reported lifetime CVD.[22] Ethnic discrimination was associated with 
psychosocial stress in SAMINOR 1.[156] Psychosocial stress is a risk factor for CS,[245] and the 
excess risk of IS and CS in Sami might come from the psychosocial stress of assimilation and 
subsequent marginalisation,[22] which we did not measured nor adjusted for. The lower height 
in Sami can also be a marker of some ethnic-specific exposure, such as marginalisation.[22] 
However, the association between discrimination, stress and CS in this population is at this 
point only a speculation, but might serve as a foundation for further research on the topic.   
 
5.4 Comparable indigenous populations  
Alaska natives have found to have higher CS mortality than white populations in the US,[246] 
and the incidence of CS has been suggested to be higher in the Inuit population in Greenland 
than in Western populations.[247] The inferior cardiovascular health of American Indians and 
Alaska Natives relative to non-indigenous peoples has been suggested to be due to lower 
socioeconomic status and poorer access to quality healthcare among the indigenous 
population.[248, 249] It is challenging to compare the health of Sami to the Inuit, and Alaska 
natives, as the countries they inhabit differ in health care and education, which are 
determinants of health.[250] However, regarding the higher susceptibility to CS in Greenland 
Inuit populations, some have suggested that genetic, foetal, and early life factors, in addition 
to mental stress, should be of concern when considering Inuit health.[247] CVD is a complex 
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group of disease, and susceptibility to different types of CVD is a result of both genetic and 
environmental factors, which makes it difficult to disentangle which risk factors are relevant 





1. Based on our findings, Sami and non-Sami populations living in 10 rural municipalities of 
Finnmark and Troms, and Nordland Counties had rather similar levels of estimated 10-
year risk of AMI or CS, which reflected similar levels of conventional cardiovascular risk 
factors. 
2. In these regions, we found that both Sami and non-Sami had substantial reductions in total 
cholesterol, blood pressure, and smoking from 2003–2004 to 2012–2014, that are likely to 
reduce the number of fatal and non-fatal CHD and CS cases in these populations. Small 
ethnic differences were observed mainly in total cholesterol (men only), HDL cholesterol, 
triglycerides (men only), and the 10-year risk of AMI or CS (women only), for which 
Sami had a slightly less favourable change than non-Sami. However, as the differences 
were small, it is likely that they are of little clinical value and may be due to random 
variation.  
3. Comparing the incidence of CVD in Sami and non-Sami in 24 municipalities of Northern 
and Mid Norway revealed no ethnic differences the in risk of AMI and CHD, which is in 
accordance with previous studies. We found an approximately 31% higher risk of CS in 
Sami; this represents a relatively small excess risk, which might have been partly caused 
by residual confounding.  
4. The excess risk of CS in Sami men and women was explained to some extent by 
adjustment for adult height. Height might be as relevant as conventional risk factors in 
explaining elevated risk between ethnic groups that differ in height. Low height was 
associated with Sami ethnicity. However, height might not be a causal factor in itself, nor 




6.1 Public health relevance 
The findings from the papers included in this thesis provide important knowledge on the CVD 
burden in Sami. A substantial proportion of fatal or non-fatal CVD cases are attributable to 
modifiable risk factors [9, 29, 32] that can be prevented by public health measures. The 
distribution of conventional risk factors and the 10-year risk were rather similar in Sami and 
non-Sami (Paper 1). This suggests that potential ethnic differences in Sami and non-Sami 
lifestyles might not lead to large differences in conventional risk factors and future risks. 
Moreover, it is likely that the favourable decline in conventional risk factors observed in 
Paper 2 will give fewer new cases of fatal or non-fatal CHD and CS in both ethnic groups. 
However, this will depend on the demographic structure of the population.   
 
A substantial and favourable decline observed in total cholesterol, blood pressure, and 
smoking was observed in both ethnic group (Paper 2), which suggests that population-based 
preventive strategies are measures that work independent of Sami ethnicity. However, this 
does not exclude the possibility of other regional-specific, or ethnicity-specific protective or 
detrimental factors that influence the risk of CVD. Therefore, national health campaigns 
should also be promoted in the Sami languages to ensure similar health benefits in Sami and 
non-Sami communities.  
 
The excess risk of IS and CS in Sami observed was small and possible due to residual 
confounding (Paper 3). The observed excess risk of CS was relatively small, which suggests 
that special clinical or public health measures in Sami communities are not necessary at the 
time. Moreover, as we do not know how low height is associated with risk of CS, it is difficult 
to know how to prevent new cases. On the other hand, as CS survivors can suffer significant 
physical and cognitive impairments, reduced capacity to perform daily activities, and might 
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become partially or fully dependent on caregivers, the observation of excess risk of CS in 
Sami calls for awareness. It is therefore important that Sami patients are offered care in 
culturally adapted nursing homes, and offered care in their own language.   
 
6.2 Suggestions for further research  
The findings of Paper 3 should be reproduced in a study including Sami from Norwegian 
cities and comparing reindeer herding Sami with Sami with other occupations, to see if the 
strength of associations changes overall and by these factors. Moreover, the endpoints 
included in Paper 3 should be divided into fatal and non-fatal cases to explore if the ethnic 
differences are more related to fatal than non-fatal events. Also, future research projects on 
cardiovascular health in Sami and non-Sami should try to disentangle what height actually 
represents as an intermediate variable between ethnicity and CS. This could be done with 
mediation analyses. Additionally, as one of the main differences between Sami and non-Sami 
is their exposure to governmental assimilation policies,[138] it would be interesting to 
investigate if Sami experience any long-term cardiovascular health consequences due to 
marginalisation and chronic stress.   
 
Despite the findings of small or no ethnic differences in conventional risk factors and risk of 
CVD, it is necessary with a continuous health surveillance in rural Northern Norway, to make 
sure that health promotion campaigns have a national impact, and to avoid unintended ethnic 
or regional differences in health over time. Moreover, the studies that contribute to the present 
knowledge of small or no ethnic in risks, have used different ethnic categorisation, are from 
different time periods, and include different geographical population. These conditions make 
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Introduction
Indigenous populations often have poorer health than 
their respective majority reference populations [1], 
and recent reviews have indicated poorer cardiovascu-
lar health in Inuit populations and other indigenous 
populations in North America [2–4]. Population 
health is sculptured by many factors: level of educa-
tion, wealth, environmental quality and protection, 
diet, behaviour traits such as physical activity and 
smoking, occupational and domestic stresses and 
genetics. Varying exposures to such factors over time 
can generate ethnic differences in health [5].
The Sami are an indigenous people whose tradi-
tional settlement area, Sápmi, stretches from the 
Kola Peninsula in the north to Engerdal and Idre in 
the south of Norway and Sweden, respectively [6]. 
Finnmark is the northernmost county in Norway and 
the region most influenced by Sami language and 
culture [6]. The Kven are descendants of Finnish-
speaking settlers who emigrated from Sweden and 
Finland to the northern parts of Norway in the 1700s 
and 1800s [7].
In 1974–1975, a cardiovascular risk score among 
Sami and Kven/Finnish men aged 35–49 years in 
Finnmark was about 40% higher than that among 
Norwegian men [8]. The score only included systolic 
blood pressure, serum total cholesterol and smoking 
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habits. however, later studies restricted to Finnmark 
county in the period 1974–1989 [9–12] and the 
SAMINOR 1 Survey from 2003–2004 [13] also 
including the southern regions of Sápmi showed 
none or only minor differences in the distribution of 
cardiovascular risk factors and in the burden of car-
diovascular disease (cVD) between Sami and non-
Sami populations in Norway. In terms of differences 
in cVD mortality between these ethnic groups, there 
have been conflicting results [14,15]. Furthermore, 
in Northern Norway, risk-factor levels and cVD 
mortality have declined over the last decades [16]. 
Whether this decline has been the same in Sami and 
non-Sami populations is unknown. hence, updated 
knowledge concerning the distribution of cVD risk 
factors and a comprehensive cVD risk assessment of 
the Sami and non-Sami populations settled in Sápmi 
is needed.
cVD is multifactorial. Thus, guidelines for pre-
vention recommend assessing the impact of several 
risk factors simultaneously [17]. The NORRISK 2 
model is a cardiovascular risk model based on 
Norwegian data. It estimates the 10-year risk of fatal 
or non-fatal acute myocardial infarction (AMI) or 
cerebral stroke (cS) by combining information from 
several risk factors [18]. using this model and data 
from the second survey of the Population-based 
Study on health and living conditions in Regions 
with Sami and Norwegian Populations (the 
SAMINOR 2 clinical Survey), the primary objective 
of the present study was to compare the distribution 
of risk factors included in the NORRISK 2 model 
and the estimated 10-year risk of AMI or cS in Sami 
and non-Sami populations. Furthermore, to give a 
comprehensive cardiovascular risk profile to Sami 
and non-Sami populations, we also present the distri-
bution of other established risk factors and education 
attainment. The 10-year risk for AMI or cS has not 
previously been computed and compared for Sami 
and non-Sami populations.
Methods
The Population-based Study on health and living 
conditions in Regions with Sami and Norwegian 
Populations – the SAMINOR Study – is run by the 
centre for Sami health Research at uiT – The Arctic 
university of Norway. The present analyses are based 
on cross-sectional data from the second survey, the 
SAMINOR 2 clinical Survey (hereafter referred to 
as SAMINOR 2), conducted in 2012–2014. 
Invitation to SAMINOR 2 included all inhabitants 
(n=12,455) aged 40–79 years residing in the munici-
palities of Evenes in Nordland county; Skånland, 
Kåfjord, Storfjord and lyngen in Troms county; and 
Karasjok, Kautokeino, Porsanger, Tana and Nesseby 
in Finnmark county. In total, 6004 inhabitants 
accepted. The overall response rate was 48.2% (i.e. 
45.8% men and 54.2% women) and varied from 
41% in Evenes to 56% in Kautokeino. The partici-
pants completed a self-administered questionnaire 
that was mailed with the invitation letter and returned 
at the clinical examination. Participants aged 40–69 
years completed an eight-page questionnaire; those 
aged 70–79 years completed a four-page question-
naire, with fewer questions and larger fonts. 
Questionnaires were prepared in Norwegian and 
translated into Northern Sami. Both the Sami and 
the Norwegian versions of the questionnaire were 
distributed to participants in Kautokeino, Karasjok, 
Nesseby and Tana, and the Sami version was availa-
ble upon request to participants in Kåfjord, Storfjord, 
Porsanger and lyngen. Invitees in Skånland and 
Evenes received the Norwegian questionnaire only. 
The SAMINOR Study was accredited by the 
Norwegian Data Inspectorate and approved by the 
Regional committee for Medical and health 
Research Ethics. The committee also approved this 
study, for which all participants gave written informed 
consent.
Clinical examination and blood-sample 
collection
Waist circumference was measured at the umbilicus 
with the participant standing, and abdominal obesity 
was determined by using the thresholds >102 cm 
and >88 cm for men and women, respectively. At 
least 15 minutes after participant arrival, blood pres-
sure was measured with an automatic device 
(cAREScAPE™ V100 monitor), with the partici-
pants in a seated position with their arms resting at 
heart level. Following a two-minute rest, three meas-
urements were taken at one-minute intervals. The 
average of the last two measurements was used in the 
statistical analysis.
Non-fasting blood samples were collected with 
participants in a seated position. Tubes with antico-
agulant were used for glycated haemoglobin 
(hbA1c) measurements conducted on-site within 
15 minutes of blood collection using DcA Vantage™ 
(Siemens Medical Solutions Diagnostics, Tarrytown, 
NY), which uses an agglutination inhibition immu-
noassay method. Tubes for serum samples were cen-
trifuged within two hours of blood collection. Serum 
was separated and stored at −20°c, transported for 
further storage at –70°c and later used to analyse 
high-density lipoprotein (hDl) cholesterol, triglyc-
erides and total cholesterol at the university hospital 
of North Norway using an enzymatic colorimetric 
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test run with cobas 8000B (Roche Diagnostics 
Gmbh, Mannheim, Germany). Thresholds for tri-
glycerides and hbA1c were taken from European 
[17] and World health Organization guidelines [19], 
respectively.
Questionnaire
Ethnicity was ascertained by the questions: ‘What 
language(s) do/did you, your parents and your grand-
parents use at home?’, ‘What is your, your father’s 
and your mother’s ethnic background?’ and ‘What 
ethnicity do you consider yourself to be?’ On all 
items, the response options were ‘Norwegian’, ‘Sami’, 
‘Kven’ and ‘other’. The questions were answered sep-
arately for each relative (11 questions in total), and 
multiple answers were allowed. Participants were 
defined as Sami if they considered themselves to be 
Sami or reported a Sami ethnic background and at 
least one of their grandparents, parents or they them-
selves spoke a Sami language at home. All others 
were categorised as non-Sami.
We identified current smokers and non-smokers 
from the questions: ‘have you ever smoked daily?’ (yes/
no) and ‘Are you currently a daily smoker?’ (yes/no). 
Previous smokers were categorised as non-smokers.
Anti-hypertensive treatment was ascertained from 
the question: ‘Are you taking medication for high 
blood pressure?’ The response options were ‘yes, cur-
rently’, ‘in the past, but not currently’ and ‘no’. 
Participants reporting former use were merged with 
non-users, and missing values were ad hoc imputed 
as non-users.
Both questionnaire information and hbA1c meas-
urements were applied to identify participants with 
diabetes mellitus. The question was: ‘have you ever 
been diagnosed with diabetes (high blood sugar)?’ 
(yes/no). Missing values were classified as ‘no’. In 
addition, all participants with hbA1c values ≥6.5% 
(48 mmol/mol) were classified as having diabetes mel-
litus, regardless of their reply on the questionnaire.
Physical activity was measured by asking: ‘Please 
indicate your levels of physical activity at the ages of 
14, 30 and at your current age, on a scale from 1 to 
10. “Physical activity” includes household chores 
and professional activities, as well as regular exercise 
and other physical activity, such as walking/hiking. 
Please mark (with an ‘X’) below the number that 
most accurately denotes your physical activity levels’. 
In this study, we used physical activity at current age, 
an instrument validated in middle-aged women liv-
ing in Tromsø, Norway [20]. We recoded the 10-level 
physical activity scale into three categories: low (lev-
els 1–3), moderate (levels 4–7) and high physical 
activity (levels 8–10).
Years of education was measured with the ques-
tion: ‘how many years of education have you com-
pleted? (Include any and all years in which you 
attended school or studied)’. We categorised this item 
into three levels: 0–9 years, 10–12 years and ≥13 
years, which roughly corresponds to compulsory pri-
mary and lower secondary school, upper secondary 
school and higher education, respectively.
The NORRISK 2 model
The NORRISK 2 model is validated and intended to 
be used in primary prevention of cVD in the 
Norwegian population aged 40–79 years [18]. The 
model is used to estimate the 10-year risk (%) of hos-
pitalisation with AMI (International classification of 
Diseases [IcD-10] codes I21–22) as main or second-
ary diagnosis, death from ischaemic heart diseases 
(IcD-10 codes I20–25) as the underlying cause, or 
hospitalisation with cS (IcD-10 codes I60–61 and 
I63–64 except I63.6) as main or secondary diagnosis 
or death from cS as underlying cause [18]. The 
10-year risk estimations are based on sex, age, total 
cholesterol, hDl-cholesterol, systolic blood pres-
sure, smoking habits, anti-hypertensive treatment 
and family history of premature coronary heart dis-
ease [18]. All but family history of premature coro-
nary heart disease were included in SAMINOR 2. In 
the model development, Selmer et al. treated death 
from other causes as competing risk. We used the 
age-specific, high-risk thresholds suggested by 
Selmer et  al. [18] to identify individuals at high 
10-year risk of fatal or non-fatal AMI or cS events 
who should be offered pharmacological treatment: 
≥5% in the age group 45–54, ≥10% in the age group 
55–64 and ≥15% in the age group 65–74 years. For 
those aged 40–44 and 75–79 years included in our 
study, we used the high risk threshold ≥5% and 
≥15%, respectively.
Statistical analyses
Statistical analyses were performed using Stata v14.0 
(Statacorp, college Station, TX). Ethnic differences 
in characteristics and age-specific cardiovascular 
risks were tested by two-sample t-tests with equal 
variance for continuous variables and Pearson’s chi-
square test (Tables I and II) and Fisher’s exact test 
(Tables III and IV) for categorical variables. Test of 
trends across ordered groups (Tables I and II) was 
done with Wilcoxon’s rank-sum test. Age standardi-
sation of means and proportions was done separately 
in men and women using the direct method and hav-
ing the sex-specific invited SAMINOR 2 sample in 
five-year age groups as the standard population. 
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comparisons of age-standardised means and pro-
portions were done with a two-sample t-test with 
equal variance and a two-sample test for propor-
tions, respectively, using the age-standardised esti-
mates of means, proportions and standard deviations. 
We considered p-values <0.05 to be statistically 
significant.
In sensitivity analyses, three ethnic categories were 
compared with regard to mean risk scores and pro-
portions at high risk: (1) those who reported ‘Sami’ 
on all 11 questions on ethnicity, (2) those who 
reported ‘Sami’ on at least one question and (3) 
those not reporting ‘Sami’ on any of the questions. 
We assessed whether region of residence modified 
mean risk scores and proportions at high risk (using 
the original ethnic categorisation) by merging munic-
ipalities that may be perceived as similar in terms of 
number of Sami inhabitants, Sami language users 
and geographical location: (1) Kautokeino and 
Karasjok; (2) Nesseby, Tana and Porsanger; and (3) 
Skånland, Evenes, Storfjord, lyngen and Kåfjord. 
Additionally, in a separate set of analyses, we excluded 
participants on anti-hypertensive treatment (n=1382) 
to explore whether there were ethnic differences in 
non-users of anti-hypertensive medication.
Results
Of the 6004 SAMINOR 2 participants, 21 did not 
answer the questionnaire, 75 did not answer the 
questions on ethnicity, 26 had missing cholesterol 
values, three had missing systolic blood pressure, 193 
reported angina pectoris, 244 reported AMI and 124 
had missing information on smoking habits and were 
excluded. Thus, our analyses included 5318 individ-
uals (44.1% of the sample were men and 40.8% were 
Sami), representing 42.7% of the invited sample.
In men, statistically significant differences were 
found in mean total cholesterol, the distribution of 
hDl-cholesterol and triglycerides, mean diastolic 
blood pressure, hbA1c, proportions with diabetes 
mellitus, mean waist circumference and the level of 
Table I. unadjusted sample characteristics of non-Sami and Sami men (n=2346): The SAMINOR 2 clinical Survey (2012–2014).
Variables Non-Sami, n = 1372 Sami, n = 974 p-value
Age (years), mean (SD) 59.4 (10.2) 58.8 (10.1) 0.11
 40–54 years, % (n) 32.9 (451) 36.3 (353) 0.03
 55–64 years, % (n) 31.4 (431) 32.4 (316)  
 65–79 years, % (n) 35.7 (490) 31.3 (305)  
Total cholesterol (mmol/l), mean (SD) 5.42 (1.0) 5.52 (1.1) 0.03
Total cholesterol >5.0 mmol/l, % (n) 67.6 (928) 69.7 (679) 0.29
hDl-cholesterol (mmol/l), mean (SD) 1.29 (0.4) 1.24 (0.4) <0.001
hDl-cholesterol <1.0 mmol/l, % (n) 17.9 (246) 21.6 (210) 0.03
Triglycerides (mmol/l), mean (SD) 1.80 (1.1) 1.94 (1.1) 0.002
Triglycerides >1.7 mmol/l, % (n) 44.1 (605) 51.2 (499) 0.001
Systolic blood pressure (mmhg), mean (SD) 134.9 (17.2) 134.3 (18.1) 0.39
Systolic blood pressure ≥140 mmhg, % (n) 34.4 (472) 33.8 (329) 0.75
Diastolic blood pressure (mmhg), mean (SD) 78.1 (9.4) 77.3 (9.9) 0.04
Diastolic blood pressure ≥90 mmhg, % (n) 11.0 (151) 11.4 (111) 0.77
Anti-hypertensive treatment (yes), % (n) 26.7 (366) 23.4 (228) 0.07
current smoking (yes), % (n) 16.0 (220) 19.1 (186) 0.05
hbA1ca (%), mean (SD) 5.69 (0.6) 5.79 (0.8) <0.001
Diabetes mellitusb (yes), % (n) 8.3 (114) 11.0 (107) 0.03
Waist circumferencec (cm), mean (SD) 100.0 (10.6) 98.5 (10.8) 0.001
Waist circumference >102 cm, % (n) 35.0 (479) 31.8 (309) 0.11
Physical activityd, mean (SD) 5.3 (2.0) 5.2 (2.2) 0.08
 low (1–3), % (n) 19.6 (263) 23.4 (220) 0.43
 Moderate (4–7), % (n) 66.3 (892) 60.6 (569)  
 high (8–10), % (n) 14.1 (190) 16.0 (150)  
Years of educatione, mean (SD) 12.0 (3.6) 11.7 (3.7) 0.14
 0–9 years, % (n) 27.7 (369) 32.3 (302) 0.04
 10–12 years, % (n) 33.1 (441) 31.0 (290)  
 ≥13 years, % (n) 39.2 (524) 36.7 (343)  
aMissing values: non-Sami, n = 3; Sami, n = 3.
bDiabetes mellitus: self-reported diabetes or hbA1c ≥6.5%.
cMissing values: non-Sami, n = 3; Sami, n = 2.
dMissing values: non-Sami, n = 27; Sami, n = 35.
eMissing values: non-Sami, n = 38; Sami, n = 39.
SD: standard deviation.
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education (Table I). compared with non-Sami men, 
Sami men had a more unfavourable distribution 
(except for waist circumference and diastolic blood 
pressure).
In women, Sami had statistically significantly 
lower hDl-cholesterol and physical activity level 
and higher triglycerides and higher proportions with 
waist circumference >88 cm (Table II).
Table II. unadjusted sample characteristics of non-Sami and Sami women (n=2972): The SAMINOR 2 clinical Survey (2012–2014).
Variables Non-Sami, n=1777 Sami, n=1195 p-value
Age (years), mean (SD) 58.6 (10.6) 57.9 (10.2) 0.08
 40–54 years, % (n) 37.0 (657) 37.7 (451) 0.10
 55–64 years, % (n) 30.4 (541) 34.0 (406)  
 65–79 years, % (n) 32.6 (579) 28.3 (338)  
Total cholesterol (mmol/l), mean (SD) 5.59 (1.0) 5.61 (1.1) 0.55
Total cholesterol >5.0 mmol/l, % (n) 71.1 (1264) 72.1 (861) 0.59
hDl-cholesterol (mmol/l), mean (SD) 1.55 (0.5) 1.45 (0.4) <0.001
hDl-cholesterol <1.3 mmol/l, % (n) 25.3 (450) 32.7 (391) <0.001
Triglycerides (mmol/l), mean (SD) 1.53 (0.9) 1.66 (0.9) <0.001
Triglycerides >1.7 mmol/l, % (n) 33.6 (597) 39.7 (475) 0.001
Systolic blood pressure (mmhg), mean (SD) 130.6 (18.3) 129.6 (19.3) 0.14
Systolic blood pressure ≥140 mmhg, % (n) 27.0 (479) 26.5 (317) 0.80
Diastolic blood pressure (mmhg), mean (SD) 72.4 (9.0) 71.8 (9.3) 0.08
Diastolic blood pressure ≥90 mmhg, % (n) 3.6 (64) 3.8 (45) 0.82
Anti-hypertensive treatment (yes), % (n) 26.7 (475) 26.2 (313) 0.75
current smoking (yes), % (n) 20.1 (357) 22.5 (269) 0.11
hbA1ca (%), mean (SD) 5.66 (0.6) 5.71 (0.5) 0.05
Diabetes mellitusb (yes), % (n) 8.3 (148) 10.0 (120) 0.11
Waist circumferencec (cm), mean (SD) 92.7 (12.1) 93.4 (12.0) 0.13
Waist circumference >88 cm, % (n) 61.7 (1093) 66.1 (789) 0.01
Physical activityd,mean (SD) 5.6 (2.1) 5.3 (2.1) <0.001
 low (1–3), % (n) 15.5 (257) 22.8 (261) <0.001
 Moderate (4–7), % (n) 64.8 (1076) 60.7 (696)  
 high (7–10), % (n) 19.7 (328) 16.5 (189)  
Years of educatione,mean (SD) 12.4 (4.0) 12.7 (4.4) 0.09
 0–9 years, % (n) 26.0 (445) 27.8 (316) 0.28
 10–12 years, % (n) 30.3 (517) 23.2 (263)  
 ≥13 years, % (n) 43.7 (747) 49.0 (556)  
aMissing values: non-Sami, n=1; Sami, n=6.
bDiabetes mellitus: self-reported diabetes or hbA1c ≥6.5%.
cMissing values: non-Sami, n=5; Sami, n=2.
dMissing values: non-Sami, n=116; Sami, n=49.
eMissing values: non-Sami, n=68; Sami, n=60.
SD: standard deviation.
Table III. Mean 10-year risk and proportion of participants at high risk of acute myocardial infarction (AMI) or cerebral stroke (cS) in 
non-Sami and Sami men aged 40–79 years, n=2346: The SAMINOR 2 clinical Survey (2012–2014).
Age Non-Sami (n=1372) Sami (n=974)
n n p-value
40–54 years Mean (SD) 451 3.6 (2.6) 353 4.0 (3.1) 0.06
 ≥5% (n) 21.5% (97) 23.2% (82) 0.61
55–64 years Mean (SD) 431 8.8 (4.2) 316 9.5 (5.0) 0.06
 ≥10% (n) 26.7% (115) 36.1% (114) 0.006
65–79 years Mean (SD) 490 18.0 (6.4) 305 18.1 (6.7) 0.81
 ≥15% (n) 63.5% (311) 61.3% (187) 0.55
Total  
crude mean (SE) 1372 10.4 (0.21) 974 10.2 (0.25) 0.55
Age-standardised mean (SE) 1372 9.5 (0.10) 974 9.8 (0.13) 0.05
% with high riska (n) 38.1% (523) 39.3% (383) 0.56
Age-standardised % with high risk 35.6% 37.5% 0.35
aProportions with 10-year risk of AMI or cS ≥5%, ≥10% and ≥15% in age groups 40–54, 55–64 and 65–79 years, respectively.
SD: standard deviation.
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In the total analytical population, disregarding eth-
nicity, the age-standardised mean 10-year risk of AMI 
or cS and the proportion of participants at high risk 
were 9.6% and 36.4%, respectively, for men, and 5.8% 
and 11.6%, respectively, for women (results not shown).
The mean 10-year risk of AMI or cS by age for 
Sami and non-Sami men and women is displayed in 
Figure 1. Overall, there were no ethnic differences in 
the 10-year risk of AMI or cS (Tables III and IV, and 
Figure 1). This was due to only minor ethnic differ-
ences in the distribution of the cardiovascular risk 
factors included in the NORRISK 2 model. however, 
among men aged 55–64 years, more Sami than non-
Sami had a high 10-year risk of AMI or cS (36.1% 
vs. 26.7%; p=0.006). Sami men in this age group had 
a somewhat unfavourable distribution in most of the 
risk factors included in the model (results not shown). 
Additionally, the age-standardised 10-year mean risk 
for non-Sami and Sami men was borderline signifi-
cant (9.5 vs. 9.8; p=0.05).
Overall, the sensitivity analyses did not show 
markedly different results by ethnicity or region of 
residence. Among non-users of anti-hypertensive 
medication, Sami women had lower systolic (125.9 
vs. 127.9 mmhg; p=0.008) and diastolic (71.0 vs. 
71.9 mmhg; p=0.02) blood pressure than non-Sami 
women (results not shown).
Discussion
We observed no overall differences in the 10-year risk 
of AMI or cS, as estimated by the NORRISK 2 
model, between Sami and non-Sami participants. 
This was due to minor ethnic differences in the dis-
tribution of the cardiovascular risk factors included 
in the model. Overall, 36.4% of men and 11.6% of 
women had a high 10-year risk of AMI or cS.
Our results of an overall similar distribution of 
cardiovascular risk factors between Sami and non-
Sami participants agree with previous studies from 
Norway, Sweden and Finland [9-10, 13, 21-25]. 
however, we found a somewhat unfavourable distri-
bution of triglycerides, physical activity (women 
only), waist circumference (women only) and diabe-
tes mellitus (men only) in Sami compared to non-
Sami participants. To what extent ethnic discrepancies 
in these risk factors may contribute to a different risk 
of AMI or cS in Sami relative to non-Sami popula-
tions, is uncertain.
A publication with data from 1974/1975–1989 
found that Sami men in Finnmark had a similar risk 
of AMI to Norwegian men, but indicated a 50% 
increased incidence of cerebrovascular disease [12]. 
In 1970–1998, Sami men and women (based on 
census data) living north of the Arctic circle in 
Norway had higher mortality from cerebrovascular 
diseases, that is, 14% and 28% higher mortality rates 
in men and women, respectively. however, male 
reindeer herders had a lower risk of death from 
ischaemic heart disease than other Sami and non-
Sami populations, and this was also the case, to some 
extent, for cerebrovascular disease [14]. In a follow-
up study from 1977/1978–1992, including men aged 
35–52 years in Finnmark, 67% and 52% lower mor-
tality rates were found for ischaemic heart disease 
and total cVD, respectively, in Sami compared to 
non-Sami men [15].
Among men in Sweden, the overall incidence of 
hospitalisations due to cerebrovascular disease 
was higher in Sami populations but lower in Sami 
Table IV. Mean 10-year risk and proportion of participants at high risk of acute myocardial infarction (AMI) or cerebral stroke (cS) in 
non-Sami and Sami women aged 40–79 years, n=2972: The SAMINOR 2 clinical Survey (2012–2014).
Age Non-Sami (n=1777) Sami (n=1195)
n n p-value
40–54 years Mean (SD) 657 1.3 (1.2) 451 1.4 (1.3) 0.24
 ≥5% (n) 2.3% (15) 2.7% (12) 0.70
55–64 years Mean (SD) 541 5.0 (3.0) 406 4.7 (2.8) 0.27
 ≥10% (n) 5.2% (28) 5.4% (22) 0.88
65–79 years Mean (SD) 579 12.0 (5.4) 338 12.2 (5.3) 0.68
 ≥15% (n) 24.7% (143) 28.1% (95) 0.28
Total
crude mean (SE) 1777 5.9 (0.14) 1195 5.6 (0.16) 0.12
Age-standardised mean (SE) 1777 5.8 (0.07) 1195 5.9 (0.08) 0.44
% with high riska (n) 10.5% (186) 10.8% (129) 0.78
Age-standardised % with high risk 11.0% 12.6% 0.19
aProportions with 10-year risk of AMI or cS ≥5%, ≥10% and ≥15% in age groups 40–54, 55–64 and 65–79 years, respectively.
SD: standard deviation.
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reindeer herders than in a regional non-Sami refer-
ence population [26]. Death from AMI was also 
higher in Sami women but not in female Sami rein-
deer herders [26,27], among whom the incidence of 
AMI was lower and cerebrovascular diseases higher 
[26]. In Finland, no difference in mortality from cer-
ebrovascular disease between Sami and non-Sami 
populations have been reported [28], whereas a lower 
mortality from ischaemic heart disease has been 
observed in Sami women compared to a non-Sami 
female reference population [28,29].
Overall, it seems like Sami men and women may 
have a somewhat increased risk of ischaemic heart 
disease and cerebrovascular disease that does not 
necessarily apply to male reindeer herders, who 
might have reduced risk due to assumed higher phys-
ical activity levels [30]. This seems to contrast with 
what we found in our study, that is, no overall ethnic 
difference in 10-year risk of AMI and cS in men and 
women. We did find that Sami men aged 55–64 years 
had a higher 10-year risk of AMI or cS than their 
non-Sami counterparts. however, this might be a 
chance finding.
The inferior cardiovascular health observed 
among indigenous peoples relative to non-indige-
nous peoples in North America may be due to lower 
socio-economic status and poorer access to quality 
health care among the former [4]. A publication 
from Norway found that differences in smoking hab-
its, systolic blood pressure, serum cholesterol and 
body mass index explained 72% and 56% of the 
absolute and relative educational gradients, respec-
tively, in cVD mortality [31]. Assuming that the 
educational gradient in Sami and non-Sami popula-
tions is the same, the most plausible explanation for 
the similar levels of risk factors and risk of AMI or 
cS observed in our study may be that Sami and 
non-Sami populations in Norway differ little with 
regard to education levels (Tables I and II). however, 
Sjölander et al. found a somewhat higher incidence 
of cerebrovascular diseases and AMI mortality in 
Sami compared to non-Sami women in Sweden, 
which was not explained by education or income 
[26]. Thus, variables other than traditional socio-
economic ones may also be relevant in explaining 
the disparities in the risk of cVD between Sami and 
non-Sami populations. Equal access to health care 
has also been put forward as a plausible explanation 
for the small differences in health and risk factors 
between Sami and non-Sami populations [32]. The 
fact that we observed no difference in anti-hyperten-
sive treatment indicates that ethnic discrepancies in 
access to cVD treatment may not be an issue.
This study has some strengths. The relatively large 
sample of Sami and non-Sami participants from both 
coastal and inland regions, individual information on 
ethnic background and several biological markers 
and clinical measurements enabled an in-depth anal-
ysis of the total risk of AMI or cS. The NORRISK 2 
model has a major advantage, as it takes into account 
competing risk and incorporates both fatal and non-
fatal end points. Furthermore, the NORRISK 2 
model was designed and validated for those aged 
40–79 years in the general population of Norway 
[18], which is the same age range as that included in 
SAMINOR 2.
There are also some limitations. We assumed a 
similar cVD aetiology among Sami and non-Sami 
participants, which may not be correct [15]. 
Moreover, our risk estimations are most likely over-
estimated, as risk factor levels are expected to 
decrease in the future [16]. We did not have data on 
family history of premature ischaemic heart diseases 
and thus could not include it in the model. however, 
unpublished results from the SAMINOR 1 Survey, 
restricted to the same municipalities as SAMINOR 
2, showed no ethnic differences in this regard (results 
not shown). We were not able to assess the 10-year 
risk of AMI or cS among Sami reindeer herders 
alone due to lack of information on occupation and 
association with reindeer husbandry. Finally, the 
NORRISK 2 model does not take into account all 
measured cardiovascular risk factors (e.g. triglycer-
ides, physical activity, waist circumference and diabe-
tes mellitus).
Only 10 municipalities were included in 
SAMINOR 2. Generalisations to the entire Sami or 
non-Sami populations in Norway are therefore not 
justified. Our analyses included 42.7% of the invited 
sample, with more female than male participants, 
though participation in both sexes increased with 
age, as in other studies [33]. Therefore, results for 
the youngest age group, particularly for men, are 
Figure 1. Mean 10-year risk of fatal or non-fatal acute myocardial 
infarction or cerebral stroke by age for non-Sami and Sami men 
(n=2346) and women (n=2972): The SAMINOR 2 clinical Sur-
vey (2012–2014).
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uncertain. We do not know the response rate by eth-
nic group due to lack of ethnic information in 
national registries. however, participation was high-
est in Kautokeino, Nesseby and Tana, where Sami 
are in the majority, and low in some municipalities 
where they are in the minority. This may have led to 
an over-representation of Sami participants from 
majority areas compared to Sami from minority areas 
and non-Sami. Whether this affected the results of 
this study is, however, unknown.
This study provides updated knowledge about the 
cardiovascular health of Sami and non-Sami popula-
tions in rural Northern Norway, which is needed, as 
the majority of comparable studies were conducted 
in Finnmark during 1974–1989. Furthermore, a car-
diovascular risk assessment that combines the impact 
of several risk factors simultaneous and estimates the 
10-year risk of AMI or cS has not been conducted 
previously in Sami and non-Sami populations.
Conclusion
We observed only minor ethnic differences in several 
risk factors for cVDs. Based on results from the 
NORRISK 2 model, we observed no overall differ-
ences in the 10-year risk of AMI or cS between the 
Sami and non-Sami populations living in 10 rural 
municipalities in Northern Norway. Applying the 
thresholds of Selmer et al. [18], 36.4% of men and 
11.6% of women in this population were at high risk 
of AMI or cS.
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AbstrACt
Objective To describe changes in cardiovascular risk 
factors and in the estimated 10-year risk of acute 
myocardial infarction (AMI) or cerebral stroke (CS) between 
SAMINOR 1 (2003–2004) and SAMINOR 2 (2012–2014), 
and explore if these changes differed between Sami and 
non-Sami.
Design Two cross-sectional surveys.
setting Inhabitants of rural Northern Norway.
Participants Participants were aged 40–79 years and 
participated in SAMINOR 1 (n=6417) and/or SAMINOR 2 
(n=5956).
Primary outcome measures Generalised estimating 
equation regressions with an interaction term were used 
to estimate and compare changes in cardiovascular risk 
factors and 10-year risk of AMI or CS between the two 
surveys and by ethnicity.
results Mean cholesterol declined by 0.50, 0.43 
and 0.60 mmol/L in women, Sami men and non-Sami 
men, respectively (all p<0.001). Sami men had a 
small decline in mean high-density lipoprotein (HDL) 
cholesterol and an increase in mean triglycerides (both 
p<0.001), whereas non-Sami showed no change in these 
variables. Non-Sami women had an increase in mean 
HDL cholesterol (p<0.001) whereas Sami women had 
no change. Triglycerides did not change in non-Sami 
and Sami women. Systolic and diastolic blood pressure 
declined by 3.6 and 1.0 mm Hg in women, and 3.1 
and 0.7 in men, respectively (all p<0.01). Mean waist 
circumference increased by 6.7 and 5.9 cm in women and 
men, respectively (both p<0.001). The odds of being a 
smoker declined by 35% in women and 46% in men (both 
p<0.001). Estimated 10-year risk of AMI or CS decreased 
in all strata of sex and ethnicity (p<0.001), however, Sami 
women had a smaller decline than non-Sami did.
Conclusions Independent of ethnicity, there was a 
decline in mean cholesterol, blood pressure, smoking, 
hypertension (women only) and 10-year risk of AMI or CS, 
but waist circumference increased. Relatively minor ethnic 
differences were found in changes of cardiovascular risk 
factors.
IntrODuCtIOn
Since the 1970s, a favourable decline in 
systolic blood pressure,1–4 total cholesterol5–7 
and smoking8 has been reported for the 
adult population across different regions of 
Western Europe. This decline is probably due 
to changes in lifestyle and diet,7 9 10 in addition 
to use of medication.1 5 In Norway, this decline 
has coincided with a decrease in cardiovas-
cular mortality and an increased prevalence 
of obesity and a sedentary lifestyle.11 
The Sami is an indigenous people living in 
Sápmi, that is, the northern parts of Norway, 
Sweden, Finland and the Kola Peninsula in 
the Russian Federation. There are no official 
strengths and limitations of this study
 ► We used generalised estimating equation regression 
to account for overlapping samples.
 ► We used self-reported measures to categorise par-
ticipants into ethnic groups, including questions on 
self-perceived ethnicity, ethnic background and lan-
guage use.
 ► Due to lack of ethnic identifiers in national registries, 
we do not know if participation differs by ethnicity.
 ► We have an acceptable participation rate in both 
surveys.
 ► We lack information about the use of lipid-lowering 
drugs.
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population records on the Sami population, but data 
from the 1970 national census roughly estimated that 
there were 40 000 Sami in Norway,12 whereas 55 000 is the 
population number that the Sami Parliament uses when 
considering subsidy schemes for business development.13 
In 2017, approximately 17 000 Sami adults were enrolled 
in the electoral register to the Sami Parliament in Norway, 
which gives them the right to vote and be elected.14 The 
Sami people have unique cultures and languages, but 
these have partly vanished or at least declined in practice, 
due to structural assimilation that occurred from 1850 to 
1960.15 The Norwegian part of Sápmi is also inhabited by 
Norwegians and Kvens, the latter of whom are descen-
dants of Finnish-speaking people that came from Sweden 
and Finland to Northern Norway in the 1700s and 1800s.16
Surveys from Norway have concluded that there are no 
or only minor differences in cardiovascular risk factors 
and morbidity between the Sami and non-Sami in rural 
regions.17–21 However, knowledge is lacking on changes 
in conventional cardiovascular risk factors. Thus, this 
study aimed to describe changes in cardiovascular risk 
factors and in the estimated 10-year risk of acute myocar-
dial infarction (AMI) or cerebral stroke (CS) between 
SAMINOR 1 (2003–2004) and SAMINOR 2 (2012–2014), 
and explore if these changes differed between Sami and 
non-Sami.
MethODs
We used data from two cross-sectional surveys of the 
Population-based Study on Health and Living Condi-
tions in Regions with Sami and Norwegian Populations 
(The SAMINOR Study): the SAMINOR 1 Survey carried 
out in 2003–2004 (SAMINOR 1) and the SAMINOR 2 
Clinical Survey carried out in 2012–2014 (SAMINOR 
2). SAMINOR 1 was a collaboration between the Centre 
for Sami Health Research at UiT The Arctic Univer-
sity of Norway and the Norwegian National Institute of 
Public Health,22 whereas SAMINOR 2 was performed 
by the former only.23 Participants were invited from 10 
municipalities (figure 1) that, according to the popula-
tion census from 1970,12 had high proportions of Sami 
inhabitants. Invitations were mailed to all who were 
aged 40–79 years and were registered as inhabitants in 
the 10 municipalities by the National Registry. In total, 
11 518 and 12 455 received an invitation to SAMINOR 1 
and SAMINOR 2, respectively. Participation was volun-
tarily and clinical examinations in each municipality were 
conducted within a period of 1–7 weeks, depending on 
the population size. Our analyses were restricted to those 
who attended clinical examinations, gave blood samples 
and answered the self-administered questionnaires.
Participant and public involvement
Participants that had pathological findings from the clin-
ical examination, were recommended to contact their 
primary physician. In emergency situations, participants 
were sent directly to the local health centre or the nearest 
hospital.
Before and after the surveys, the Centre for Sami 
Health Research had consultations with the Sami Parlia-
ment, Sami researchers and health workers in Sami core 
areas to identify the needs of the Sami community. Results 
from the surveys were reported to decision makers at the 
municipal and regional levels, and to the Sami Parlia-
ment and national health authorities. The population was 
informed through popular science forums, meetings and 
lectures.
study sample
There were 6550 (56.9%) and 6004 (48.2%) individuals 
who attended the clinical examinations in SAMINOR 1 
and SAMINOR 2, respectively. If information on ethnicity 
was lacking in one of the surveys, ethnicity information 
given in the other survey was used, as Sami ethnicity 
is found to be stable.24 This strategy was valuable for 
the SAMINOR 1 sample, as ethnicity information was 
lacking for some participants due to the study design.22 
In SAMINOR 1, we categorised 69 out of 201 by using 
ethnicity information from SAMINOR 2: 7 non-Sami 
and 62 Sami. In SAMINOR 2, 96 had missing data on 
ethnicity and we categorised 58: 37 non-Sami and 21 
Figure 1 Inhabitants aged 40–79 years living in these 10 
municipalities in the Norwegian part of Sápmi were invited to 
the SAMINOR 1 and SAMINOR 2 surveys. Region 1 includes 
Kautokeino and Karasjok, region 2 includes Nesseby, Tana 
and Porsanger, and region 3 includes Kåfjord, Lyngen, 
Storfjord, Skånland and Evenes. There are no copyrights 
attached to this figure. The figure is designed for this article 
by one of the co-authors, Marita Melhus, Centre for Sami 
Health Research at UiT The Arctic University of Norway. 
The figure is based on a raw map of Norway made by the 
Norwegian Mapping Authority, merged with a map of Europe 
that is available to the public domain at Wikipedia.
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Sami. Furthermore, we excluded those that did not hand 
in the main questionnaires (SAMINOR 1: n=1; SAMINOR 
2: n=10). This left us with a final sample of 6417 and 5956 
from SAMINOR 1 and SAMINOR 2, respectively, wherein 
3249 participated in both surveys.
Information from questionnaires
Participants were categorised into ethnic groups based on 
information from the following 11 questions, which were 
identical in the two surveys: ‘What language(s) do/did 
you, your parents, and your grandparents use at home?’; 
‘What is your, your father’s, and your mother’s ethnic 
background?’; ‘What do you consider yourself to be?’ The 
response options were ‘Norwegian’, ‘Sami’, ‘Kven’ and 
‘other’ and multiple answers were allowed. Participants 
were defined as Sami if they (1) considered themselves 
to be Sami, or reported a Sami ethnic background for 
themselves, and (2) spoke a Sami language themselves 
or had at least one parent or grandparent that used it at 
home. All others were categorised as non-Sami. Sensitivity 
analyses were performed, in which different ethnic cate-
gorisations were used.
Smoking status was determined by the following ques-
tions, in SAMINOR 1: ‘Are you currently, or were you 
previously a daily smoker?’ (Yes, currently/Yes, previ-
ously/Never); in SAMINOR 2: ‘Have you ever smoked 
daily?’ (Yes/No), and ‘Are you currently a daily smoker?’ 
(Yes/No). Previous and never smokers were categorised 
as non-smokers.
Use of anti-hypertensive drugs was determined by the 
following question: ‘Do you take medication for high 
blood pressure?’ (Currently/Previously, but not now/
Never used). Previous use, never-use and missing values 
were merged into non-use.
In both surveys, participates reported if they ever have 
had myocardial infarctions and age at first time. Positive 
responses to the former, or age reported for first time, 
were considered as having had a myocardial infarction.
Leisure time physical activity was measured in 
SAMINOR 1 by the ‘Saltin-Grimby’ questionnaire.25 
Overall physical activity at current age was measured in 
SAMINOR 2 by a scale ranging from 1 to 10; an instru-
ment validated in middle aged women living in Tromsø, 
Norway.26
Alcohol consumption was measured in SAMINOR 1 by 
asking: ‘How often during the last year have you consumed 
alcohol?’ (Never/Not during the last year/A few times 
during the last year/1 time per month/2–3 times per 
month/1 time per week/2–3 times per week/4–7 times 
per week). To approximate the question in SAMINOR 2, 
we created two categories: never consumed alcohol and 
consumers of alcohol. In SAMINOR 2, alcohol consump-
tion was asked as follows: ‘Do you practice total alcohol 
abstinence?’ (Yes/no).
Education was measured similarly in both surveys by 
years of education. We categorised the item to match 
roughly primary and lower secondary school, upper 
secondary school and higher education: ≤9 years, 10–12 
years and ≥13 years.
Clinical examination
Trained staff conducted the clinical examination. Waist 
circumference was measured at the umbilicus when the 
participant was standing. Blood pressure was measured 
with digital oscillometric devices (SAMINOR 1: DINA-
MAP-R, Criticon, Tampa, Florida, USA; SAMINOR 2: 
CARESCAPE V100 monitor, GE Healthcare, Milwaukee, 
Wisconsin, USA), with the participant in a seated posi-
tion. Following a 2 min rest, three recordings were made 
at 1 min intervals, and the average of the last two measure-
ments was used in the analysis. Participants were consid-
ered to have hypertension if their systolic blood pressure 
was ≥140 mm Hg, or their diastolic blood pressure was 
≥90 mm Hg, or if they reported using anti-hypertensive 
drugs.
In both surveys, non-fasting blood samples were 
collected. The blood samples were left to coagulate for 
a minimum of 30 min, after which they were centrifuged 
and serum was separated within 2 hours. In SAMINOR 1, 
serum was sent by overnight post and analysed consecu-
tively for lipids (total cholesterol, high-density lipoprotein 
(HDL) cholesterol and triglycerides) with an enzymatic 
method (Hitachi 917 auto analyser, Roche Diagnostics, 
Switzerland) at Ullevål University Hospital, Oslo, Norway. 
In SAMINOR 2, serum samples were kept at −20°C before 
they were sent to the biobank at UiT The Arctic University 
of Norway, for further storage at −70°C. The samples were 
analysed in batches during autumn 2014 at the University 
Hospital of North Norway, Tromsø, Norway. Lipids were 
measured with an enzymatic colorimetric method (Cobas 
8000B, Roche Diagnostics GmbH, Mannheim, Germany).
The 10-year absolute risk of fatal or non-fatal AMI or 
CS was estimated by the NORRISK 2 model27 and deter-
mined separately in women and men based on age, total 
cholesterol, HDL cholesterol, smoking status, systolic 
blood pressure and use of anti-hypertensive drugs.
statistical analyses
Statistical analyses were done using STATA V.15.0. Sample 
characteristics were given by sex for Sami and non-Sami 
in SAMINOR 1 and SAMINOR 2: means (SD) of contin-
uous variables and proportions (numbers) of categorical 
variables. In order to account for the partly overlapping 
samples, changes in population average means and 
prevalences of risk factors between SAMINOR 1 and 
SAMINOR 2 were estimated by sex- and ethnicity-specific 
linear or logistic generalised estimating equation regres-
sion models. Assumptions of normality and homoscedas-
ticity were assessed by a visual inspection of residual plots. 
Changes in triglycerides and in the estimated 10-year risk 
of AMI or CS were log-transformed due to skewed distri-
butions. All regression models were adjusted for age, and 
linear models were additionally adjusted for age squared. 
We assessed if changes in outcomes differed by ethnicity 
by including an interaction term between survey and 
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ethnicity in sex-specific models. If the p value for inter-
action was >0.05, the interaction term was excluded from 
the model and an overall sex-specific mean/prevalence 
was reported. In the opposite case, ethnicity-specific 
changes were reported. Marginal means/prevalences 
were estimated at age 57.5 years in women and at 58.2 
years in men, that is, the sex-specific mean ages in the 
overall sample. Two-way graphs illustrate how cardio-
vascular risk factors varied by age, ethnicity and survey 
(online supplementary figures S1 and S2). Potential 
heterogeneity by age in the overall models was assessed 
by comparing two strata divided at sex-specific mean age. 
The terms for interaction between ethnicity and survey 
remained non-significant across age strata for both sexes. 
Hence, we concluded that age did not modify the overall 
estimates of change in cardiovascular risk factors. We 
considered a two-sided p<0.05 to be significant.
Sensitivity analyses were done with same sex-stratified 
generalised estimating equation models by
1. Dividing the study sample into three groups: (1) those 
who reported ‘Sami’ for all 11 questions, (2) who 
reported Sami in 1–10 questions and (3) those who did 
not report Sami on any of the questions (non-Sami) 
(online supplementary tables S1 and S2).
2. Using the original ethnic categorisation, we adjusted 
for geographical regions: (1) Kautokeino and Karasjok, 
(2) Nesseby, Tana and Porsanger, (3) Kåfjord, Lyngen, 
Storfjord, Skånland and Evenes (online supplementa-
ry table S3).
results
Of the total sample, 53.5% were women. In women and 
men, 37.8% and 39.5% were Sami, respectively. The 
mean age was higher in both sexes in SAMINOR 2 than in 
SAMINOR 1. In both surveys, Sami women (table 1) and 
men (table 2) were less physically active, and Sami women 
reported more often to be non-consumers or abstainers 
of alcohol.
Both non-Sami and Sami women had a decline in 
total cholesterol between SAMINOR 1 and SAMINOR 2 
(p<0.001, table 3). The overall change in total cholesterol 
Table 1 Unadjusted means (SD) and proportions (%) of sample characteristics in women aged 40–79 years participating in 
SAMINOR 1 (2003–2004) and SAMINOR 2 (2012–2014)
Ethnicity
SAMINOR 1 (n=3390) SAMINOR 2 (n=3234)
Non-Sami Sami Non-Sami Sami
Proportions, % (n) 64.7 (2193) 35.3 (1197) 59.7 (1929) 40.4 (1305)
Age, mean (SD) 56.5 (10.1) 55.5 (10.2) 59.1 (10.3) 58.6 (10.4)
Self-reported myocardial infarction, % (n)*† 2.6 (58) 1.9 (23) 3.2 (62) 1.8 (23)
Physical activity using ‘Saltin-Grimby’ questionnaire* ‡ ‡
  Reading, watching television or other sedentary 
activity, % (n)
21.3 (415) 27.7 (297) – – 
  Walking, bicycling or moving around in other ways 
at least 4 hours/week, % (n)
68.1 (1330) 61.9 (664) – – 
  Participation in recreational sports, heavy garden 
work, etc. Duration at least 4 hours/week, % (n)
10.3 (200) 9.6 (103) – – 
  Participation in hard training or athletic competitions 
regularly and several times/week, % (n)
0.4 (7) 0.8 (8) – – 
Level of physical activity on a scale from 1 to 10, 
mean (SD)*
‡ ‡ 5.6 (2.1) 5.2 (2.2)
Never consumed alcohol, % (n)* 14.8 (309) 24.5 (279) ‡ ‡
Alcohol abstinence, yes % (n)* ‡ ‡ 18.4 (341) 27.0 (337)
Years of education, mean (SD)* 10.9 (3.8) 10.7 (4.6) 12.2 (4.0) 12.4 (4.5)
  0–9 years education, % (n) 41.7 (864) 43.6 (497) 28.0 (530) 30.3 (385)
  10–12 years education, % (n) 30.2 (626) 23.2 (265) 29.9 (565) 23.2 (295)
  ≥13 years of education, % (n) 28.1 (584) 33.1 (378) 42.1 (797) 46.5 (592)
Region 1: Kautokeino and Karasjok, % (n) 3.8 (84) 44.8 (537) 5.2 (101) 48.4 (631)
Region 2: Nesseby, Tana and Porsanger, % (n) 27.5 (603) 38.3 (458) 30.1 (580) 36.6 (478)
Region 3: Kåfjord, Lyngen, Storfjord, Skånland and 
Evenes, % (n)
68.7 (1506) 16.9 (202) 64.7 (1248) 15.0 (196)
*Based on a lower number due to missing values.
†Measured differently in SAMINOR 1 and SAMINOR 2.
‡Question not posed.
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in women was −0.50 mmol/L. Sami women had lower 
HDL cholesterol and higher triglycerides than non-Sami 
in both surveys (table 3). The change in triglycerides did 
not differ by ethnicity, but the change in HDL cholesterol 
did, with non-Sami showing a minor increase, and Sami 
showing no change.
In both surveys, Sami women had somewhat lower 
blood pressure than non-Sami did (table 3). The overall 
decline in systolic and diastolic blood pressure was 3.6 and 
1.0 mm Hg (both p<0.001), respectively; these changes did 
not differ by ethnicity. Roughly, 23% of women reported 
use of anti-hypertensive drugs, and this did not change 
over time. The prevalence of hypertension declined in a 
similar magnitude in Sami and non-Sami women: by 6.2 
percentage points (p<0.001) (table 3).
Non-Sami and Sami women had a similar increase of 
6.7 cm in mean waist circumference. The prevalence of 
smoking in non-Sami and Sami women declined by 10.0 
and 5.6 percentage points, respectively (both p<0.001); 
this change did not differ by ethnicity. Overall, the odds 
of current smoking declined by 35% (table 3).
The estimated 10-year risk of AMI or CS declined 
between SAMINOR 1 and SAMINOR 2 in both Sami and 
non-Sami women (both p<0.001, table 3), but more so in 
non-Sami.
Between SAMINOR 1 and SAMINOR 2, total choles-
terol declined more in non-Sami than in Sami men (0.60 
vs 0.43 mmol/L; both p<0.001, table 4), and this change 
varied by ethnicity. Between the surveys, Sami men had a 
slight decline in HDL cholesterol (p<0.001) and a slight 
increase in triglycerides (p<0.001); whereas non-Sami 
men had no changes, hence, changes in HDL cholesterol 
and triglyceride differed for Sami and non-Sami (table 4).
In men, the decline in systolic and diastolic blood pres-
sure did not differ by ethnicity (table 4). The overall decline 
in systolic and diastolic blood pressure in men were 3.1 and 
0.7 mm Hg (both p<0.05), respectively. Overall, we found 
an increase in the prevalence of anti-hypertensive drug 
use, from 21.1% to 23.9% in men, which did not differ 
by ethnicity. The prevalence of hypertension remained 
similar in SAMINOR 1 and SAMINOR 2, with roughly half 
of men being considered hypertensive (table 4).
Table 2 Unadjusted means (SD) and proportions (%) of sample characteristics in men aged 40–79 years participating in 
SAMINOR 1 (2003–2004) and SAMINOR 2 (2012–2014)
Ethnicity
SAMINOR 1 (n=3027) SAMINOR 2 (n=2722)
Non-Sami Sami Non-Sami Sami
Proportions, % (n) 62.1 (1881) 37.9 (1146) 58.7 (1597) 41.3 (1125)
Age, mean (SD) 56.5 (9.8) 56.3 (10.1) 60.4 (10.2) 59.8 (10.3)
Self-reported myocardial infarction, % (n)*† 6.9 (130) 6.5 (75) 8.8 (140) 8.1 (91)
Physical activity using ‘Saltin-Grimby’ questionnaire* ‡ ‡
  Reading, watching television or other sedentary 
activity, % (n)
20.2 (351) 24.3 (254) – – 
  Walking, bicycling or moving around in other ways at 
least 4 hours/week, % (n)
59.5 (1034) 53.0 (555) – – 
  Participation in recreational sports, heavy garden work 
etc. Duration at least 4 hours/week, % (n)
18.6 (324) 20.2 (212) – – 
  Participation in hard training or athletic competitions 
regularly and several times/week, % (n)
1.7 (29) 2.5 (26) – – 
Level of physical activity on a scale from 1 to 10, mean 
(SD)*
‡ ‡ 5.2 (2.01) 5.12 (2.16)
Never consumed alcohol, % (n)* 5.4 (99) 4.5 (50) ‡ ‡
Alcohol abstinence, yes % (n)* ‡ ‡ 10.6 (164) 13.4 (150)
Years of education, mean (SD)* 10.9 (3.7) 10.2 (4.1) 11.8 (3.6) 11.4 (3.8)
  0–9 years education, % (n) 39.6 (719) 47.3 (519) 29.7 (467) 36.3 (400)
  10–12 years education, % (n) 32.7 (594) 27.6 (303) 33.1 (520) 30.3 (333)
  ≥13 years of education, % (n) 27.7 (502) 25.1 (276) 37.2 (584) 33.4 (368)
Region 1: Kautokeino and Karasjok, % (n) 3.3 (63) 37.9 (434) 4.6 (73) 42.4 (477)
Region 2: Nesseby, Tana and Porsanger, % (n) 28.9 (543) 39.0 (447) 32.9 (525) 37.2 (419)
Region 3: Kåfjord, Lyngen, Storfjord, Skånland and 
Evenes, % (n)
67.8 (1275) 23.1 (265) 62.6 (999) 20.4 (229)
*Based on a lower number due to missing values.
†Measured differently in SAMINOR 1 and SAMINOR 2.
‡Question not posed.
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Waist circumference increased similarly in Sami 
and non-Sami men, with an overall increase of 5.9 cm 
(p<0.001). The prevalence of smoking declined similarly 
in non-Sami and Sami men, by 12.3 and 10.0 percentage 
points (both p<0.001), respectively. The overall decline in 
the odds of being a smoker was 46%.
The estimated 10-year risk of AMI or CS declined in 
non-Sami and Sami men (both p<0.001, table 4), but not 
differently in the two ethnic groups.
sensitivity analyses
Overall, the sensitivity analyses were consistent with the 
main findings when using a different ethnic categorisa-
tion (online supplementary tables S1 and S2) and when 
adjusting for region (online supplementary table S3).
DIsCussIOn
From SAMINOR 1 (2003–2004) to SAMINOR 2 (2012–
2014), participants from the selected 10 municipalities 
in Northern Norway had a favourable decline in total 
cholesterol, blood pressure, proportion of smokers and 
the estimated 10-year risk of AMI or CS, whereas waist 
circumference increased. The changes in total cholesterol 
(men only), HDL cholesterol (both sexes), triglycerides 
(men only) and the estimated 10-year risk of AMS or CS 
(women only), were statistically significantly different 
between Sami and non-Sami. The odds of anti-hyperten-
sive drug use increased only in men, whereas the prev-
alence of hypertension decreased only in women. To 
our knowledge, there are no other studies in Sápmi that 
explore whether changes in cardiovascular risk factors 
differ between Sami and non-Sami over time.
In both SAMINOR 1 and SAMINOR 2, the participa-
tion rate was lowest among the youngest participants, 
especially young men. In both surveys, less than half of 
those invited participated, hence, selection bias might be 
an issue. Also, as there is no official registry on ethnicity, 
we do not know if non-participation differed by ethnicity. 
It might be expected that Sami would be less willing to 
participate, given the history of assimilation15 and uneth-
ical research.28 On the other hand, as the surveys were 
carried out by a Sami research centre, invitees with Sami 
affiliations might have been more motivated to partic-
ipate. If that is the case, the slightly adverse pattern in 
Sami, might be partly due to a different selection of Sami 
compared with non-Sami participants.
Further, due to design issues of SAMINOR 1,22 the 
study sample included a lower proportion of participants 
from Sami-dominated municipalities in Finnmark, while 
the same municipalities had an overall high response rate 
in SAMINOR 2. This influences the ethnic and regional 
compositions of the two samples, and makes compari-
sons between the surveys challenging. However, when 
using a different categorisation of ethnicity or adjusting 
for region, the results remained consistent with the main 
results. Moreover, generalisation to the entire Sami and 
non-Sami populations in Northern Norway is not advised, 
as only 10 municipalities were included. However, 
assuming a similar response rate in Sami and non-Sami 
participants, we believe the findings are applicable to 
Sami and non-Sami women and men over 50 years of age 
living in the given geographical regions.
The use of antihypertensive drugs increases with age2 
and during 1975–2010, the prevalence of treatment for 
hypertension increased by a factor of four in Norway.29 
In our study, the use of anti-hypertensive drugs in women 
remained similar in the surveys, whereas the prevalence 
of hypertension in women declined, which corresponds 
to a decline that is independent of treatment with anti-hy-
pertensive drugs.2 In men, we observed an increase in the 
use of anti-hypertensive drugs, whereas the prevalence 
of hypertension remained the same, which may indicate 
that treatment with anti-hypertensive drugs could have 
contributed to a decline in blood pressure.
The observed decreases in cholesterol, systolic blood 
pressure and proportion of smokers, and the increase 
in waist circumference, corresponds well with studies in 
Western Europe3 4 6 7 and with national trends.1 2 5 8 11 30 
Possible explanations are changes in lifestyle and diet—
in line with what is observed nationally11—decreases in 
smoking, less occupational physical activity, more frequent 
use of vehicles for transportation, higher consumption 
of fruits and vegetables, lower consumption of saturated 
fats and an assumed lower consumption of salt.31 The 
decrease in systolic blood pressure may have been halted 
due to the increase in obesity over the last decades.32
In a cohort study in Finnmark (1987–2003), based on 
a follow-up of those participating in both the Finnmark 3 
and SAMINOR 1 surveys, Hermansen et al33 observed—
using the same ethnicity definition as in our study—
that changes in cardiovascular risk factors according to 
change in physical activity level occurred independently 
of ethnicity. Similarly, we observed that changes in 
cardiovascular risk factors did not differ substantially 
by ethnicity, only small and probably negligible differ-
ences were observed in total cholesterol and triglycerides 
in men, and in HDL cholesterol in both sexes, which 
suggests that Sami and non-Sami populations overall have 
undergone similar lifestyle changes. This might be consid-
ered unexpected, as Sami may be perceived as distinct 
from non-Sami in terms of diet34 35 and physical activity.33 
A recent study from SAMINOR 2 found that partici-
pants who defined themselves solely as Sami had a lower 
consumption of vegetables, and a higher consumption 
of moose meat, reindeer meat and fat spread on bread 
than non-Sami and those who regard themselves as both 
Sami and non-Sami.34 In SAMINOR 1 (24 municipalities 
included), a higher consumption of unfiltered coffee was 
observed in Sami participants compared with non-Sami 
and Sami of mixed ethnic descent.35 Furthermore, 
unpublished results from SAMINOR 2 (Borch, personal 
communication, 2018), show that, in women, Sami 
ethnicity was associated with lower total physical activity. 
In the cohort study by Hermansen et al, the proportion of 
leisure-time sedentary individuals in Finnmark decreased 
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between 1987 and 2003; however, the proportions who 
were sedentary was higher in Sami than in non-Sami, 
both at baseline and at the end of follow-up.33 Nonethe-
less, evidence of relevant ethnic differences in changes in 
cardiovascular risk factors and estimated 10-year risk of 
AMI and CS, was not found in our study.
The observed decline in cardiovascular risk factors is 
likely to have a beneficial impact on the incidence of 
coronary heart diseases36 and ischaemic stroke37 in this 
population, which is also reflected by a decrease in the 
estimated 10-year risk of AMI or CS. The decrease in risk 
was smaller in Sami than non-Sami women, which might 
be due to the increase in HDL cholesterol in non-Sami 
women. However, the causal effect of low levels of HDL 
cholesterol on cardiovascular disease is debated.38 39
Inuit populations are characterised by a rapid increase 
in obesity, diabetes and hypertension in parallel with 
decreasing physical activity and deterioration of the lipid 
profile.40 On the other hand, decline in smoking and 
alcohol use have been observed.40 But still, there are 
disparities in cardiovascular health between Indigenous 
peoples and their benchmark populations in high-income 
countries.40 41 Our study indicated that such disparities in 
cardiovascular risk factors are not present in the 10 rural 
municipalities in Northern Norway. Previous studies have 
also shown similar burdens of cardiovascular risk factors 
and morbidity among Sami and non-Sami in Norway.17–21 
This might be due to the fact that the non-Sami reference 
population in these studies17–21 lives side by side with the 
Sami in the same rural regions. This is a stark contrast to, 
for instance, the Inuit and reference Danish population, 
who live on different continents. If we had compared the 
Sami in this study to the general Norwegian population, 
we might have found larger differences in cardiovascular 
risk factors, as there are disparities in health issues across 
regions.11 Second, the small or non-existent disparities 
in health between Sami and non-Sami are suggested to 
be due to similar access to healthcare and education,42 
whereas the lack of similar access has been put forward 
as a reason for health disparities between the Inuit and 
their reference population.40 In summary, differences 
in settlement patterns and in the social determinants of 
health challenge our ability to compare our results with 
international data.
We were not able to adjust for lipid-lowering drugs, 
physical activity, coffee and alcohol consumption, affil-
iation with reindeer herding, or diet in our study, as 
questions relating to these items in the two surveys were 
not comparable. Lipid-lowering drugs are estimated to 
account for approximately 20%–30% of the decline in 
total cholesterol over time,5 6 and therefore it is likely 
that some of the decline in cholesterol is due to the use 
of these drugs. The public health relevance of this study 
is that preventive measures aimed to reduce cardiovas-
cular risk seem to have worked independent of ethnicity. 
Nevertheless, further surveillance of cardiovascular risk 
factors is advisable due to the adverse pattern—although 
minor—in Sami compared with non-Sami.
COnClusIOn
From SAMINOR 1 (2003–2004) to SAMINOR 2 (2012–
2014), the population in rural Northern Norway had a 
favourable decline in total cholesterol, blood pressure, 
hypertension (women only), smoking and the estimated 
10-year risk of AMI or CS; however, they had an increase 
in waist circumference. We found only minor differences 
between Sami and non-Sami subjects regarding change 
in cardiovascular risk factors during this period, which 
suggests that the population of Northern Norway have 
had similar changes in lifestyle and diet.
Author affiliations
1Department of Community Medicine, Centre for Sami Health Research, UiT The 
Arctic University of Norway, Tromsø, 9037, Norway
2Faculty of Nursing and Health Sciences, Nord University, Bodø, Norway
3Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, 
Norway
Acknowledgements The authors thank the participants of the SAMINOR 1 and 
SAMINOR 2. 
Contributors The study was conceived by BME and TB. SRAS performed all the 
data analyses, produced the tables and drafted the manuscript. MM produced the 
figure. TB guided and assisted with statistical analyses. BME, BKJ, MM, ARB, VLM 
and TB helped with the interpretation of the results, and contributed to the revision 
of the manuscript and approved the final version. 
Funding SAMINOR 1 and SAMINOR 2 were financed by the Norwegian Ministry 
of Health and Care Services. SAMINOR 2 was also financially supported by the 
Northern Norway Regional Health Authority; the Regional Research Fund of Northern 
Norway; the Sami Parliament; the Sami Norwegian National Advisory Unit on Mental 
Health and Substance Use; Finnmark, Troms, and Nordland county councils. 
Map disclaimer The depiction of boundaries on the map(s) in this article do not 
imply the expression of any opinion whatsoever on the part of BMJ (or any member 
of its group) concerning the legal status of any country, territory, jurisdiction or 
area or of its authorities. The map(s) are provided without any warranty of any kind, 
either express or implied. 
Competing interests None declared. 
Patient consent for publication Not required.
ethics approval The Norwegian Data Inspectorate and the Regional Committee 
for Medical and Health Research Ethics for region North (REC North) have approved 
The SAMINOR Study which SAMINOR 1 survey and SAMINOR 2 surveys are part of. 
The REC North (2015/2204–11) have approved this study. All participants included 
in this study gave written informed consent and consented to linkage between the 
surveys.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Data are available upon reasonable request.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
reFerenCes
 1. Holmen J, Holmen TL, Tverdal A, et al. Blood pressure changes 
during 22-year of follow-up in large general population - the HUNT 
Study, Norway. BMC Cardiovasc Disord 2016;16:94.
 2. Hopstock LA, Bønaa KH, Eggen AE, et al. Longitudinal and secular 
trends in blood pressure among women and men in birth cohorts 
born between 1905 and 1977: The Tromsø Study 1979 to 2008. 
Hypertension 2015;66:496–501.
 3. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global 
trends in systolic blood pressure since 1980: systematic analysis of 









pen: first published as 10.1136/bm




10 Siri SRA, et al. BMJ Open 2019;9:e028939. doi:10.1136/bmjopen-2019-028939
Open access 
health examination surveys and epidemiological studies with 786 
country-years and 5·4 million participants. Lancet 2011;377:568–77.
 4. Zhou B, Bentham J, Di Cesare M, et al. Worldwide trends in blood 
pressure from 1975 to 2015: a pooled analysis of 1479 population-
based measurement studies with 19·1 million participants. Lancet 
2017;389:37–55.
 5. Hopstock LA, Bønaa KH, Eggen AE, et al. Longitudinal and secular 
trends in total cholesterol levels and impact of lipid-lowering 
drug use among Norwegian women and men born in 1905-1977 
in the population-based Tromsø Study 1979-2016. BMJ Open 
2017;7:e015001.
 6. Eriksson M, Forslund AS, Jansson JH, et al. Greater decreases in 
cholesterol levels among individuals with high cardiovascular risk 
than among the general population: the northern Sweden MONICA 
study 1994 to 2014. Eur Heart J 2016;37:1985–92.
 7. Farzadfar F, Finucane MM, Danaei G, et al. National, regional, and 
global trends in serum total cholesterol since 1980: systematic 
analysis of health examination surveys and epidemiological 
studies with 321 country-years and 3·0 million participants. Lancet 
2011;377:578–86.
 8. Jenum A, Graff-Iversen S, Selmer R, et al. Risikofaktorer for 
hjerte- og karsykdom og diabetes gjennom 30 år [Risk factors for 
cardiovascular diseases and diabetes through 30 years]. Tidsskr Nor 
Laegeforen 2007;127:2532–6.
 9. Capewell S, Ford ES. Why have total cholesterol levels declined in 
most developed countries? BMC Public Health 2011;11:641.
 10. Aburto NJ, Ziolkovska A, Hooper L, et al. Effect of lower sodium 
intake on health: systematic review and meta-analyses. BMJ 
2013;346:f1326.
 11. Folkehelserapporten. Helsetilstanden i Norge [Public health report 
2014, the health in Norway]. Oslo: Norwegian Institute of Public 
Health; 2014 [Norwegian], 2014.
 12. Aubert V. Artikler fra Statistisk sentralbyrå. Den samiske befolkning 
i Nord-Norge [The Sami population in Northern Norway]. Oslo: 
Statistics Norway, 1978. Report No.: 107 [Norwegian].
 13. Statistics Norway. Samiske forhold [Conditions for the Sami] Oslo: 
Statistics Norway [Norwegian]. https://www. ssb. no/ befolkning/ 
statistikker/ samisk (cited 2018.05.05).
 14. Sametingets valgmanntall. 2017 per 30.06.2017 [The Sami 
parliament census for 2017 per 2017.06.30]: The Sami Parliament 
[Norwegian]; 2017 [updated 2017.09.25. https://www. sametinget. 
no/ Valg/ Valgmanntall/ Sametingets- valgmanntall- 2017 (cited 
2018.08.05).
 15. Minde H. Assimilation of the Sami – Implementation and 
Consequences1. Acta Borealia 2003;20:121–46.
 16. Niemi E. The Finns in Northern Scandinavia and minority policy. Tägil 
S, ed. Ethnicity and nation building in the Nordic world. London: 
Hurst, 1995:145–78.
 17. Eliassen B-M, Graff-Iversen S, Braaten T, et al. Prevalence of self-
reported myocardial infarction in Sami and non-Sami populations: 
the SAMINOR study. Int J Circumpolar Health 2015;74:24424.
 18. Eliassen B-M, Graff-Iversen S, Melhus M, et al. Ethnic difference in 
the prevalence of angina pectoris in Sami and non-Sami populations: 
the SAMINOR study. Int J Circumpolar Health 2014;73:21310.
 19. Njølstad I, Arnesen E, Lund-Larsen PG. Cardiovascular diseases 
and diabetes mellitus in different ethnic groups: the Finnmark study. 
Epidemiology 1998;9:550–6.
 20. Nystad T, Utsi E, Selmer R, et al. Distribution of apoB/apoA-1 ratio 
and blood lipids in Sami, Kven and Norwegian populations: the 
SAMINOR study. Int J Circumpolar Health 2008;67:69–83.
 21. Njølstad I, Arnesen E, Lund-Larsen PG. Body height, cardiovascular 
risk factors, and risk of stroke in middle-aged men and women. A 14-
year follow-up of the Finnmark study. Circulation 1996;94:2877–82.
 22. Lund E, Melhus M, Hansen KL, et al. Population based study of 
health and living conditions in areas with both Sámi and Norwegian 
populations--the SAMINOR study. Int J Circumpolar Health 
2007;66:113–28.
 23. Broderstad AR, Hansen S, Melhus M. The second clinical survey of 
the population-based study on health and living conditions in regions 
with Sami and Norwegian populations - the SAMINOR 2 Clinical 
Survey: Performing indigenous health research in a multiethnic 
landscape. Scand J Public Health 2019:140349481984557.
 24. Pettersen T, Brustad M. Same Sámi? A comparison of self-reported 
Sámi ethnicity measures in 1970 and 2003 in selected rural areas in 
northern Norway. Ethn Racial Stud 2015;38:2071–89.
 25. Grimby G, Börjesson M, Jonsdottir IH, et al. The "Saltin-Grimby 
Physical Activity Level Scale" and its application to health research. 
Scand J Med Sci Sports 2015;25(Suppl.):119–25.
 26. Borch KB, Ekelund U, Brage S, et al. Criterion validity of a 
10-category scale for ranking physical activity in Norwegian women. 
Int J Behav Nutr Phys Act 2012;9:2.
 27. Selmer R, Igland J, Ariansen I, et al. NORRISK 2: A Norwegian risk 
model for acute cerebral stroke and myocardial infarction. Eur J Prev 
Cardiol 2017;24:773–82.
 28. Kyllingstad JR. Norwegian Physical Anthropology and the Idea of a 
Nordic Master Race. Curr Anthropol 2012;53(S5):S46–56.
 29. Blix HS, Landmark K, Selmer R, et al. [Patterns in the prescription 
of antihypertensive drugs in Norway, 1975-2010]. Tidsskr Nor 
Laegeforen 2012;132:1224–8.
 30. Jacobsen BK, Aars NA. Changes in waist circumference and the 
prevalence of abdominal obesity during 1994-2008 - cross-sectional 
and longitudinal results from two surveys: the Tromsø Study. BMC 
Obes 2016;3:41.
 31. Directory of Health. Utvikling av norsk kosthold 2014. [Development 
in Norwegian nutrion 2014]. Report No. IS-2680 [Norwegian]. 2017 
https:// helsedirektoratet. no/ Lists/ Publikasjoner/ Attachments/ 802/ 
Utviklingen- i- norsk- kosthold- 2014- IS- 2255. pdf (cited 2018.09.20).
 32. Goff DC, Gillespie C, Howard G, et al. Is the obesity epidemic 
reversing favorable trends in blood pressure? Evidence from cohorts 
born between 1890 and 1990 in the United States. Ann Epidemiol 
2012;22:554–61.
 33. Hermansen R, Broderstad AR, Jacobsen BK, et al. The impact of 
changes in leisure time physical activity on changes in cardiovascular 
risk factors: results from The Finnmark 3 Study and SAMINOR 1, 
1987-2003. Int J Circumpolar Health 2018;77:1459145.
 34. Petrenya N, Skeie G, Melhus M, et al. Food in rural northern Norway 
in relation to Sami ethnicity: the SAMINOR 2 Clinical Survey. Public 
Health Nutr 2018;21:2665–77.
 35. Nystad T, Melhus M, Brustad M, et al. The effect of coffee 
consumption on serum total cholesterol in the Sami and Norwegian 
populations. Public Health Nutr 2010;13:1818–25.
 36. Mannsverk J, Wilsgaard T, Mathiesen EB, et al. Trends in modifiable 
risk factors are associated with declining incidence of hospitalized 
and nonhospitalized acute coronary heart disease in a population. 
Circulation 2016;133:74–81.
 37. Vangen-Lønne AM, Wilsgaard T, Johnsen SH, et al. Declining 
incidence of ischemic stroke: what is the impact of changing risk 
factors? the Tromsø Study 1995 to 2012. Stroke 2017;48:544–50.
 38. Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet 
2014;384:618–25.
 39. Wu Z, Lou Y, Qiu X, et al. Association of cholesteryl ester transfer 
protein (CETP) gene polymorphism, high density lipoprotein 
cholesterol and risk of coronary artery disease: a meta-analysis using 
a Mendelian randomization approach. BMC Med Genet 2014;15:118.
 40. Tvermosegaard M, Dahl-Petersen IK, Nielsen NO, et al. 
Cardiovascular disease susceptibility and resistance in circumpolar 
inuit populations. Can J Cardiol 2015;31:1116–23.
 41. Cameron VA, Faatoese AF, Gillies MW, et al. A cohort study 
comparing cardiovascular risk factors in rural Māori, urban Māori and 
non-Māori communities in New Zealand. BMJ Open 2012;2:e000799.
 42. Brustad M. The Health of the Sámi - A knowledge summary of 
published findings from population studies in Norway. In: Broderstad 
EG, Brustad M, Kalstad JA, eds. Sámi Figures Reveal 2 - Annotated 
Sámi statistics 2009. Guovdageaidnu, 2009.









pen: first published as 10.1136/bm











Siri, Susanna Ragnhild Andersdatter; Eliassen, Bent Martin; Broderstad, Ann Ragnhild; 
Melhus, Marita; Michalsen, Vilde Lehne; Jacobsen, Bjarne Koster; Burchill, Luke; Braaten, 
Tonje. Coronary heart disease and stroke in the Sami and non-Sami population in rural 
Northern and Mid Norway–the SAMINOR Study. Open Heart. 2020;7(1):e001213. Online 
ISSN: 2053-3624. Doi: 10.1136/openhrt-2019-001213 
 
Open access 
  1Siri SRA, et al. Open Heart 2020;7:e001213. doi:10.1136/openhrt-2019-001213
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
openhrt- 2019- 001213).
To cite: Siri SRA, Eliassen BM, 
Broderstad AR, et al. Coronary 
heart disease and stroke in the 
Sami and non- Sami populations 
in rural Northern and Mid 
Norway—the SAMINOR Study. 
Open Heart 2020;7:e001213. 
doi:10.1136/
openhrt-2019-001213
Received 28 November 2019
Revised 27 February 2020
Accepted 26 March 2020
1Department of Community 
Medicine, Centre for Sami 
Health Research, Faculty of 
Health Sciences, UiT The Arctic 
University of Norway, Tromso, 
Norway
2Faculty of Nursing and Health 
Sciences, Nord University, Bodo, 
Nordland, Norway
3Department of Medicine, 
University Hospital of North 
Norway, Harstad, Troms, Norway
4Department of Medicine, 
Royal Melbourne Hospital, 
The University of Melbourne, 
Melbourne, Victoria, Australia
Correspondence to
Susanna R A Siri;  susanna. r. 
siri@ uit. no
Coronary heart disease and stroke in the 
Sami and non- Sami populations in rural 
Northern and Mid Norway—the 
SAMINOR Study
Susanna R A Siri  ,1 Bent M Eliassen,2 Ann R Broderstad,1,3 Marita Melhus,1 
Vilde L Michalsen,1 Bjarne K Jacobsen,1 Luke J Burchill,4 Tonje Braaten1
Cardiac risk factors and prevention
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
Key questions
What is already known about this subject?
 ► Previous studies have found similar risk of coronary 
heart disease and a possible higher risk of stroke in 
Sami compared to non- Sami populations.
What does this study add?
 ► In the SAMINOR 1 Survey (2003–2004), the Sami 
population has a higher risk of stroke and isch-
aemic stroke compared with non- Sami. Differences 
in height explained more than conventional risk 
factors.
How might this impact on clinical practice?
 ► Our findings have predominantly public health rel-
evance. The clinical relevance depend on the inter-
pretation of height and ethnicity as risk predictors of 
ischemic stroke and stroke.
AbstrAct
Background Previous studies have suggested that Sami 
have a similar risk of myocardial infarction and a possible 
higher risk of stroke compared with non- Sami living in the 
same geographical area.
Design Participants in the SAMINOR 1 Survey (2003–
2004) aged 30 and 36–79 years were followed to the 
31 December 2016 for observation of fatal or non- fatal 
events of acute myocardial infarction (AMI), coronary 
heart disease (CHD), ischaemic stroke (IS), stroke and a 
composite endpoint (fatal or non- fatal AMI or stroke).
Aim Compare the risk of AMI, CHD, IS, stroke and the 
composite endpoint in Sami and non- Sami populations, 
and identify intermediate factors if ethnic differences in 
risks are observed.
Methods Cox regression models.
Results The sex- adjusted and age- adjusted risks of AMI 
(HR for Sami versus non- Sami 0.99, 95% CI: 0.83 to 1.17), 
CHD (HR 1.03, 95% CI: 0.93 to 1.15) and of the composite 
endpoint (HR 1.09, 95% CI: 0.95 to 1.24) were similar 
in Sami and non- Sami populations. Sami ethnicity was, 
however, associated with increased risk of IS (HR 1.36, 
95% CI: 1.10 to 1.68) and stroke (HR 1.31, 95% CI: 1.08 to 
1.58). Height explained more of the excess risk observed 
in Sami than conventional risk factors.
Conclusions The risk of IS and stroke were higher 
in Sami and height was identified as an important 
intermediate factor as it explained a considerable 
proportion of the ethnic differences in IS and stroke. The 
risk of AMI, CHD and the composite endpoint was similar 
in Sami and non- Sami populations.
IntRoDuCtIon
Through 2001 to 2014, the incidence of 
non- fatal acute myocardial infarction (AMI) 
and fatal coronary heart disease (CHD) 
declined in Norway in both sexes,1 even 
among people aged 25–44 years.1 Between 
1994 and 2012, a decline was observed in the 
incidence of CHD2 and stroke3 in the largest 
city in Northern Norway, which is close to the 
regions included in the present study. The 
decline in the incidence of CHD and stroke 
was mainly driven by the improvement of 
cardiovascular risk factors3; for fatal CHD, 
fewer out- of- hospital sudden deaths and 
hospitalisations with severe myocardial infarc-
tion (MI) contributed to the decline.2
The Sami people live across Norway, 
Sweden, Finland and on the Kola Penin-
sula in the Russian Federation. In Norway, 
the Sami are acknowledged as indigenous 
people, and the majority live in Northern 
Norway, together with the Kven people and 
Norwegian majority population. The Kven 
people are descendants of Finnish- speaking 
immigrants who arrived in the 1700s and 
1800s from northern Sweden and Finland.4 
As with other indigenous people, the Norwe-
gian government imposed harsh assimilation 
policies on the Sami from 1850 until 1960,5 
when a revitalisation of Sami culture and 
languages began, but many had already given 
up using Sami languages. In the 1970 popu-
lation census, information on Sami and Kven 
ethnicities was collected in selected areas of 
Northern Norway, and it was estimated that 
around 40 000 people in Norway were Sami.6 
by copyright.
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Unlike other indigenous populations,7 the somatic health 
in Sami has been shown to be similar to that in the non- 
Sami population in the same geographical areas.8
Two studies regarding CHD mortality in Sami, covering 
roughly the same time period but different geograph-
ical areas, show contradicting mortality rates,9 10 whereas 
similar incidence of MI was observed in Sami and non- 
Sami in 1973/1974 through 1989 in Finnmark County, 
in Northern Norway.11 With regards to stroke, higher 
mortality9 and possibly higher incidence11 12 were 
observed in Sami compared with their reference popu-
lations in the years 1974–1998. Moreover, several studies 
observed lower average heights in Sami than in non- Sami 
populations,10 13 14 and a possible inverse association 
between height and degree of Sami affiliation.13 More-
over, an increase in height has been found to be inversely 
associated with CHD and stroke,15 16 which has also been 
observed in Finnmark,12 however, for MI, this was only 
found in women.11
We have previously reported overall similar levels of 
cardiovascular risk factors in Sami and non- Sami popu-
lations in rural Northern Norway.17 18 However, it is not 
known whether the incidence of cardiovascular disease 
(CVD) differs in Sami and non- Sami in this population. 
Thus, the aim of this study was to compare the risk of 
fatal or non- fatal AMI, CHD, ischaemic stroke (IS), stroke 
and a composite endpoint (AMI or stroke) in Sami and 
non- Sami populations, and identify intermediate factors 
if ethnic differences in risks are observed.
MetHoDs
The SAMINOR 1 Survey (SAMINOR 1) was conducted 
in 2003–2004 and was the first of three population- based 
cross- sectional surveys, which together constitute the 
SAMINOR Study. The SAMINOR 1 was initiated due to 
limited knowledge about the health of the Sami popula-
tion, and it was conducted by the Centre for Sami Health 
Research at UiT the Arctic University of Norway, together 
with the Norwegian Institute of Public Health. There 
is no registry of ethnicity in Norway; thus, SAMINOR 1 
invited all inhabitants aged 30, 36–78/79 years (birth 
cohorts 1925–1967 and 1973 in 2003; birth cohorts 1925–
1968 and 1974 in 2004) residing in 24 selected munic-
ipalities of Northern and Mid Norway, all of which had 
a considerable Sami population according to the 1970 
census6 and local knowledge. SAMINOR 1 included a 
clinical examination and self- administrated question-
naires, which included questions related to ethnicity. In 
total, 27 987 individuals were invited and 16 865 (60.3%) 
attended SAMINOR 1.19
Clinical examination
Trained staff conducted the clinical examinations, 
during which waist circumference was measured at the 
umbilicus to the nearest centimetre when participants 
were standing. Height in centimetres and weight in 
kilograms were measured with an electronic height and 
weight scale (DS-102, Dongsahn Jenix, Seoul, Korea) to 
the nearest 0.1 decimal, with the participant standing 
and wearing no shoes. A digital oscillometric device 
(DINAMAP- R, Critikon, Tampa, Florida, USA) was used 
to measure blood pressure three times at 1- minute inter-
vals, and the average of the last two measurements was 
reported. Those who used antihypertensive medications 
or had systolic or diastolic blood pressure ≥140/90 mm 
Hg, respectively, were categorised as hypertensive. Non- 
fasting venous blood samples were taken while partici-
pants were resting. The samples were centrifuged within 
30 min, separated within 2 hours and sent by overnight 
post to Ullevål University Hospital in Oslo, Norway, 
where total cholesterol, high- density lipoprotein (HDL) 
cholesterol, glucose and triglycerides were measured with 
an enzymatic method (Hitachi 917 autoanalyser, Roche 
Diagnostics, Switzerland).
self-administered questionnaires
There is no registry on ethnicity in Norway and health 
surveys rely on self- reported ethnic information. There 
is no consensus on how ethnicity should be operation-
alised in health research except that it is recommended 
that several markers of ethnicity are applied, as ethnicity 
is a multifaceted concept.20–22 The following 11 questions 
provided information about ethnicity: (1) What language 
do/did you, (2) your mother, (3) your father, (4–7) your grand-
parents (all four) speak at home? (8) What is your, (9) your 
mother’s, (10) your father’s ethnic background? (11) What do 
you consider yourself to be? To each of the questions, one or 
more of the following alternatives could be ticked: Sami, 
Kven, Norwegian and other (specify). Participants who 
(1) considered themselves as Sami or ticked ‘Sami’ as 
their own ethnic background, and (2) either spoke the 
Sami language themselves, or had at least one parent 
or grandparent who used it at home, were categorised 
as Sami. All others were categorised as non- Sami. Sensi-
tivity analyses were performed using an alternative ethnic 
categorisation: (1) high Sami affiliation, that is, reported 
Sami to all 11 questions (n=1385), (2) some Sami affilia-
tion, that is, reported Sami in 1–10 questions (n=3168), 
and (3) no Sami affiliation, that is, did not answer Sami 
in any of the questions (n=9234).
A family history of premature MI was considered present 
if first- degree relatives (parents, siblings or children) had 
MI before the age of 60 years. Disease status was obtained by 
asking if participants had MI, stroke/brain haemorrhage, 
angina pectoris and diabetes mellitus, and, if so, then age 
at which the condition first occurred. Participants with 
self- reported diabetes mellitus or glucose ≥11.1 mmol/L 
were categorised as having diabetes. Participants reported 
whether they were current, previous, or never users of anti-
hypertensive or lipid- lowering medications. Previous and 
never users were merged with those who failed to reply to 
the question (missing values for antihypertension medica-
tion, n=142) and categorised as non- users.
Information on education and behaviour were 
collected through the questions: How many years of 
by copyright.
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education have you completed? Are you currently, or were you 
previously a daily smoker? (Response alternatives: currently, 
previously, or never – previous smokers and never- 
smokers were merged into non- smokers); what was your 
alcohol consumption in the last year? (Response alternatives: 
never consumed alcohol, not during the last year, a few 
times during the last year, one time per month, two to 
three times per month, one time per week, two to three 
times per week or four to seven times per week). We 
created a three- level category, consisting of (1) never 
consumers together with those who did not consume in 
the last year, (2) those who consumed less than weekly 
and (3) those who consumed at least weekly. Leisure- time 
physical activity in the last year was measured using the 
‘Saltin- Grimby’ four- level scale.23 Being sedentary during 
leisure time was defined as: reading, watching television 
or other sedentary activity, whereas the remaining three 
alternatives, all of which compromised some physical 
activity, were merged to describe those who were phys-
ically active during leisure time. The estimated 10- year 
risk of fatal or non- fatal AMI or stroke was computed 
using the NORRISK 2 score.24
Data from national registries
Linkage to the following national registries was done 
using each participant’s unique, 11- digit national identity 
number: the Norwegian Cause of Death Registry provided 
dates and underlying causes of death for 2003–2016; the 
Cardiovascular Disease Project25 provided information 
on all hospitalisations with CVD as the main or secondary 
discharge code for 1993–2009; the Norwegian Patient 
Registry provided records from all hospitalisations with 
discharge codes including CVD as the main or secondary 
diagnoses for 2010–2016; and Statistics Norway provided 
information on emigrations.
The five endpoints included the following codes from 
the International Classification of Disease, 10th Revision: 
(1) AMI: I21–22 as the hospital discharge code, or I20–25 
as the underlying cause of death code. (2) CHD: I20–25 
as the hospital discharge code or the underlying cause of 
death code. (3) IS: I63 as the hospital discharge code or 
the underlying cause of death code. (4) Stroke: I60–61 
and I63–64 (except I63.6) as hospital discharge code or 
underlying cause of death code. (5) Composite endpoint, 
representing the NORRISK 2 endpoint: I21–22 and 
I60–61, I63–64 (except I63.6) as the hospital discharge 
code, or I20–25 and I60–61, I63–64 (except I63.6) as the 
underlying cause of death code.24
study sample
Among the 16 865 individuals who attended the SAMINOR 
1, we excluded 87 who did not consent to have their data 
linked to registries; 1027 who did not complete one or 
both of the questionnaires; 35 who did not attend the 
clinical examination; and 51 who had missing informa-
tion on ethnicity. Furthermore, we excluded 1580 with 
self- reported angina pectoris, MI and stroke (the two 
latter have moderate to high agreement in this population 
when validated against hospital discharge diagnoses)26 
and 151 with CHD or stroke as main or secondary hospital 
discharge code prior to participation in SAMINOR 1. Due 
to missing values in conventional risk factors (n=128) and 
height (n=19), the final sample consisted of 13 787 individ-
uals (49.3% of the invited sample).
statistical analyses
Sample characteristics are given for each stratum of sex 
and ethnicity, as mean values with SD or as proportions 
with numbers. The instantaneous hazards in Sami and 
non- Sami were compared by Cox regression models using 
age as the time axis,27 28 whereby each model was adjusted 
for age. In model 1, the risk estimates for ethnicity were 
adjusted for age and sex. We then adjusted for potential 
intermediate factors: first for height per 5 cm (model 2), 
and then for conventional risk factors included in the 
risk prediction model NORRISK 2 score,24 systolic blood 
pressure, total cholesterol, HDL cholesterol, current 
smoking, use of antihypertensive medication and whether 
one or two family members had a history of premature 
MI (model 3). Due to the potential for non- linearity in 
risk for the continuous variables,29 we re- ran model 3 
(and model 4 in sensitivity analyses) while allowing for 
multiple fractional polynomials using the ‘mfp’ function 
in STATA, an extension of the conventional polynomial 
model allowing for flexible parametrisation of a contin-
uous predictor. The results from these models showed 
that only systolic blood pressure could be transformed 
using different power and degree of freedom, but only 
in models with AMI, CHD and the composite endpoint. 
Importantly, the β-coefficients for ethnicity did not differ 
in the linear models compared with the models that 
included the transformed variable, thus, linear models 
were chosen for all endpoints.
For all endpoints, we assessed the presence of interaction 
by including product terms with ethnicity and sex, respec-
tively, in separate models for each covariate included in 
models 2 and 3. In the presence of interaction (AMI: sex 
and antihypertensive medication; stroke and composite 
endpoint: sex and height), we included a product term 
in the models. The proportional hazard assumption was 
assessed by checking if the Schoenfeld residuals were inde-
pendent of attained age at a 5% significance level, and if 
necessary, by visual inspection of log- minus- log graphs. If 
a covariate violated the proportional hazards assumption, 
then it was included as a time- varying covariate.
Participants in the study were followed from the date of 
enrolment in SAMINOR 1 until the date of the first non- 
fatal or fatal event of the specific CVD endpoint, death 
from other causes, emigration or end of follow- up (31 
December 2016), whichever occurred first. A two- sided 
p- value <0.05 was considered statistically significant. All 
statistical analyses were performed using STATA V.15.1. 
Figure 1 was made using the open- source software R 
V.3.6.0 (Foundation for Statistical Computing, Vienna, 
Austria).
We conducted the following sensitivity analyses:
by copyright.
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Figure 1 Number of cardiovascular events, person- years and incidence rates in Sami and non- Sami people who participated 
in the SAMINOR 1 Survey in 2003/2004 and were followed to the end of 2016. The forest plot gives the adjusted risk (HR 
with 95% CI) in Sami (n=2990) for different cardiovascular endpoints using non- Sami (n=10 797) as reference and age as the 
time axis in Cox regressions models, adjusting for the following covariates: model 1, sex; model 2, sex and height; model 3, 
sex, height, systolic blood pressure, total cholesterol, high- density lipoprotein cholesterol, current smoking (yes/no), use of 
antihypertensive medication (yes/no) and if one or two family members had a history of premature myocardial infarction (yes/
no).
1. We additionally adjusted for waist circumference, di-
abetes, physical activity in leisure time, alcohol con-
sumption and years of education (model 4), but in a 
smaller sample due to missing values in these covari-
ates (n=12 078, results not shown).
2. We performed Fine & Gray competing risk survival 
analyses with deaths from other causes as competing 
events, as previous studies have found somewhat high-
er rates of total mortality and violent death in Sami 
than non- Sami populations.9
3. Models 1–3 were repeated using the alternative ethnic 
categorisations.
4. To account for potential geographical heterogeneity, 
we adjusted for regions in all three models, using re-
gion 1 (see table 1 for the definition of regions) as 
reference.
Results
The final sample constituted of 21.7% Sami and more 
women (53.7%) than men. The age distribution was 
similar in Sami and non- Sami, both in men and women. 
The crude mean values for height showed that Sami 
men and women in this sample were 6.0 and 5.7 cm 
shorter than non- Sami men and women, respectively 
(both p<0.001, age- adjusted linear regression, results 
not shown). A higher proportion of Sami partici-
pants reported a family history of premature MI, and 
a higher proportion reported abstaining from alcohol 
or a seldom alcohol consumption. A higher proportion 
of Sami than non- Sami men reported being current 
smokers, and Sami men had a somewhat higher mean 
estimated 10- year risk of AMI or stroke. In this sample, 
Sami women had a somewhat lower mean systolic blood 
pressure than non- Sami women, whereas a higher 
proportion of non- Sami was categorised as hyperten-
sive. Additionally, a lower proportion of Sami women 
reported being physically active in their leisure time 
(table 1).
The median follow- up time and age for the composite 
endpoints were 13.0 and 65.2 years, respectively. The 
number of fatal and non- fatal events by investigated 
endpoints were as follows: AMI, 102 and 672; CHD, 89 and 
1882; IS, 9 and 423; stroke, 36 and 525; and the composite 
endpoint, 129 and 1130, respectively. Among censored 
cases, there were 101 participants who emigrated during 
follow- up.
For all endpoints considered, we found no statistically 
significant interactions between ethnicity and height, 
between ethnicity and sex, or between ethnicity and year 
of birth. Although the estimates for men and women 
were not different in Sami and non- Sami, we included 
the sex- specific and ethnicity specific incidence rates 
per 1000 person- years in a supplementary table (online 
supplementary table 1).
The number of cases, person- years and incidence rates 
(per 1000) by ethnic group are listed in figure 1. For each 
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Age (years) 52.8 (10.8) 52.9 (10.8) 52.8 (11.3) 52.1 (11.2)
Height (cm) 175.6 (6.9) 169.6 (6.4) 162.5 (6.4) 156.8 (6.0)
Systolic blood pressure (mm Hg) 134.0 (18.0) 133.3 (19.0) 129.2 (20.9) 127.2 (20.9)
Diastolic blood pressure (mm Hg) 78.3 (10.0) 77.9 (9.8) 72.7 (10.2) 72.1 (10.1)
Total cholesterol (mmol/L) 6.02 (1.1) 6.04 (1.1) 5.99 (1.2) 6.01 (1.1)
HDL cholesterol (mmol/L) 1.26 (0.33) 1.27 (0.35) 1.49 (0.38) 1.44 (0.37)
Smoking
  Current smoker 31.5 (1566) 34.7 (488) 32.3 (1882) 33.0 (522)
  Previous smoker 37.7 (1876) 37.0 (522) 30.5 (1777) 28.1 (445)
  Never smoker 30.8 (1529) 28.3 (398) 37.2 (2167) 38.9 (615)
Family history of premature MI*
One family member 19.4 (960) 20.0 (281) 20.1 (1171) 21.4 (337)
Two family members 3.0 (147) 4.5 (63) 4.2 (242) 5.8 (91)
Users of antihypertensive medication† 13.7 (681) 13.5 (190) 16.6 (969) 16.1 (254)
Estimated 10- year risk of fatal or non- fatal AMI or stroke†‡ 8.82 (7.9) 9.13 (8.1) 4.76 (6.0) 5.73 (4.4)
Triglycerides (mmol/L)† 1.87 (1.31) 1.87 (1.16) 1.50 (0.86) 1.55 (0.88)
Hypertensive 39.5 (1963) 38.6 (543) 35.7 (2078) 32.1 (508)
Users of lipid- lowering drugs† 7.1 (354) 8.6 (121) 8.7 (506) 8.7 (137)
Waist circumference (cm)† 94.3 (10.3) 92.3 (10.9) 85.1 (11.9) 85.3 (11.9)
Diabetes mellitus 3.4 (167) 4.1 (58) 3.5 (202) 3.4 (53)
Physically active in leisure time† 76.7 (3565) 75.7 (977) 78.4 (4 134) 72.1 (1037)
Alcohol consumption†
  Never/not last year 8.5 (416) 12.9 (177) 17.1 (966) 28.6 (436)
  Less than weekly 58.2 (2843) 61.2 (838) 60.9 (3443) 58.3 (890)
  Weekly or more often 33.3 (1626) 25.9 (354) 22.0 (1241) 13.1 (199)
Years of education† 11.5 (3.7) 11.0 (4.0) 11.7 (3.8) 11.6 (4.5)
Region 1: Alta, Loppa, Kvalsund, Lebesby, Lyngen, Storfjord, Kåfjord, 
Kvænangen§
62.7 (3117) 31.9 (449) 62.6 (3646) 28.2 (446)
Region 2: Kautokeino. Karasjok§ 1.3 (66) 28.7 (404) 1.5 (89) 33.1 (524)
Region 3: Tana, Nesseby, Porsanger§ 10.6 (527) 28.1 (396) 11.0 (639) 29.1 (460)
Region 4: Narvik, Evenes, Tysfjord, Skånland, Lavangen, Røros, Snåsa, 
Røyrvik, Namsskogan, Grane, Hattfjelldal§
25.4 (1261) 11.3 (159) 24.9 (1452) 9.6 (152)
*Parents, siblings or children with MI before the age of 60 years.
†Missing values: users of antihypertensive medication, n=142; estimated 10- year risk in men, n=13; triglycerides, n=12; waist 
circumference, n=47; education, n=770; users of lipid lowering drugs, n=300; physical activity, n=1185; alcohol consumption, n=358.
‡Estimated 10- year risk is measured with the NORRISK 2 risk score including sex, age, systolic blood pressure, total and HDL 
cholesterol, smoking (yes/no), use of antihypertensive medication (yes/no) and if one or two family members had a history of premature 
MI (yes/no).
§Included the listed municipalities.
HDL, high- density lipoprotein; MI, myocardial infarction.
endpoint, the HRs and 95% CIs in Sami versus non- Sami 
are visualised for model 1 to 3 with a forest plot (figure 1). 
We found no ethnic differences in the age- adjusted and sex- 
adjusted (model 1) or the multivariable- adjusted (model 
2–3) risk of AMI, CHD or in the composite endpoint. 
Regarding IS and stroke, Sami had higher age- adjusted and 
sex- adjusted risks than non- Sami, with HR of 1.36 (95% 
CI: 1.10 to 1.68) and 1.31 (95% CI: 1.08 to 1.58), respec-
tively. Adjustment for height attenuated the relationships 
between ethnicity and IS, and ethnicity and stroke to HR 
1.26 (95% CI: 1.00 to 1.59) and 1.18 (95% CI: 0.96 to 
1.44), respectively. Further adjustment for conventional 
risk factors (model 3) increased the risk of IS and stroke 
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somewhat (to HR 1.30 (95% CI: 1.03 to 1.64) and 1.19 
(95% CI: 0.97 to 1.47), respectively) (figure 1).
A significant interaction between sex and height was 
present in the models for stroke and the composite 
endpoint. Sex- stratified analyses revealed that height was 
inversely associated with stroke (model 2, HR per 5 cm 
increase: 0.84, 95% Cl: 0.76 to 0.94) and the composite 
endpoint (model 2, HR per 5 cm increase: 0.89, 95% Cl: 
0.82 to 0.96), only in women (online supplementary table 
2).
The sensitivity analyses rendered results that were 
consistent with those reported above.
DIsCussIon
In this population- based study from Northern and Mid 
Norway with a median of 13 years of follow- up, we found 
that Sami had a higher risk of IS and stroke than non- 
Sami, and a considerable part was explained by differ-
ences in height. No ethnic differences were observed 
with regards to AMI, CHD and the composite endpoint 
consisting of fatal or non- fatal AMI or stroke.
Our findings of higher incidence of IS and stroke in 
Sami compared with non- Sami is supported by studies in 
Norway and Sweden that indicate a higher incidence11 12 30 
and higher mortality of stroke in Sami.9 However, similar 
mortality of stroke was found between Sami and non- 
Sami in Sweden and Northern Finland.30 31
We observed a similar risk of CHD and AMI in Sami and 
non- Sami, which is consistent with the results regarding 
MI from a study based on data from 1974/1975 to 1989 
that included the population in the Finnmark County.11 
A different study, covering the same population and time 
period, found lower total mortality, CVD mortality and 
CHD mortality in Sami men, whereas no ethnic differ-
ence was observed between Sami and non- Sami women.10 
Another study followed Sami identified through a popu-
lation census in Northern Norway from 1970 to 1998 and 
found that Sami had higher total mortality, CVD mortality 
and CHD mortality than their benchmark population.9 
However, as we included both fatal and non- fatal events, 
direct comparisons of mortality rates are challenging. In 
Finland, lower and similar mortalities have been observed 
in Sami,31 32 whereas in Sweden, no overall differences in 
incidence and mortality are observed when compared with 
reference non- Sami populations.30 Being a member of a 
Sami reindeer herding household may, however, be protec-
tive.9 30
It seems likely that Sami people have a higher risk of 
IS and stroke than non- Sami, and similar risk of AMI 
and CHD, as this corresponds well with previous studies. 
We note that our age- adjusted and sex- adjusted effect 
estimates (model 1) are important from a public health 
perspective, as they reflect the actual distribution of 
risk in these populations. In our study, we were able to 
provide some explanation for the differences in risks, as 
the results for IS and stroke were attenuated, becoming 
only borderline significant after adjustment for height 
and conventional risk factors. However, the effect esti-
mates for IS and stroke remained elevated after adjust-
ments (models 2 and 3), which suggests that there might 
be other intermediate factors that we have not accounted 
for.
When adjusting for height, we most likely adjusted for 
factors that are related to health, nutrition and socioeco-
nomic conditions, within and across generations,33 34 and 
genetic factors,15 35 which all influence the body height 
of an individual. Adjusting for baseline values of conven-
tional risk factors (model 3) had only a small impact on 
the associations between ethnicity and IS, and ethnicity 
and stroke. This was as expected, given the similar base-
line levels of conventional risk factors found in Sami 
and non- Sami at two time points.17 18 The Emerging Risk 
Factors Collaboration included over 1 million people and 
found that after adjusting for height, further adjustments 
for long- term exposure to cardiovascular risk factors had 
little impact on the mortality- specific risk estimations.16 
They suggested that adult height is influenced by factors 
that also influence cardiovascular risk through the shared 
biological process between genes that determine adult 
height and atherosclerosis,16 which has been considered 
by others.36 For the risk of CHD, an increase in genet-
ically determined height (6.5 cm) has been associated 
with the lower body mass index,37 lower cholesterol36 37 
and better lung function,37 38 whereas for stroke, the asso-
ciations were less certain.37 Some argue that height has a 
direct effect as short people have proportionally smaller 
coronary arteries that are occluded earlier than in tall 
persons by a similar burden of plaque.39 Shorter people 
are found to have higher blood pressure40 and increased 
heart rate due to a smaller arterial tree41 than in taller 
people. The precise mechanism linking short stature with 
increased risk of CHD and stroke remains uncertain.
We found no ethnic differences in the risk of AMI and 
CHD. CVD is multifactorial in origin, and comparison 
groups may differ with regards to unmeasured risk or 
protective factors. Poor socioeconomic circumstances 
during childhood are found to have a stronger impact 
on stroke mortality than CHD mortality,42 which suggests 
some differences in the aetiology of stroke and CHD.
Education and healthcare are publicly financed in 
Norway, and this has been suggested as the underlying 
reason for the rather similar health observed previously 
in Sami and their majority population, as opposed to the 
situation in other indigenous populations.43 Adjusting 
for baseline education and lifestyle factors (model 4 
in sensitivity analyses) had a small impact in our study, 
and expenditures to secondary healthcare services are 
found to be similar in geographical areas that represent 
Sami and non- Sami populations.44 Hence, differences in 
healthcare utilisation and education are most likely not 
an issue in this population.
All inhabitants, within the selected region and birth 
cohorts, were invited to the SAMINOR 1, regardless of 
ethnicity, which should help control some environmental 
confounding factors that can distort comparison between 
by copyright.
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ethnic groups. However, ethnicity itself is rarely the causal 
factor for diseases, but a risk marker,20 representing 
certain ‘exposures’ that is determined by group member-
ship. The height difference explained more of the risk 
of IS and stroke observed in Sami than conventional risk 
factors, which is interesting but challenging to interpret, as 
there are complex relationships between height, genetics, 
ethnicity and environmental factors across generations.34 45 
Moreover, we cannot rule out that the excess risk in Sami 
might be due to residual confounding.
Psychosocial stress has been found to be an important 
risk factor for stroke,46 and the Sami people have been 
exposed to marginalisation47 and ethnic discrimina-
tion.48 If marginalisation and discrimination cause 
chronic psychosocial stress, they may lead to a higher 
risk of IS and stroke in Sami, as was previously suggested 
by Eliassen et al, who reported that marginalised Sami 
were more likely to report lifetime CVD.47 Thus, further 
studies that clarify how height and possibly other inter-
mediate factors lead to a higher risk of IS and stroke in 
Sami are warranted.
strengths and limitations
The use of 11- digit national identity numbers to obtain 
complete follow- up to high- quality registries,25 49 and the 
possibility to remove prevalent cases at baseline repre-
sents the strengths of this study. A limitation is that we 
have only adjusted for baseline values and cannot account 
for changes in risk factors or in the use of medication.
Potential misclassification of ethnicity is likely to be non- 
differential and would have led us to underestimate the 
associations. With regards to the reliability of ethnicity, 
Sami ethnicity was found to be stable when comparing 
information in the 1970 census, that is, language use 
in three generations and self- reported ethnicity, with 
corresponding information in SAMINOR 1.50 However, 
we do not know if participation differed by ethnicity as 
there are no national registries that include this informa-
tion. Moreover, participants in health surveys tend to be 
healthier than the underlying population,51 which can 
lead to lower incidence rates.
In conclusion, over 13 years of follow- up, Sami in 
Northern and Mid Norway showed a higher risk of IS 
and stroke than non- Sami, and height was identified as 
an important intermediate factor, as it explained more of 
the excess risk observed in Sami than conventional risk 
factors did. Sami and non- Sami participants had similar 
risk of AMI, CHD and the composite endpoint (AMI or 
stroke).
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Supplementary table 1. Number of cases, crude incidence rates (with 95% confidence intervals) and adjusted 
hazard ratios (with 95% confidence intervals) for cardiovascular diseases in Sami (n= 2 990) and non-Sami 





Incidence rates per 
1 000 person-years 
(95% CI) 
Hazard ratio (95%  CI) 
    Model 1 Model 2 Model 3 
Acute myocardial infarction     
Men       
Non-Sami  394 60 713 6.5 (5.88, 7.16) 1 1 1 
Sami  121 17 413 6.9 (5.82, 8.30) 1.06 (0.86, 1.30) 1.02 (0.82, 1.27) 1.03 (0.83, 1.28) 
Women        
Non-Sami 212 73 962 2.9 (2.51, 3.28) 1 1 1 
Sami 47 20 606 2.3 (1.71, 3.04) 0.85 (0.62, 1.17) 0.78 (0.56, 1.10) 0.82 (0.58, 1.15) 
Coronary heart diseases     
Men       
Non-Sami  895 57 608 15.5 (14.55, 16.59) 1 1 1 
Sami  282 16 453 17.1 (15.25, 19.26) 1.10 (0.96, 1.26) 1.04 (0.90, 1.20) 1.05 (0.91, 1.21) 
Women        
Non-Sami 635 71 434 8.9 (8.22, 9.61) 1 1 1 
Sami 159 19 927 8.0 (6.83, 9.32) 0.93 (0.79, 1.11) 0.86 (0.71, 1.03) 0.87 (0.72, 1.04) 
Ischemic stroke    
Men       
Non-Sami  181 61 799 2.9 (2.53, 3.39) 1 1 1 
Sami  70 17 593 4.0 (3.15, 5.03) 1.36 (1.03, 1.79)* 1.32 (0.98, 1.78) 1.34 (0.99, 1.82) 
Women        
Non-Sami 133 74 178 1.8 (1.51, 2.13) 1 1 1 
Sami 48 20 594 2.3 (1.76, 3.09) 1.38 (0.99, 1.92) 1.18 (0.82, 1.69) 1.20 (0.83, 1.72) 
Stroke §    
Men       
Non-Sami  235 61 602    3.8 (3.36, 4.34) 1 1 1 
Sami  87 17 511 5.0 (4.03, 6.13) 1.29 (1.01, 1.65) 1.26 (0.97, 1.65) 1.28 (0.98, 1.67) 
Women        
Non-Sami 177 74 003 2.4 (2.06, 2.77) 1 1 1 
Sami 62 20 554 3.0 (2.35, 3.87) 1.34 (1.00, 1.79) 1.08 (0.79, 1.48) 1.10 (0.80, 1.51) 
Composite endpoint §    
Men       
Non-Sami  596 59 759 10.0 (9.20, 10.81) 1 1 1 
Sami  194 17 057 11.4 (9.88, 13.09) 1.12 (0.96, 1.32) 1.10 (0.92, 1.31) 1.13 (0.95, 1.34) 
Women        
Non-Sami 370 73 255 5.05 (4.56, 5.59) 1 1 1 
Sami 99 20 384 4.86 (3.99, 5.91) 1.03 (0.82, 1.28) 0.88 (0.70, 1.13) 0.92 (0.72, 1.17) 
* p-value <0.05, ** <0.01, ***<0.001 
§ Interaction between sex and height. 
Model 1, adjusted for age.  
Model 2, adjusted for age and height.  
Model 3, model 2 additionally adjusted for: systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, 
current smoking (yes/no), use of antihypertensive medication (yes/no) and if one or two family members had a history of 
premature myocardial infarction (yes/no).     
Acute myocardial infarction: ICD10-codes I21–I22 as discharge code from hospitalisation, or I20–I25 as the underlying 
cause of death.  
Coronary heart diseases: ICD10-codes I20–I25 as discharge code from hospitalisation, or as the underlying cause of death.  
Ischemic stroke: ICD-10 code I63 as discharge code from hospitalisation, or as the underlying cause of death.  
Stroke: ICD-10 codes I60–I61 or I63–I64 (except 163.6) as a discharge code from hospitalisation, or as the underlying cause 
of death.  
Composition endpoint includes ICD-codes I21–I22, I60–I61 or I63–I64 (except 163.6) as discharge code from 
hospitalisation, or I21–I25, I60–I61 or I63–I64 (except 163.6) as the underlying cause of death.  
Abbreviations: HR, hazard ratio; CI Confidence interval; ICD-10 International Classification of Diseases, 10th Revision. 
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Supplementary table 2. Overall and sex-specific hazard ratios (with 95% confidence intervals) for acute 
myocardial infarction, coronary heart diseases, ischemic stroke, cerebral stroke and the composite endpoint 
associated with a 5-cm increase in height. SAMINOR 1 Survey (n=13 787). 
  Model 2 Model 3  
   Hazard ratio (95% CI)  Hazard ratio (95% CI)  
Acute myocardial infarction     
Overall   0.96 (0.91, 1.02)  1.00 (0.94, 1.05)  
Men      0.97 (0.91, 1.04)  1.00 (0.94, 1.08)  
Women   0.94 (0.84, 1.04)  0.97 (0.87, 1.08)  
Coronary heart disease        
Overall   0.95 (0.91, 0.98)**  0.97 (0.94, 1.01)  
Men   0.96 (0.91, 1.00)*  0.98 (0.94, 1.02)  
Women   0.93 (0.88, 0.99)*  0.97 (0.91, 1.02)  
Ischemic stroke       
Overall            0.94 (0.87, 1.02)  0.96 (0.89, 1.03)  
Men      0.98 (0.89, 1.08)  1.00 (0.90, 1.10)  
Women   0.88 (0.78, 1.00)*  0.90 (0.80, 1.02)  
Stroke       
Overall   §  §  
Men      0.98 (0.90, 1.07)  1.00 (0.92, 1.08)  
Female      0.84 (0.76, 0.94)**  0.86 (0.77, 0.96)**  
Composition endpoint       
Overall            §  §  
Men     0.98 (0.93, 1.03)  1.01 (0.96, 1.07)  
Women   0.89 (0.82, 0.96)**  0.92 (0.85, 0.99)*  
* p-value <0.05, ** <0.01, ***<0.001 
§ Interaction between height and sex. 
Model 2, overall models adjusted for age, sex and ethnicity. Sex-specific models adjusted for age and ethnicity.  
Model 3, as model 2 and additionally adjusted for: systolic blood pressure, total cholesterol, high-density lipoprotein 
cholesterol, current smoking (yes/no), use of antihypertensive medication (yes/no) and if one or two family members had a 
history of premature myocardial infarction (yes/no).   
Acute myocardial infarction: ICD10-codes I21–I22 as discharge code from hospitalisation, or I20–I25 as the underlying 
cause of death.  
Coronary heart diseases: ICD10-codes I20–I25 as discharge code from hospitalisation, or as the underlying cause of death.  
Ischemic stroke: ICD-10 code I63 as discharge code from hospitalisation, or as the underlying cause of death.  
Stroke: ICD-10 codes I60–I61 or I63–I64 (except 163.6) as a discharge code from hospitalisation, or as the underlying cause 
of death.  
Composition endpoint includes ICD-codes I21–I22, I60–I61 or I63–I64 (except 163.6) as discharge code from 
hospitalisation, or I21–I25, I60–I61 or I63–I64 (except 163.6) as the underlying cause of death.  
Abbreviations: CI Confidence interval; ICD-10 International Classification of Diseases, 10th Revision 
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SAMINOR 1 Survey 
- Information brochure 
o Design 1 
o Design 2 
- Invitation letter, design 1 
- Informed written consent form 
- Remainder card 
- Screening questionnaire (english translation), design 2 
 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Helsedepartementet har bedt oss undersøke helse- og levekårsforhold hos alle født
i 1925–1967 og i 1973 i utvalgte kommuner med samisk og norsk bosetting i
Nord-Norge og Nord-Trøndelag. Formålet er å innhente opplysninger om hjerte- og
karsykdommer, kreft, allergier, smerter og andre lidelser samt ulykker for å kunne
forebygge dem. Videre er målet å få et bilde av folks oppfatning av helsetjenestetil-
budet, deres levesett slik som kosthold og røyking, levekår og tilhørighet. De som
ønsker å delta, blir med i et forskningsprosjekt som består av spørreskjemaer og
helseundersøkelse. Alle opplysninger fra undersøkelsen vil bli behandlet konfiden-
sielt.
Helse- og levekårsundersøkelsen er nærmere beskrevet i brosjyren, som ligger ved-
lagt. Dersom du er i tvil om noe, kan du kontakte oss på tlf. 78 46 89 04 eller på
e-post: helseus@fagmed.uit.no
Du kan delta  på følgende måter: (kryss av øverst på spørreskjema under «samtyk-
ke til deltakelse»)
A Dersom du ønsker å delta i helseundersøkelsen og forskningsprosjektet, krysser
du av punkt A, fyller ut spørreskjemaet og returnerer det til oss i vedlagte kon-
volutt. Du vil senere få et brev med tid og sted for fremmøte sammen med et
nytt spørreskjema.
B Dersom du bare ønsker å delta i en innledende del av forskningsprosjektet uten
helseundersøkelse, krysser du av punkt B , fyller ut spørreskjemaet og returnerer
det til oss i vedlagte konvolutt. 
C Du kan unngå purring fra oss ved å krysse av punkt C og returnere spørre-
skjemaet til oss. Purring vil skje skriftlig.
Datatilsynet har gitt konsesjon for lagring av opplysninger fra undersøkelsen og
forskningsprosjektet er tilrådd av Regional komite for medisinsk forskningsetikk i
Nord- Norge.
For forskningen sin del vil det være av stor interesse at vi får inn så mange opplys-
ninger som mulig. Du deltar frivillig og kan, etter å ha sagt ja til deltakelse, senere
trekke deg uten å begrunne hvorfor og uten at det vil ha noen konsekvenser for
deg. Det samme gjelder dersom man i utgangspunktet ikke ønsker å delta.
Opplysninger du har gitt kan du be om å få slettet.
Resultatene vil bli publisert i massemedia, og det utformes en rapport fra helse- og
levekårsundersøkelsen når den er avsluttet.
De som fullfører hele helse- og levekårsundersøkelsen vil være med i trekningen av
3 reisegavekort til en verdi av á kr. 10 000,–. Vi regner med en deltakelse på ca.
15000 personer.
Med hilsen
Anne Kirsten Anti Eiliv Lund Per G. Lund-Larsen





Dearvvasvuođadepartementa lea min bivdán iskat dearvvasvuođa- ja eallindili
juohkehaččas riegádan 1925–1967 ja 1973 dihto gielddain sámi ja dáža ássamiin
Davvi-Norggas ja Davvi-Trøndelágas. Ulbmilin lea viežžat dieđuid váibmo- ja
suotnadávddaid, borasdávdda, allergiaid, bákčasiid ja eará gillámušaid ja lihkohis-
vuođaid birra vai daid sáhtášii eastadit. Dasto lea ulbmilin diehtit olbmuid oaivila
dearvvasvuođabálvalusa birra, sin eallinvuogi nugo biepmu ja borgguheami, eallin-
dili ja gullevašvuođa birra. Geat háliidit searvat, leat mielde dutkanprošeavttas mas
leat gažadanskovit ja dearvvasvuođaiskkadeapmi. Iskkadeami visot dieđut meannu-
duvvojit čiegusvuođas. 
Dearvvasvuođa- ja eallindilleiskkadeapmi lea dárkilat válddahallon gihppagis mii
čuovvu mielde. Jus eahpidat maidege, sáhtát gulahallat minguin tlf. 78 46 89 04
dahje e-poasta: helseus@fagmed.uit.no
Dán láhkai sáhtát searvat: (russe bajimuččas gažadanskovis  «mieđan searvamii»
buohta)
A. Jus háliidat searvat dearvvasvuođaiskkadeapmái ja dutkanprošektii, de russet A
čuoggá, deavddát gažadanskovi ja máhcahat dan midjiide čuovvu konfaluhtas.
Maŋŋil oaččut reivve mas čuožžu goas ja gosa boađát oktan ođđa gažadansko-
viin. 
B. Jus háliidat searvat dušše dutkanprošeavtta álgooasis almmá dearvvasvuođa-
iskkadeami haga, de russet B čuoggá, deavddát gažadanskovi ja máhcahat dan
midjiide čuovvu konfaluhtas. 
C. Eat rása jus russet C čuoggá ja máhcahat gažadanskovi midjiide. Rássan lea
čálalaččat.
Datatilsynet lea addán sierralobi rádjat iskkadeami dieđuid ja dutkanprošeavtta lea
rávven Regional komite for medisinsk forskningsetikk i Nord-Norge.
Dutkama dáfus lea hui miellagiddevaš ahte oažžut nu olu dieđuid go vejolaš. Don
searvvat eaktodáhtolaččat ja sáhtát, maŋŋil go leat miehtan searvamii, geassádit
vuođuškeahttá ja dutnje čuozakeahttá. Seamma guoská jus álggus juo ii hálit sear-
vat. Dieđuid maid leat almmuhan sáhtát bivdit sihkkut. 
Bohtosiid almmuhat mediain, ja čállo raporta dearvvasvuođa- ja eallindilleiskka-
deamis go dat lea loahpahuvvon.
Sii geat čađahit olles dearvvasvuođa- ja eallindilleiskkadeami leat mielde vuorbá-
deamen 3 mátkeskeaŋkakoartta man árvu lea 10 000,– ru. guđesge. Doaivut ahte
su. 15000 olbmo servet.
Dearvvuođaiguin
Anne Kirsten Anti Eiliv Lund Per G. Lund-Larsen
Sámi dearvvašvuođadutkama Institutt for samfunnsmedisin Nasjonalt folkehelseinstitutt



















































































































































































































































































































































































































































































































































































































































































































































































































































































































1. Your own health
what is your current state of health? (Mark only one)
 Poor  Not so good  Good  Very good
Do you have or have you had the following? Yes No
Age first 
time
Asthma .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Chronic bronchitis, emphysema, COPD  .  .  .  .  .  .  .
Diabetes  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Fibromyalgia/chronic pain syndrome  .  .  .  .  .  .  .  .  .  .
Psychological problems  
for which you have sought help  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Myocardial infarction (heart attack)  .  .  .  .  .  .  .  .  .  .  .
Angina pectoris (heart cramp)  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
 .  .  .  .  .  .  .  .  .  .  .  .Cerebral stroke/brain haemorrhage 
Multiple sclerosis  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Ulcerative colitis .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . .
Yes No
Do you get chest pain or discomfort when   walking 
up hills or stairs, or walking fast on level  
ground? .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Do you get such pain or discomfort even if you are 
resting?  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
2. MusculAR anD skeletal pain
have you during the last year suffered from pain and/
or stiffness in muscles or joints that has lasted for 
at least 3 months?  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Yes No
have you ever had the following? Yes No
Age last 
time
A wrist/forearm fracture?  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
A hip fracture?  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
3. stoMach anD intestinal sYMptoMs
Yes Nohave you experienced pyrosis/heartburn almost daily 
for at least a 
week?  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
have you ever had stomach pains/aches lasting for at 
least 2 weeks?  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
if yes, where in the stomach are the pains situated? (Mark only one)
 Upper part  Lower part  The whole stomach
normally, for how long are the stomach pains present?(Mark 
one)
For periods of weeks in length .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
For periods of months in length  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   .
Always  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   .
Do you often suffer from flatulence, a 
rumbling stomach or much wind?  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Yes No
What consistency is your stool usually? (Tick one or more boxes)
 Normal  Loose  Hard and lumpy 
 Alternating hard and loose Smelly
 Do you sometimes have three stools per day  Yes No
or more? .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
have you had stomach/intestinal problems after  
consuming milk?  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
are there others in your family with similar stomach symptoms?
 Mother  Father  Siblings  Child  None
4. other pains/probleMs
listed below are some symptoms or problems. have you 
experienced any of these during the last week (including today)?









Suddenly scared for no reason. . . . .
Feeling fearful or anxious . . . . . . . .
Faintness or dizziness .  .  .  .  .  .  .  .  .  . .
Feeling tense or keyed up  .  .  .  .  .  .  .  .
Blaming yourself for things .  .  .  .  .  .  .
Insomnia/sleeplessness  .  .  .  .  .  .  .  .  .
Feeling blue/melancholic  .  .  .  .
Feeling of worthlessness/of little 
value .  .  .  .  .  .
Feeling everything is an effort. .
Feeling hopeless about 
future .  .  .  .  .  .  .  .  .  . . . . . . . . . . . . . . . . .  .
Thinking of ending your life 
5. illness in the faMilY
have one or more of your parents or siblings 




tick off relatives who have, or have ever had, any of the following 
conditions, and report the age of when they got the illnesses.
(If several siblings were affected by a condition, report the one who got the illness at the 
youngest age)




before age 60  .  .  .  .  .  .  .  .  .
Myocardial infarction 
after age 60  .  .  .  .  .  .  .  .  .  .  .
 .Diabetes  .  .  .  .  .  .  .  .  .  .  .  .  .  
Cerebral stroke or 
brain hemorrhage  .  .  .  .
Asthma .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Colon cancer  .  .  .  .  .  .  .  .  .  .
Breast cancer .  .  .  .  .  .  .  .  .  .
Ovarian cancer  .  .  .  .  .  .  .  .
Brothers Sisters
how many siblings do you have?  .  .  .  .  .  .  .  .  .  .  .  .  .
Skjema 1.indd   1 29-01-08   15:45:47
6. use of MeDication
Medicines, in this context, means medicines bought at a pharmacy . 
Food supplements and vitamins are not included here .





Medications for high blood pressure  .
Cholesterol reducing medication  .  .  .  .  .
Insulin .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Tablets for diabetes  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
how often during the last 4 weeks have you used the following 
medications? (Tick one box for each line)
Not used 









Painkillers without prescription 
Painkillers with prescription  .  .  . 
Sleeping pills  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Tranquilizers  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Antidepressants  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Other prescribed medicines  .  .  .
For those medicines you have ticked off in the last two 
questions, and you have taken during the last 4 weeks:
state the name of the medicines and your reason for taking/
having taken them (disease, symptom): (Tick one box on each line)
Brand name of medicine  






If there is not enough space here, continue on a separate page and enclose it with 
the form .
7. fooD anD beverages














Fruit. . . . . . . . . . . . . .
Berries . . . . . . . . . . . .
Cheese (all types). . . .
Potatoes. . . . . . . . . . .
Boiled vegetables . . .
Fresh vegetables/salad







On bread .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
For cooking  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Do you use the following food supplements?
Yes, daily Sometimes No
Cod liver oil or cod liver oil capsules 
Fish oil capsules (omega 3)
Vitamins and/or mineral supplements
how much do you normally drink of the following?













a day or 
more
Full-fat milk, full‑fat curdled 
milk or yoghurt  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Semi‑skimmed milk, semi‑
skimmed curdled milk or low‑
fat yoghurt  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Skimmed milk or skimmed 
curdled milk  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Semi‑skimmed milk  .  .  .  .  .  .  .  .  .  .  .
Fruitjuice  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Water  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Soft drinks/cola drinks with 
sugar  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Soft drinks/cola drinks without 
sugar  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
how many cups of coffee and tea do you usually drink per day?
(Write 0 for the types you do not drink daily)
Number of 
cups
Filtered coffee  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Boiled coffee (coarsely ground coffee for brewing)
Other coffee  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Tea .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
how often during the last year have you consumed alcohol?
(Low-alcohol beer and non-alcoholic beer are not included)
Never consumed alcohol  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Not during the last year  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
A few times during the last year  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
1 time per month  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
2–3 times per month .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
1 time per week  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
2–3 times per week  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
4–7 times per week .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
when you drink alcohol, how many glasses or 
drinks do you normally drink?  .  .  .  .  .  .  .  .  .
approximately how many times during the last 
year have you consumed alcohol equivalent to 
5 glasses or drinks within 24 hours?  .  .  .  .  .  .  .  .
which of the following types of alcohol do you normally drink? 
(Tick one or more boxes)
 Beer  Wine Spirits
8. sMoking anD snuff use
how many hours a day do you normally spend in 
smoke-filled rooms? .  .  .  .  .  .  .  .  .  . . . .  . (Number of whole hours)
Did any adults living at home with you while you
were growing up smoke? .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . . . . . . . .  .
Yes No




To those who have consumed alcohol during the past year:
Number 
of times
Do you currently, or did you previously live with a 
daily smoker after your 20th birthday?  .  .  .  .  .  .  .  .  .
are you currently, or were you 






If you are current a daily smoker, do you smoke the 
following? 
Cigarettes .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Cigars/cigarillos/pipe .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Rolling tobacco .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
If you previously smoked daily, how many years is it since 
you stopped smoking?. . . . . . . . . . . . . . . . . . . (Number of years)
If you currently smoke, or have smoked before, how many 
cigarettes do/did you smoke per day? . . . . . . (Number of cigarettes)
If you currently smoke, or have smoked before, how old 
were you when you began smoking daily? . . . . (Age in years)
If you currently smoke, or have smoked before, how 
many years in all have you smoked daily? . (Number of years)
Do you take or have you been 
taking snuff daily?  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Yes, currently Yes, previously Never
if you have been taking snuff, for how many years in 
total have you been taking snuff? .  .  .  .  .  .  .  . (Number of years)
9. exercise anD phYsical activitY
how has your physical activity in leisure time been during this 
last year? (Think of your weekly average for the year . Time spent going to work 









light activity (not sweating or out of breath) .  .
hard physical activity (sweating/out of breath) 
Describe your exercise and physical exertion in leisure time. if 
your activity varies much, for example between summer and 
winter, then give an average. the question refers only to the last 
twelve months. (Tick the box that is most appropriate)
Reading, watching TV, or other sedentary activity  .  .  .  .  .  .  .  .  .  .  .
Walking, cycling, or other forms of exercise at least 4 hours a 
week (This should include walking or cycling to work, Sunday stroll/walk, etc .) 
Participation in recreational sports, heavy gardening, etc. 
(Note: duration of activity at least 4 hours a week)  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Participation in hard training or sports competitions regularly 
and several times a week  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
10. eDucation anD work
how many years of schooling/education  
have you completed? (Count all years you 
have attended school or been studying)  .  .  .  .  .  .  .  .  . (Number of years)
how content are you with your job?
 Very content  Content Discontent  Very discontent
Do you believe that you are in danger of losing your 
current work or income within the next 2 years?  .  .  .  .  .  .
Yes No
Do you receive any of the following benefits? Yes No
Sickness benefit/Sick pay  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Rehabilitation benefit  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Social welfare benefits  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Transition benefit for single parents  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
11. the rest of the questionnaire is to be answereD 
bY woMen onlY
(Age in years)
how old were you when you started  
menstruating? .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
if you no longer menstruate, how old were 
you when you stopped menstruating?  .  .  .  . (Age in years)
are you pregnant at the moment?
 Yes  No  Uncertain  Past fertile age
how many children have you given 
birth to?  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . (Number of children)
if you have given birth, enter what year each child was born 
and how many months you did breastfeed after the birth?
(If you didn’t breastfeed, write 0)




1st child  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
2nd child  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
3rd child  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
4th child  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
5th child  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
(If you have had more children, use an extra sheet of paper)







contraceptive injection . . . . . . . . . . . . . .
Hormonal intrauterine device . . . . . . . . 
Estrogen (tablets or patches). . . . . . . . . . 
Estrogen (cream or suppositories). . . . .
if you use/have used prescribed estrogen,
for how many years have you used it?  .  .  . (Number of years)
if you use contraceptive pills, a hormonal intrauterine device, 
or estrogen, what brand do you currently use? (Specify)
use of health services
how many times during the past year have you personally used 




GP (general practitioner)  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Medical specialist  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Emergency GP  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Admission to a hospital  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Home nursing care  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .





 .  .  .  .  .  .  .  .  .Home aid, organized by the municipality 
Physiotherapist  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Chiropractor .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Dentist  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Alternative medical practitioner  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
how many doctors have you seen in the
last 12 months? .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .(Number)
have you been given a regular gp, 
whose name you know?  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Yes No
when you are being examined, which language do you and 
your doctor communicate in? (Tick one or more boxes)
 Norwegian  Sami  Use an interpreter 
 Other language
Do you and your doctor sometimes misunderstand
each other due to linguistic problems?
 Never  Rarely  Sometimes  Often  Not sure
if an interpreter is needed, is your doctor good enough to 
request one?
 Yes, always  Yes, most of the time  No, not always 
 No, never  Don’t like to use interpreter
How satisfied/dissatisfied are you with the following aspects 
of the municipal health service in your municipality?







The distance to your doctor  .  .  .  .  .  .  .  .  .  .   .
Your doctor’s availability by telephone
How soon you can get an appointment 
with your doctor .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   .
How long you are allowed with your 
doctor .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   .
The chance you get to describe your 
pains and problems .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   .
Your doctor’s understanding of your 
cultural background  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   .
The information your doctor gives 
about your health and the examination 
and treatment you get  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   .
Your doctor’s language skills (Sami or 
Norwegian) .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
The local health services in your 
municipality as a whole  .  .  .  .  .  .  .  .  .  .  .  .  .  .   .
On the whole, how satisfied/
dissatisfied are you with the local 
health services in your municipality  .  .  .
how long is it since you last went to see a 
doctor?  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . (Report whole numbers)
Years Months
if you have ever used an alternative practitioner,  
which did you use? (Tick one or more boxes)
A traditional healer (guvllar, reader, “blåser”, laying on of hands)
A (modern) healer  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
An acupuncture practitioner  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
A zone therapist, homeopath, kinesiologist etc. .  .  .  .  .  .  .  .  .  .  .  .  .
how long is it since you last used an 
alternative practitioner?  . (Report whole numbers)
Years Months
suppose you need help/assistance from the local health- and 
social services (home nursing care, home assistance services, 
social services, physiotherapy, etc .):
Yes No Uncertain
Do you know where to go (who to contact)? .  .  .  .
Do you feel confident you will receive help if 
you need it?  .  .  .  .  .  .  .  .  .  .  .  .  . . . . . . .  .  .  .  .  .  .  .  .  .  .  .  .  .   .
If you already receive help from local health 
and social services, are you satisfied with the 
help they offer? .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   .
injuries/acciDents
have you been in accidents that resulted in treatment by a 
doctor and/or hospital admission?
Yes No Number of times
Doctor  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
Hospital admission  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .








 .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  .




Tractor accident .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . . .
Accident caused by falling  .  .  .  .  .  .  .  .  .  .
Cutting injury  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Other  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
has/have the accident(s) led to reduced ability to work?
 Completely  Partly  Not at all
faMilY anD linguistic backgrounD
People of different ethnic backgrounds live in Northern 
Norway. that is, they speak different languages and have 
different cultures. examples of ethnic background, or ethnic 
group, are norwegian, sami and kven.
which language did/do you, your parents, and your grand parents 
speak at home? (Tick one or more boxes)





Skjema 1.indd   4 29-01-08   15:45:52
Norwegian Sami Kven Other, specify
Father  .  .  .  .  .  .  .  .  .
Mother  .  .  .  .  .  .  .  .
Myself .  .  .  .  .  .  .  .  .
what are your, your father’s, and your mother’s ethnic
backgrounds? (Tick one or more boxes)
Norwegian Sami Kven Other, specify
My ethnic 
background  .  .  .
My father's ethnic 
background  .  .  .
My mother's ethnic 
background  .  .  .
what do you consider yourself to be? (Tick one or more boxes)
 Norwegian  Sami  Kven 
 Other,  
specify: 
eMploYMent/econoMY
what type of work/livelihood do you have? (Tick one or more boxes)
 Full time job with a fixed salary
 Part time job with a fixed salary
 Seasonal work Self‑employed
Unemployed  Homemaker (fulltime housework)
 Old‑age pension  Disability pension
 Other,  
specify: 
would you be willing to move if you were offered work 
somewhere else?
 Yes  No  Parts of the year Uncertain
Years Months
if you are out of work, for how long have you 
been seeking employment? (Report whole numbers)
if you are self-employed, what work do you do?
(Tick one or more boxes)




how many persons are living 
in your household? .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . (Number of persons)
What is your family’s/household’s gross income each year?
 Less than 150 000 NOK  150 000–300 000 NOK
 301 000–450 000 NOK  451 000–600 000 NOK
 601 000–750 000 NOK  More than 750 000 NOK
how often do you participate in gambling (national lottery, 
football betting, gambling machines, etc.)?
Never/rarely  1–3 times a month  Once a week
 2–6 times a week  Daily
for how much money do you gamble per week on average?
 Less than 100 NOK  100–500 NOK
 501–1000 NOK  More than 1000 NOK
bullYing
by bullying we mean when one or more persons systematically 
and over time say or do bad things against you, and you have 
difficulty in defending yourself against them.
have you experienced bullying? 
Yes, in the last 12 months  Yes, previously No
if you have been bullied, what kind of bullying did you experience?
(Tick one or more boxes)
 Talking behind your back/gossip  Being ignored
Discriminating remarks
 Other,  
specify: 
can you state where the bullying takes/took place?
 At school  At boarding school/dormitory
 At work  In local community
 Other,  
specify: 






SAMINOR 2 Clinical Survey 
- Pamphlet 
- Information brochure 
- Invitation letter (example from the municipality of Evenes) 
- Informed written consent form 
- Questionnaires (english translation):  
o 40–69 years 
o 70–79 years 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Det helsevitenskapelige fakultet, Institutt for samfunnsmedisin, 








Forespørsel om deltakelse i forskingsprosjekt
Vi spør deg om å delta i en helse- og livsstilsundersøkelse som Universitetet i Tromsø 












17. september til 25. oktober 2012 ved:












Du har fått tildelt frammøtetid:
Dato:
Tid:          
         








12:30, og vi har lunsj i tidsrommet 12:00 -12:30.
 Mandag Tirsdag Onsdag Torsdag Fredag
Lørdag 29.sept 
og 20.okt

























Helse og livsstil 






Det helsevitenskapelige fakultet, Institutt for samfunnsmedisin, 









På stedet undersøker vi ditt blodtrykk, din puls, høyde, vekt og liv-hoftevidde, samt at 
vi tar en blodprøve av deg.
Ta med ditt utfylte spørreskjema til undersøkelsen
Vi ber deg om å svare på vedlagte spørreskjema og ta dette med for levering på 
undersøkelsesdagen. Her kan du også få hjelp til utfylling av skjemaet om du trenger 
det. Du kan la være å svare på enkelte spørsmål. Spørreskjemaet omhandler i 
hovedsak spørsmål vedrørende hjerte-karsykdommer, diabetes og kosthold. &	1
kunne beregne næringsinntak (kalorier, næringsstoffer o.l.) er det nødvendig med en 
grundig kartlegging av hva du normalt spiser.
Forberedelser til undersøkelsen
Ha gjerne på et kortermet plagg innerst som ikke strammer da det letter 
blodtrykksmålingen. Vekt og liv-hoftevidde måles også med lett påkledning og vekt 
uten sko. Ingen andre forberedelser som fasting o.l. er nødvendig. 
Det er frivillig å delta. For mer informasjon om undersøkelsen, vennligst se 
vedlagte informasjonsfolder. Vi viser også til vår nettside http://site.uit.no/
helseoglivsstil/
















1. In what year were you born? ......................................................
2. What is your gender? ..............................................................................
Female Male






4. How many people live in your household? .............................
Number
of years
5. How many years of education have you completed?
(Include all years you have attended school or studied) ...................................




Less than NOK 150,000
NOK 301,000–450,000 
NOK 601,000–750,000 
More than NOK 900,000
Cardiovascular disease
7. Are you taking medication
for high blood pressure? ...........................
 Yes,     Previously,   Never
currently     but not now   used
8. If you are taking high blood pressure medication,
or have taken high blood pressure medication in 
the past, at what age did you start taking this type 
of medicine?
Age
9. Have you ever had one or more heart attacks?






10. If yes, at what age did you have your first
heart attack? ...............................................................................................................
Age
11. Do you suffer from angina pectoris
Yes No
12. If yes, at what age did your symptoms of
angina pectoris first emerge? ..........................................................
Age









a week or more
14. Have you had heart (bypass) surgery? Yes No
15. Have you had your arteries unblocked/
had stent(s) placed
Yes No




17. We will now ask you to state your physical activity at the
ages of 14, 30 and at your current age, on a scale from very 
low to very high. The scale below runs from 1 to 10. Physical 
activity includes both housework and activity at work, as well as 
exercise and other physical activities such as walking/hiking, 
etc. Mark the number that best matches your level of activity:
Very low Very high





18. Have you ever been diagnosed with
diabetes (elevated blood sugar levels)?  ................. Yes No
If no, please skip to question 28 regarding eating habits
19. If yes, please specify your diabetes diagnosis:
(chose one or more options)
Gestational diabetes  ....................................................................................
Type 1 diabetes  ....................................................................................................
Type 2 diabetes  ....................................................................................................
20. How was your diabetes discovered?
I consulted my doctor/physician because of 
symptoms ................................................................................................................. Yes No
It was discovered without the appearance of 
symptoms (medical certificate, work-related medical 
examination, pregnancy health examination, medical 
consultation for illness other than diabetes, etc.)
Yes No
Age
21. At what age was your diabetes discovered/
diagnosed? ..................................................................................................................................................
INSULIN
22. Are you taking insulin for
your diabetes? ...........................................................
Yes,   Previously,      Never




We kindly request that you fill in the form as thoroughly and accurately as possible,
and bring it with you to your scheduled physical examination. The form will be optically scanned. Please use 
blue or black ink. Use capital letters. Do not use decimals; for example, "0.5" should be rounded off to "1".
(heart cramp)? ...........................................................................................................
If you are taking (or have taken) insulin: 
Age
23. At what age did you start your
insulin treatment? ...........................................................................................
24. How many times per day do you/did you
usually take insulin? ..................................................................................... times
25. In total, how many units of insulin
do you/did you take on an average day? ............... units (E)
ORAL MEDICATION
26. Are you taking oral
medication for diabetes? ..........................
Yes,      Previously,     Never
currently     but not now   used
If you are taking or have taken oral medication: 
Age
27. At what age did you start taking oral
medication for diabetes? .....................................................................
Eating habits
Mark the square below the number that best describes your 
eating habits, taking the past four weeks into consideration:
28. How satisfied are you with your eating habits?
(Choose only one option)
1 2 3 4 5 6 7
Very dissatisfied Very satisfied
29. Have you resorted to ‘comfort food’ or excessive eating
due to sadness or feelings of discontentment? (Choose only one
1 2 3 4 5 6 7
Never Every day 
30. Have you ever felt guilty about eating/food? (Choose only one option)
1 2 3 4 5 6 7
Never Every day 
31. Have you felt that strict diets (or other food-related rituals)
are necessary for controlling the amount of food that you 
eat? (Choose only one option)
1 2 3 4 5 6 7
Never Every day 
32. Have you felt that you are too fat? (Choose only one option)
1 2 3 4 5 6 7
Never Every day 
Smoking habits
33. Have you ever smoked daily? ........................................... Yes No
If you have never smoked daily, please skip to question 38.
34. Are you currently a daily smoker? ............................. Yes No
Age
35. If you are no longer a daily smoker, at what age
daily? .............................................................................................................................................................
Years
36. In total, for how many years have you smoked
37. Considering all the years in which you smoked
regularly (daily), how many cigarettes/rolling
tobacco did you smoke per day, on average?................
38. Do you live with someone who smokes? ........ Yes No
Chronic pain
39. Are you experiencing pain that has lasted
three months or longer? ........................................................................ Yes No
40. If yes, please indicate the intensity of your pain in the





0 1 2 3 4 5 6 7 8 9 10
41. Please indicate where your pain is most severe:
Diet
We would like to know more about your usual diet. For each 
of the following foods and beverages, please indicate how 
often (the number of times) you have consumed the food 
item in question on average in the past year, and the 
amount you usually eat/drink each time.
BEVERAGES
42. How many glasses of milk do you normally drink?

















Low fat milk ("Extra lett") .............
Skimmed (regular, sour/fermented)
43. How many cups of coffee/tea do you normally drink?






















44. Do you take any of the following in your coffee?
Sugar (not including artificial sweeteners) .............................................. Yes No
Milk or cream ................................................................................................................ Yes No
45. Do you take any of the following in your tea?
Sugar (not including artificial sweeteners) .............................................. Yes No
Milk or cream ................................................................................................................ Yes No
option)
did you quit?....................................................................................................................................
(Choose only one option)
Neck    Lower back        Other
46. How many glasses of water do you drink on average?

















47. How many glasses of juice, squash/lemonade, and
carbonated/soft drinks do you drink on a typical day?

















drink containing sugar ...
Squash/lemonade/soft
drink without sugar .............
YOGHURT/CEREAL
48. How often do you eat yoghurt (1 tub)? (Choose only one option)
Never/rarely 1-3 per week
4-6 per week 1 or more per day
49. How often do you eat (breakfast) cereal, oatmeal or muesli?
(Choose only one option)
1-3 per weekNever/rarely 
4-6 per week 1 or more per day
BREAD/SANDWICHES
50. How many slices of bread (or equivalent; bread rolls, buns,
crispbread, rye bread) do you normally eat? (1/2 bread roll = 1 slice 
of bread) (Choose only one option for each variety listed)
Never/
rarely














The following questions are in regards to various sandwich spreads/
fillings. For each of the following sandwich spreads, we would like to 
know how many slices of bread/crispbread you normally eat with these 
spreads/fillings. If you regularly eat the given sandwich spreads with 
items other than bread (i.e., waffles, breakfast cereal, porridge) please 
include such use when answering the questions.












Jam.....................................................................     
Brown (charamelised)
whey cheese (full fat) ................     
Brown cheese (reduced fat)     
Cheese (full fat) .....................................     
Cheese (reduced fat)......................     
Mayonnaise based salads 
(prawn salad, italian salad, etc.)     
Liver pâté ....................................................     
Preserved meats, low fat
(boiled ham, etc.) .......................................     
Never/
rarely










Preserved meats, high fat
(salami, cured mutton, etc.) .........     
52. Please indicate how many slices of bread/crispbread you
have eaten on average per week in the past year with: (Choose 
one option for each line) Never/
rarely











sauce; smoked mackerel          
Caviar .........................................................      
Herring/anchovies .................      
Salmon (gravlax/smoked) .....      
Other types of fish ..................      
53. If you use butter/margarine on your sandwich/bread, how
thick a layer do you normally spread onto it? (A single portion 
packet weighs 12 grams) (Choose only one option)
Extra thin layer (3 grams) Thin layer (5 grams)
Thick layer (8 grams) Extra thick layer (12 grams)
54. What type of butter/margarine do you normally put on your
I do not use butter/margarine on bread
Butter
Hard margarine (e.g. Melange)
Soft margarine (e.g. Soft, Vita)
Butter and margarine blends (e.g. Bremyk)
Brelett (fat reduced butter and margarine blend)
Reduced fat margarine (e.g. Soft light, Vita Lett)
Olive oil margarine (e.g. Brelett oliven, Soft oliven)
FRUITS AND VEGETABLES
55. How often do you eat fruit? (Choose only one option for each line)
Never/
rarely












Apple/pear ..............................       
Orange/citrus fruit......       
Banana .............................................       
Other fruit ................................       











Boiled .....................................................     
Mashed .................................................     
Pan-fried/fried ...........................     















Carrot ....................................................       
Cabbage  ..........................................       
Swede ...................................................       
Broccoli/cauliflower.......       









normally eat with the following sandwich spreads?

bread? (You may choose several options)
















Mixed salad .....................................       
Tomato....................................................       
Mixed vegetables (frozen)         
Onion ..........................................................       
Beans ..........................................................       
Peas...............................................................       
Other vegetables ....................       
58. For the following vegetables in your diet, please indicate
how much you typically eat each time: (Choose only one option for
each vegetable type)
Carrot ........................  1/2 a carrot  1 carrot        1 1/2 carrot  2+ carrots
Potato ....  1-2 potatoes    3-4 potatoes    5-6 potatoes    7+ potatoes
Cabbage ..............................................  1/2 dl  1 dl  1 1/2 dl  2+ dl
Swede ......................................................  1/2 dl  1 dl  1 1/2 dl  2+ dl
Mixed salad ....................................  1 dl  2 dl  3 dl  4+ dl
Tomato  1/4 of a tomato    1/2 a tomato    1 tomato  2+ tomatoes
Mixed vegetables (frozen)     1/2 dl       1 dl  2 dl  3+ dl
Beans ...................................  1–2 tbsp  3–4 tbsp  5–6 tbsp     7+ tbsp
Peas........................................  1–2 tbsp  3–4 tbsp  5–6 tbsp     7+ tbsp
RICE, PASTA, PORRIDGE AND SOUP
59. How often do you eat rice and pasta (spaghetti, macaroni)?











Rice .....................................................................................     
Pasta (spaghetti, macaroni, noodles)      













Rice porridge .............................................      
Other porridge (oatmeal, etc.)      











As a main course ................................................     
As appetizer, lunch or supper .......     
FISH
62. We would like to know how often you eat fish, and kindly
ask you to indicate your fish consumption below, as 
accurately as possible. The availability of fish products may be 
seasonal; please indicate at which season you eat the various 




 all year    Winter   Spring   Summer  Autumn
Cod, saithe/coalfish,
    
(Atlantic) wolf fish, 
    
Salmon, sea trout............      




all year    Winter  Spring   Summer   Autumn
Mackerel .....................................................      
Herring ........................................................      
Freshwater fish (perch, pike,
   
Other fish ..................................................      
63. Considering the season(s) in which you eat fish, how often do
you normally eat the following for dinner (main meal/course)?










Boiled cod, saithe, pollack,
haddock .................................................................... 
Pan-fried cod, saithe, pollack,
haddocktorsk, sei, hyse, lyr ..........





Other fish ................................................................. 
64. If you eat fish, how much do you normally eat each time?
(1 piece/serving = 150 grams)
Boiled fish (piece(s)/servings) ......................................  1  3+
Pan-fried/oven-baked (piece(s)/servings)  1
 1 ½  2 
 1 ½  2  3+
65. How many times per year do you eat fish roe and fish liver?
(Choose only one option for each food)
0 1–3 4–6 7–9 10+
Fish roe ...................................................................     
Fish liver ...................................................................     
66. If you eat fish liver, how many tablespoons do you eat each
time? (Choose only one option)
 1  2  3–4  5–6  7+











Fishcakes/fish pudding/fish balls      
Fish stew/fish gratin ......................................     
Fried fish/fish fingers .................................     
Other fish products/dishes .............     
68. In which amounts do you normally eat the various
following dishes? (Choose only one option per line)
(pcs) (2 fish balls=1 fishcake) .......................................  1  2  3  4+
Fish stew, fish gratin (dl) ..................................  1–2  3–4   5+
Fried fish/fish fingers (pcs) ............................  1–2  3–4   5–6  7+
Broccoli/cauliflower..........  pieces (bouquets)  pieces        pieces
 1–2        3–4          5 + 
porridge type)
haddock, pollack ............. 
flounder, redfish .............. 
Freshwater fish (perch, pike,
grayling, charr, lavaret, trout) ............................. 
                 
                 
                 
                 
                 
                 
                 
                 
                 
 one option per line)
Fishcakes/fish pudding/fish balls 
grayling, charr, lavaret and trout)     
In addition to information regarding fish consumption, it is 
important to detail the sauces/fat that accompany fish meals.











Melted/solid butter ......................................     
Melted/solid margarine ..........................     
Sour cream, full fat (35% fat) ...............     
Sour cream, reduced fat (20% fat)         
Sauce, high fat (white/brown) ...............           
Sauce, fat free (white/brown) ................     
70. For the various types of fat/sauces that you regularly eat
with your fish, please indicate how much you normally eat: 
Melted/solid butter (tbsp) ..   ½  1  2  3   4+ 
Melted/solid margarine (tbsp)  ½  1  2  3    4+
Sour cream full fat (tbsp) .....   ½  1  2  3    4+ 
Sour cream, red. fat (tbsp) ..   ½  1  2  3    4+
Sauce, high fat (dl) .......................   ¼       ½       ¾        1    2+ 
Sauce, fat free (dl)  ........................   ¼       ½      ¾        1    2+
71. How often do you eat shellfish? (i.e., prawns/shrimp, crabs, molluscs)
(Choose only one option)
 Never/rarely 
 2-3 times per month
 Once a month
 Once a week or more
72. How many seagull eggs or eggs of other seabirds do you
eat during the course of one year? (Choose only one option)
Never 1-3 4-6 7-9 10-15 16+
73. How often have you eaten freshwater fish? (perch, pike, grayling,













Childhood............................................      
    Adolescence (13-19 yrs) 
Adulthood (past  year excl.)     
MEATS
74. How often do you eat the following meat dishes?
(Choose only one option for each meat type)
Never/
rarely










Reindeer meat .....      
Moose/elk meat       
75. How often do you eat the following meat and poultry dishes?











Roast (beef, pork, mutton)....................     
Cutlets (beef, pork, mutton) ................     
Steak (beef, pork, mutton) ....................     
Hamburger/meat patties .......     
Sausages/hot dogs ..........................     
Grouse, other game birds .............     
Meat casserole, stew ......................     











Chicken, unskinned .........................     
Chicken, skinned ..................................     
Bacon  ....................................................................     
Other meat dishes .............................     
Blood-based dishes
   
76. If any of the following dishes are in your diet, please indicate
your typical serving sizes: (Choose only one option for each dish)
Roast (slices) .........................................  1  2  3  4  5+
Cutlets(pcs) ..................................................   ½      1  1½  2+
Hamburgers, meat 
patties (pcs) ..........................................  1 2 3 4+
Sausages (pcs; 1=150g) ...........   ½      1  1½  2+
Casserole/stew (dl) ......................  1–2  3  4  5+
Pizza with meat toppings
(slices of 100 grams each) ..............  1  2  3  4+











Brown sauce  .......................................................     
Gravy ...................................................................................     
Tomato-based sauce .............................     
Sauce with cream/sour cream     
78. For the various sauces listed, what amounts do you
Brown sauce (dl) ................................................
Gravy (dl) ...................................................................................
Tomato-based sauce (dl) ....................
Sauce with cream/sour cream (dl)
OTHER FOODS
79. How many eggs do you normally eat in the course of one
 0  1  2  3–4  5–7  8-14  15+
80. How often do you eat ice cream? (for dessert, Cornetto, etc.)
(Choose one option for your ice cream consumption in summer, and one for the 











In the summer ..................................     
The rest of the year ....................     
81. How much ice cream do you normally eat each time?
(Choose only one option)
 1 dl  2 dl  3 dl  4+ dl
82. How often do you eat bakery goods, such as buns, cakes,
danishes/pastries and cookies? (Choose only one option for each line)
Never/
rarely











    
Danish pastries ................................      
Cakes ...................................................................      

(lamb/sheep, cattle, reindeer, moose)  
and pasta dishes? (Choose only one option for each sauce variety)
normally apply to your meals?
¼         ½          ¾           1          2+
¼         ½          ¾           1          2+
¼         ½          ¾           1          2+
¼         ½          ¾           1          2+
week? (pan-fried, boiled, scrambled, omelette) (Choose only one option)
(buns, etc.) .......................................................       
Never/
rarely










Pancakes .....................................................      
Waffles .............................................................      
Cookies, biscuits ............................      
Lefse, potato pancake ...........      














caramel pudding )..................................      
Creamed rice, mousse/
    
Compote, stewed fruit,
canned fruit ..........................................      
Strawberries (fresh, frozen) ..      
Other berries (fresh, frozen)            













Dark chocolate ........      
Milk chocolate ..........
 
     
85. If you eat chocolate, how much do you normally eat each
time? Imagine the size of a Kvikk Lunsj chocolate bar (47g), and indicate your 
serving size according to that.
 ¼  ½  ¾  1  1½  2+













     
87. How often do you eat salty snacks? (Choose only one option for
Potato crisps .................      
Peanuts ..................................      
Other nuts.........................      
Other snacks .................      
COD LIVER OIL AND FISH OIL CAPSULES
88. Do you take bottled cod liver oil supplements? Yes No









In the winter ......................................................     
Other seasons .................................................     
90. If you take bottled cod liver oil, what amounts do you take
1 teaspoon ½ tablespoon  1+ tablespoons
91. Do you take cod liver oil capsules/fish oil capsules?
Yes No
92. If yes, how often do you take cod liver oil capsules/fish
In the winter .........................................     
Other seasons .....................................     
93. What brand/type of cod liver oil/fish oil capsules do you
take, and how many capsules do you take each time?
Product/brand name:____________________________________________________________ 
Number of capsules:     1       2          3+
Other dietary supplements
94. Do you take other dietary supplements?
(vitamins/minerals) ................................................................................................... Yes No
Alcohol
95. Do you practice total alcohol abstinence? Yes No
96. If no, how often and how much did you drink, on average, in















Beer/alcopops (½ l)          
Wine (glass) .............................        
spirits (drink/shot) ..............        
Liqueur/fortified
Dental health
97. In your most recent visit to the dentist, did you see a dentist/
dental hygienist in private practice or a dentist/dental hygienist 
employed in the public dental health service? (Mark with an "X") 
Dentist in private practice
Dental specialist in private practice
Dental hygienist in private practice
Dentist employed in public dental health service
Dental specialist employed in public dental health service 
Dental hygienist employed in public dental health service 
Dentist abroad (outside of Norway)
Less than a year ago
3-5 years ago 
         1-2 years ago
          More than 5 years ago
99. If your most recent dental appointment was more than two
I have not been scheduled for
a regular appointment
Long waiting time for 
appointment
I have not had the time Economic/financial reasons
I am afraid or anxious 
about seeing the dentist
Other reasons:














one option per line)
each time?










wine (glass) ..............................        
98. When did you last see a dentist or dental nurse?(Choose only 
one option)
years ago, please supply the reason for not going more 
frequently to the dentist: (Choose only one option)
I have not required dental
care
food)
100. In the past 12 months, how much money have you 
spent on dental care (dentist, dental specialist, dental 
hygienist)? (Choose only one option)
Nothing (I have not had 
dental appointments)
Less than NOK 1000 NOK 1000-5000
NOK 5001-10,000 NOK 10,001-20,000
More than NOK 20,000
101. Please mark the two aspects that are most important to 
you in regards to your teeth/oral health:
That my teeth are nice-looking when I talk and smile
That my teeth are pain-free (do not hurt) ........................................
That I can chew/eat without any trouble ..........................................
That I have fresh breath .................................................................................................
That I keep my teeth for the rest of my life .....................................
102. How would you rate your dental health? (Choose only one
 Poor               Not so good Good Very good
103. Do you have dentures/a dental bridge? Yes No
Sunlight exposure/Tanning
104. Have you been on holiday in southern countries or other
beach/sunbathing holiday in the past month? Yes No
105. Please estimate the total number of hours during which
you have been outside (during daylight
hours) in the past seven days? ............................................... hours
106. Have you used a solarium in the past month? 
No 1 - 2 times 3+ times
Skin care products/Cosmetics
107. How often (number of times) do you use the following 















Face cream ....................................       
Hand cream .................................       
Body lotion ....................................       
Perfume/aftershave ........       
Deodorant ........................................       
Hair products (not incl. 
shampoo/conditioner) .................       
Children and breastfeeding
108. This question applies to mothers only: What is the birth 
year of your child(ren), and what was the approximate 
number of months during which the
child(ren) was/were breastfed?                    Number of monthsduring which the 




Second child ......................................... 
Third child ................................................ 
Fourth child ............................................ 
Fifth child ................................................... 
If you had more than five children, please continue on a separate sheet.
Family and linguistic background
109. How would you describe your family’s financial
situation when you were growing up? (Choose only one option)
Very good Good Challenging
Extremely
challenging
People of different ethnic backgrounds live in Northern 
Norway. That is, they have different languages and cultures. 
Examples of ethnic backgrounds, or ethnic groups, are 
Norwegian, Sami and Kven.
110. What language(s) do/did you, your parents and your 
grandparents speak at home? (Put one or more crosses for each line)








111. What is your, your father's and your mother's ethnic 
backgrounds? (Put one or more crosses for each line)
Norwegian  Sami     Kven       Other, describe:
My ethnic background is ................................
My father's ethnic background is .....
My mother's ethnic background is
112. What do you consider yourself to be? (Put one or more crosses)
Norwegian   Sami          Kven          Other, describe:




1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
Figure
number
113. Which of the above figures/illustrations most 
closely resembles your own body type/size? ................................
Male figure number Female figure number
114. In your opinion, which figure
corresponds to a healthy body type/size ?
115. Which figure is the first (in ascending 
numerical order) that you think of as
representing a fat person? ..................................................
116. Which figure/illustration is the first 
(in descending numerical order) that you
think of as representing a skinny person?
117. How would you describe yourself? (Choose only one response)
Extremely fat             Too fat           Average/Just right   Too thin/skinny      Extremely skinny
118. Have you attempted to lose weight (diet)
in the past six months? ........................................................................... Yes No
119. If yes, how many kilograms have you lost
in the past six months ? ....................................................................... Kg
120. Please indicate the methods used in order to lose weight? 
(You may choose one or more alternatives)







121. Below you will find a number of common health issues. 
Please consider each one carefully and individually, and then 
indicate the extent to which each individual health issue has 










Nervousness or shakiness inside.................
Feeling fearful ...........................................................................
Feeling hopeless about the future ..........
Worrying too much about things ..............
Feeling blue/melancholic .......................................
Sleep/Sleeping habits
We would like to ask some questions concerning your sleeping 
habits. Please use the 24-hour time format, in which 11:00 
corresponds to eleven o’clock in the morning and 23:00 
corresponds to eleven o’clock at night.
122. Have you taken part in shift work (worked night/evening
 shifts) in the past three months ? ................................ Yes No
123. Please indicate the number of days a week in which you do 
not have the opportunity to choose freely when to go to sleep 
and when to get out of bed? (This may apply, for instance, to any days in 
which you have to go to work, attend school, etc.) (Choose only one option)
0 1 2 3 4 5 6 7
       
124. On the days that I do not have the opportunity to 
choose freely when to go to sleep/get out of bed,
Hours   Minutes
I go to bed at ...............................................................................................................
I get ready to fall asleep at .......................................................................
Number of minutes that it normally takes before I
fall asleep (fully): ...................................................................................................
I wake up at..................................................................................................................
I wake up due to/using:
Alarm clock
External circumstances 
(i.e., noise caused by 
family members or others)
I wake up naturally
Number of minutes normally passing from I wake up
till I get out of bed: ......................................................................................................
On such days, do you sleep in other hours of
the day? (i.e., afternoon nap) .................................................................. Yes No
Hours    Minutes
When (what hour) does this normally occur? ................
Provide the number of minutes of daytime sleeping: 
125. On days in which I can freely choose my rising/waking/
sleeping hours: Hours    Minutes
I go to bed at ..............................................................................................................
I get ready to sleep at ....................................................................................
Number of minutes that it normally takes before
I fall asleep (fully):  ...............................................................................................
I wake up at..................................................................................................................
I wake up due to/using:
Alarm clock External circumstances
(i.e., noise caused by 
family members or others)
I wake up naturally
Number of minutes normally passing from I wake up
till I get out of bed: ............................................................................................
On such days, do you sleep in other hours of
the day (i.e., afternoon nap) ........................................................................ Yes No






























































1. In what year were you born? ..................................
2. What is your gender? ....................................................
Female      Male





4. How many years of education have you
completed? (Include any and all years in which
you attended school or studied).........................................................................
Number
of years
5. If you are a woman: How many children
have you given birth to? .....................................................................
Number
of children





7. How is you state of health? (Put one cross only)
GoodPoor
Not so good Very good
8. How is your dental health? (Put one cross only)
GoodPoor
Not so good Very good
9. Do you have dentures/
a dental bridge?  .................................................................................... Yes No
10. When did you last see a dentist or dental nurse?
Less than a year ago
3–5 years ago
1–2 years ago
More than 5 years ago
11. How satisfied are you with the dental health care






12. Do you have, or have you ever had,
high blood pressure?  ............................................................... Yes No
Age
13. If yes, how old were you when you
developed high blood pressure?............................................
14. Are you taking medication
for high blood pressure? 
Yes, Previously,
but not now Never
15. If you are taking high blood pressure medication,
or have taken high blood pressure 
medication in the past, at what age did you 
start taking this type of medicine? ...................................
Age










17. If yes, at what age did you have your first
 heart attack? ................................................................................................................
18. Do you suffer from angina pectoris
(heart cramp)?  ...................................................................................... Yes No
19. If yes, how often have you experienced such pain
in the past month?  ........................................................................................................................................
Rarely 2-3 times a week
4-6 times
a week
7 times a 
week or more
Age
20. How old were you when you had your
 first attack of angina pectoris? ................................................
21. Have you had heart (bypass)
surgery?  ................................................................................................................... Yes No
22. Have you had your arteries
unblocked/had stent(s) placed?  .................... Yes No
23. Has your doctor told you that you
have atrial fibrillation?  ......................................................... Yes No
Age
24. How old were you when you first




We kindly request that you fill in the form as thoroughly
and accurately as possible, and bring it with you to your scheduled physical 
examination. The form will be optically scanned. Please use blue or black ink. Use 









25. Have you ever been diagnosed with diabetes
(elevated blood sugar levels)?  ........................... Yes No
If no, please skip to question 35. 
26. If yes, please specify your diabetes diagnosis:
(chose one or more options)
Gestational diabetes  ....................................................................................................................
Type 1 diabetes  ......................................................................................................................................
Type 2 diabetes   ....................................................................................................................................
27. How was your diabetes discovered?
I consulted my doctor/physician
because of symptoms ................................................................ No
It was discovered without the 
appearance of symptoms (medical 
certificate, work-related medical examination, 
pregnancy health examination, medical 
consultation for illness other than diabetes, etc.).......
Age
28. At what age was your diabetes
discovered/diagnosed? ...................................................................................
INSULIN
29. Are you taking insulin







If you are taking (or have taken) insulin: 
Age
30. At what age did you start your
insulin treatment? ........................................................................
31. How many times per day do you/
did you usually take insulin? ............................... times
32. In total, how many units of
insulin do you/did you take on an
average day? .............................................................................................. units (E)
ORAL MEDICATION








If you are taking or have taken oral medication: 
Age
34. At what age did you start taking oral
medication for diabetes? ..............................................................................
Other illnesses
35. Do you have, or have you ever had, any of the






Multiple sclerosis (MS)  ......................
Psoriasis  .............................................................................
Bechterew's disease  ...............................
Chronic pain 
36. Are you experiencing pain that
has lasted three months or longer? ......... Yes No
37. If yes, please indicate the intensity of your pain





0 1 2 3 4 5 6 7 8 9 10
38. Please indicate where your pain is most severe:
(Choose only one option)
Neck Lower back Other
Physical activity 
39. We will now ask you to state your physical
activity at the ages of 14, 30 and at your current 
age, on a scale from very low to very high. The scale 
below runs from 1 to 10. Physical activity includes 
both housework and activity at work, as well as 
exercise and other physical activities such as 
walking/hiking, etc. Mark the number that best 
matches your level of activity:
Very low Very high








40. Do you practice total alcohol abstinence?
Yes No
41. If no, how often and how much did you drink, on

























(½ l.) ................................... c c c c c c c c
Wine
(glass) .............................. c c c c c c c c
Liquor/distilled spirits
(drink/shot) ............... c c c c c c c c
Liqueur/fortified wine
(glass) .............................. c c c c c c c c
Smoking habits
42. Have you ever smoked daily? ..................... Yes No
If you have never smoked daily, please skip to 
question 47.
43. Are you currently a daily smoker? Yes No
44. If you are no longer a daily smoker, at
which age did you quit? ...................................................................................
Age
45. In total, for how many years have you
smoked daily? .............................................................................................................................
Years
46. Considering all the years in which you smoked
regularly (daily), how many cigarettes/rolling
tobacco did you smoke per day, on average?
Number of cigarettes 
47. Do you live with someone who
smokes? ......................................................................................................................... Yes No
Language and use of interpreter
48. In what language(s) do you primarily want to talk
to health personnel? (Put one or more crosses)
Norwegian  Sami     Other, describe:
49. If you have answered “Sami” but were not offered
a Sami-speaking doctor at your last doctors visit, did 
they offer you an interpreter?
With your general practitioner:
NoYes
I do not want an interpreter Not relevant
In the hospital/with a specialist:
NoYes
I do not want an interpreter Not relevant
Family and linguistic background
50. How would you describe your family’s financial
situation when you were growing up?
(Choose only one option)
Very good                Good Challenging
Extremely
challenging
People of different ethnic backgrounds live in 
Northern Norway. That is, they have different 
languages and cultures. Examples of ethnic 
backgrounds, or ethnic groups, are Norwegian, 
Sami and Kven.
51. What language(s) do/did you, your parents and
your grandparents speak at home? (Put one or more 








52. What is your, your father's and your mother's
ethnic backgrounds? (Put one or more crosses)
Norwegian Sami Kven Other, describe:
My ethnic background is
My father's ethnic background is
My mother's ethnic background is
53. What do you consider yourself to be?
(Put one or more crosses)
Norwegian   Sami           Kven          Other, describe:
Andre sykdommer
35. Har du eller har du noen gang hatt?




Kronisk bronkitt, emfysem, 
KOLS.......................................................................................




36. Har du smerter nå som har vart i 
tre måneder eller lengre? ................................................ Ja Nei
37. Hvis ja, vennligst angi hvor sterke smerter du har 





0 1 2 3 4 5 6 7 8 9 10




39. Vi ber deg angi din fysiske aktivitet etter en 
skala fra svært lite til svært mye da du var 14 år, 
30 år og i dag. Skalaen nedenfor går fra 1-10. Med 
fysisk aktivitet mener vi både arbeid i hjemmet og i 
yrkeslivet, samt trening og annen fysisk aktivitet som 
turgåing o.l. Sett kryss under det tallet som best angir 
ditt nivå av fysisk aktivitet.
Svært lite Svært mye




Experience and use of health services
54. Who is the doctor you normally use?
Your GP Another doctor
55. How long have you had your current GP?
Less than 6 months
12 to 24 months
6 to 11 months 
More than two years
56. In the last 12 months, have you
contacted your doctor for help
or advice for yourself?............................................................. Yes No
If yes, did you get the help you asked for?
Never           Sometimes       Usually Always
57. How satisfied are you with the following aspects
of the doctor’s service (regular GP scheme)?















The waiting time for
an appointment ......................





about your health 
issues, examination 
and treatment plan..........
In total, how satisfied 
are you with the 
municipal health
service?........................................................
The next questions are about the
specialized health service.
Specialized health service refers to hospitals, 
district psychiatric centers (DPS), specialized 
doctors services and individual specialists.
58. In the last 12 months, have you been for
examination or treatment for physical problems to 
the following?
The hospital Specialist medical center
Private specialist None of these
59. In the last 12 months, have you been for
examination or treatment for psychological problems 
to the following?
Psychiatric hospital District psychiatric center
Private specialist None of these
60. If you have been for treatment with a specialist
for physical or psychological problems in the 
last 12 months, answer the following questions:
(Put one cross only) Answer on a scale from 0 to 10,
where 0 = to a small extent, 10 = to a large extent.
Did you get a chance to say what you felt was 
important about your condition? 
Not




Did the doctors speak to you in a way you 
understood?
Not




All in all, do you trust the hospital or specialist 
who saw you?
Not




All in all, how satisfied are you with the care 
and treatment you eventually received?
Not




Thank you for participating in the survey!
 
 
 
